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ABSTRACT
HIV infection remains a worldwide concern and new drug treatments are required to 
tackle drug resistance and to reduce drug-associated host toxicity. Raltegravir, a new 
anti-HIV drug which targets the HIV integrase enzyme, is now being used in anti-HIV 
treatment and has shown impressive efficacy and low toxicity. However, the drug shows 
high pharmacokinetic (PK) variability between subjects and it has been difficult to 
associate PK parameters with treatment outcome. The aim of this thesis was to improve 
the current understanding of the factors influencing raltegravir PK and cellular exposure 
using in vitro and in silico techniques.
It is unknown whether efflux transporter ABCB1 influences raltegravir disposition. 
Chapter 2 confirmed raltegravir efflux transport by ABCB1 and found that raltegravir 
was unable to inhibit or induce ABCB1 activity. Cellular toxicity of raltegravir was also 
assessed and shown to be minimal. Although ABCB1-mediated transport was confirmed, 
transport was low compared to control substrates and ABCB1 is unlikely to influence 
raltegravir in vivo.
The influence of influx transporters on raltegravir disposition has not previously been 
determined and may help explain variable raltegravir PK. Chapter 3 investigated 
raltegravir influx transport using the Xenopus laevis oocyte expression system and also 
investigated SLC22A1 inhibition by raltegravir. Raltegravir concentration was increased 
in oocytes expressing influx transporters SLC22A6 and SLC15A1. Raltegravir did not 
inhibit the transport of tetraethylammonium by SLC22A1.
Chapter 4 investigated in more detail raltegravir influx transport by kidney-expressed 
SLC22A6. Rahegravir Km and Vmax for SLC22A6 were 150 pM and 36 pmol/oocyte/hr, 
respectively, in the oocyte expression system. Competition between tenofovir and 
raltegravir for SLC22A6 transport was assessed (IC50 values of 27.3 pM and 14.0 pM 
for tenofovir and raltegravir, respectively). Inhibitors of SLC22A6 and SLC15A1 were 
unable to alter raltegravir accumulation in peripheral blood mononuclear cells (PBMC), 
suggesting these transporters are not important in raltegravir PBMC exposure.
Chapter 5 investigated the physicochemical characteristics of raltegravir. An increase in 
pH led to increased raltegravir solubility and tablet breakdown, decreased lipophilicity 
and, at low raltegravir concentrations, decreased cell permeation. Raltegravir pKa was 
calculated as 6.7. At pH 7.4, raltegravir Caco-2 cell membrane permeation was also 
shown to decrease in the presence of 25 mM divalent metals magnesium and calcium but 
not in the presence of 25 mM monovalent metal potassium, suggesting that divalent 
metal-containing products may reduce raltegravir intestinal absorption when co­
administered.
Data from Chapter 5 and from literature was used to create a PK simulation modelling 
program (Simcyp) to help explain and predict the effects of food, pH-altering agents and 
divalent metal cation-containing products on raltegravir PK (Chapter 6). Simulated data 
correlated well with real PK values (AUC +4% deviation, Ctrough -30% deviation, Cmax 
+3% deviation). Increased gastrointestinal pH, the presence of ingested divalent metals 
and an increased gut transit time were all associated with raltegravir PK exposure.
The investigations in this thesis have improved our understanding of the factors 
influencing raltegravir cellular exposure. Transporters such as ABCB1 and SLC22A6 
may play a role in raltegravir PK. However, they are unlikely to fully explain high 
raltegravir PK variability. Factors such as gastrointestinal pH and divalent metals 
influence raltegravir physicochemical properties and human trial studies are now 
underway to define their role in the high inter-patient and intra-patient PK variability 
seen in people receiving raltegravir.
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1-1 HIV and AIDS: the current situation
Autoimmune deficiency syndrome (AIDS) remains a serious concern for worldwide 
public health. AIDS is caused by the human immunodeficiency virus (HIV). Unlike 
some other infectious diseases, HIV uses no animal to transmit the disease between 
humans and is instead directly spread between humans by sexual intercourse, blood 
transfusions, needle sharing and general blood to blood contact. Therefore, HIV has 
been able to spread from its site of origin in Africa to virtually all the countries in the 
world.
According to the 2011 UNAIDS report (www.unaids.org), an estimated 34 million 
people were living with HIV worldwide at the end of 2010, which is 17% higher than 
in 2001. This figure is a message of both concern and hope: the number of new HIV 
infection cases remains high, but the yearly number of AIDS-related deaths has 
reduced to 1.8 million in 2010 from a peak of 2.2 million in 2005. This reduction in 
AIDS-related deaths is a result of multiple factors, including improved education and 
increased availability of antiretroviral treatment to HIV patients in developing 
countries. This emphasises the essential and continuing role that antiretroviral drugs 
play in reducing HIV-related mortality and transmission worldwide.
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1.2 Pathogenesis of HIV-1 infection
1-2.1 The structure and genome of an HIV-1 virion
The HIV-1 virion was first described in 1983 (Barre-Sinoussi et al., 1983) and a 
description of HIV-2 followed in 1986 (Clavel et al, 1986). HIV is approximately 
120nM in diameter and has a spherical shape (Briggs et al, 2006). Contained within 
the virion are two identical single-stranded RNA strands which are enclosed within a 
conical antigen named p24. Surrounding p24 is the spherical matrix antigen pi7 
which maintains the shape of the virion. The outer surface consists of a lipid bilayer 
taken from a host cell membrane and this contains both host cell proteins and viral 
proteins gp41 and gpl20 (Figure 1.1). Various viral proteins are contained in the core 
antigen including reverse transcriptase, integrase, protease, vpr, vif, nef and the 
nucleocapsid proteins p7 and p6. Table 1.1 gives information on the locations and 
functions of the different viral proteins.
The HIV-1 genome is RNA-based and contains 9749 nucleotides (Ratner et al, 
1985) arranged into 9 genes (pol, gag, env, nef, tat, rev, vpu, vpr and vif) encoding 18 
proteins (Figure 1.2). These genes can be divided into structural genes which are 
essential for viral replication {gag, pol and env) and accessory genes which are not 
absolutely required for HIV replication in vitro {nef tat, rev, vpu, vpr and vif).
21
Protease
LipM bilayer
p7gag
HIV RNA
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Host cell protein
Figure 1.1. The structure of the HIV-1 virion.
Vpr Vpu
Figure 1.2. The HIV-1 genome.
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Name Size Function Localization
Gag
MA p17 Membrane anchoring, env interaction, Virion
nuclear transport of viral core
CA p24 Core capsid Virion
NC P7 Nucleocapsid, binds and protects RNA Virion
... P6 Binds Vpr Virion
Pol
PR p15 Gag/Pol cleavage and maturation Virion
RT p66, p51 reverse transcription, RNAse H activity Virion
RNAse H p15 degrades the RNA after DNA synthesis Virion
IN p31 DNA provirus integration Virion
Env gp120, gp41 External viral glycoproteins which bind Plasma membrane,
to CD4 and secondary receptors virion envelope
Tat p16, p14 Viral transcriptional transactivator Primarily in nucleolus/
nucleus
Rev p19 RNA transport, stability and Shuttling between
utilisation factor nucleolus and cvtooiasm
Vif p23 Promotes virion maturation and infectivity Cytoplasm, virion
Vpr p10-15 Promotes nuclear localisation of Virion, nucleus
pre-integration complex, inhibits cell
division, arrests infected cells at G2/M
Vpu p16 Promotes extracellular release of viral Integral membrane
particles, degrades CD4 in the ER protein
Nef p25-p27 CD4 and class I MHC down-regulation Primarily in nucleolus/
nucleus
Table 1.1. The proteins produced by the HIV-1 genome and their known function.
1.2.2 HIV-1 replication
HIV-l is a group VI lentivirus in the family retroviridae. The processes undertaken 
by HIV-1 to replicate itself have been extensively studied, although further research 
is still ongoing. Figure 1.3 shows a simplified version of the HIV-1 replication cycle.
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Figure 1.3. The replication cycle of HIV-1. Boxes on the left detail the roles of 
essential viral proteins reverse transcriptase, integrase and protease.
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HIV entry into CD4+ macrophages and T cells begins with the adsorption of the HIV 
gp!20 to a CD4 receptor on the cell surface (Chan et al, 1998; Wyatt et al, 1998). 
This gpl20-CD4 interaction has a high binding affinity but also requires HIV gp41 
binding to the chemokine receptor CXCR4 (Feng et al, 1996) or CCR5 (Deng et al, 
1996). Dual-tropic HIV strains have also been isolated which are able to use either 
CXCR4 or CCR5 for cell entry (Doranz et al, 1996). The HIV peptide gp41 can then 
puncture the cell membrane and the HIV virion fuses with the host membrane, 
releasing the viral nucleoplasmid into the cell. The nucleoplasmid then uncoats, 
discharging the single stranded viral RNA and various viral proteins into the cell 
cytoplasm (Aiken, 2006). The single stranded viral RNA is then used to produce 
double stranded viral cDNA by the viral enzymes reverse transcriptase and RNAse 
H. This copying process is error-prone, resulting in about 1 to 10 errors per round of 
replication (Isel et al, 2010). This feature, along with the fecundity of HIV, allows 
for rapid mutation and adaptation of the virus in response to antiretroviral treatment. 
The double stranded viral cDNA is relocated into the nucleus and integrated into the 
host cell genome by the viral enzyme integrase (see Section 1.3 for a detailed 
overview of integration).
Once integrated, the viral cDNA is termed the provirus and may remain dormant in 
this form for long periods. Several factors can affect the activation state of the HIV 
provirus, most importantly the location of the provirus in the cell genome and the 
abundance of cellular transcription factors (Bisgrove et al, 2005). The pro virus is 
efficiently expressed when integrated into actively transcribed areas of the cell 
genome. A cellular transcription factor important for HIV provirus transcription is 
NF-kB, which is upregulated in activated T cells (Hiscott et al, 2001).
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When the provims is initially transcribed, viral mRNA is spliced to produce the viral 
proteins rev and tat. Working with the cellular cofactor Cyclin T1 (Wei et al, 1998), 
tat binds to the LTR transactivation region of the provirus and upregulates HIV 
proviral DNA transcription. The viral protein rev binds to the rev response element 
in the viral env gene and similarly upregulates transcription. Rev is also a nuclear 
export factor and is important for switching the expression of regulatory viral 
proteins to the structural and enzymatic proteins (Pollard et al9 1998).
The env gp!60 is cleaved by the viral protease enzyme to form gp41 and gpl20 
which are both localised to an area of the inner cell surface (Adamson, 2012). Gp41 
anchois gpl20 to the membrane of the infected cell. Other proteins, including 
incompletely spliced polypeptides gag and gag-pol, also associate with the inner 
layer of the cell membrane along with unspliced HIV genomic RNA. The forming 
virion begins to bud from the cell, taking with it the cell membrane and associated 
cellular membrane proteins and carbohydrate chains (Spearman, 2006). Eventually 
an immature virion is released from the cell and the enclosed protease enzyme 
completes maturation by splicing the polypeptides to form working proteins. These 
virions are now able to infect new host T cells and macrophages, completing the 
replication cycle. Potentially billions of new HIV virions are created every day in an 
infected individual and this astronomical rate of replication puts enormous pressure 
on the individual’s immune system, allowing the virus population to evolve 
resistance to antiretroviral drugs, neutralising antibodies and cytotoxic T cell attack.
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1-3 Integration: an essential step in HIV-1 replication
HIV-l is a retrovirus, characterised by the ability to convert its RNA genome into 
DNA and then integrate this DNA into the host cell genome. The integration of viral 
DNA is essential for HIV-1 to replicate in vivo and in vitro (Bouyac-Bertoia et al, 
2001).
1.3.1 The HIV-1 integrase protein: structure and function
HIV-l integrase is a 32 kDa protein which is involved in the preparation and 
integration of viral DNA into the host cell genome. Approximately 40-100 integrase 
molecules are packaged within each HIV particle (Pommier et al, 2005). The 
integrase gene is located in the pol region of the HIV-l genome and is initially 
expressed as a polyprotein containing immature integrase, reverse transcriptase and 
protease. This polyprotein is cleaved by protease in a budded virion to produce 
mature enzymes. The active integrase enzyme involved in viral DNA integration is 
believed to be a pair of covalently-bound polypeptide dimers, but other multimer 
forms may be important for other stages in the HIV life cycle (Chiu et al, 2004). The 
3D crystal structure of the complete integrase enzyme has recently been described 
(Hare et al, 2010).
Integrase contains three functionally distinct regions: the N-terminal domain, the 
catalytic core domain and the C-terminal domain (Figure 1.4). The N-terminal 
domain includes a HHCC motif containing a single zinc atom. This motif is involved 
in the formation of integrase multimers via zinc coordination and is also seen to
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promote concerted integration of the viral DNA into the host genome. The C- 
terminal domain performs metal-independent non-specific DNA binding. It is the 
least conserved region of integrase, most likely due to the lack of specific DNA 
binding (Chiu et al., 2004). An SH3 fold is present in this region and is believed to 
interact with reverse transcriptase. The catalytic core domain contains several 
conserved regions which are essential for integrase activity. HIV integrase has a 
structure which is similar to other retroviral integrase enzymes (Chiu et al., 2004) 
and contains a DDE three amino acid motif. Alteration of any of these residues 
results in total loss of integrase activity and a subsequent elimination of viral 
replication. These three conserved amino acids coordinate an interaction with two 
divalent metal cations, believed to be Mg2+ or Mn2+ (Asante-Appiah et al, 1997; 
Espeseth et al, 2000). The binding of these metal cations to the integrase enzyme 
brings about a major conformational change to the enzyme (Asante-Appiah et al, 
1997) and a reduced susceptibility to proteolysis (Asante-Appiah et al, 1998).
polgene
JK. W JN
0,0-35-E motif
D64
aa 1 h,21 M
HHCC motif
D116 1^52
156 160
KELKK
Specific DNA 
binding site
N-domain Core domain C-domain
Figure 1.4. The integrase gene.
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Integrase performs at least three essential functions in the HIV-1 replication cycle: 
3’-processing, nuclear relocation and strand transfer of viral DNA (Krishan et al., 
2012). The 3’-processing stage follows the production of viral DNA by reverse 
transcriptase and involves endonucleolytic cleavage of GT nucleotides at the 3’ site 
of the conserved CA region in the long terminal repeats (LTR). This creates CA-3’- 
hydroxyl ends on the viral DNA, providing the nucleophile groups required in the 
later strand transfer stage.
Viral DNA must be relocated to the site of the host DNA for successful integration. 
A potential barrier to this relocation is the cell nuclear envelope, which surrounds the 
host cell genome in non-dividing cells (Krishan et al, 2012). The nuclear membrane 
is present in most eukaryotic cells in order to separate the nuclear contents from the 
cytoplasm (Mekhail et al., 2010). Molecules of less than 40 kDa are able to passively 
diffuse across the membrane but transport of large or hydrophilic materials such as 
RNA and protein are regulated by the nuclear pore complex (NPC).
Many viruses are unable to infect non-dividing cells (Roe et al, 1993) or are shown 
to infect non-dividing cells less effectively than cells which are actively dividing 
(Katz et al, 2005; Lewis et al, 1992). HIV is able to infect both dividing and non­
dividing cells with similar' efficacy (Lewis et al, 1992) due to the ability of HIV 
integrase to form a viral DNA-bound pre-integration complex (PIC) with various 
viral (Fassati et al, 2003; Reil et al, 1998) and cellular (Farnet et al, 1997) co­
factors. This facilitates nuclear relocation of viral DNA.
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Strand transfer occurs in the nucleus and is the ligation of the 3’-processed viral 
DNA into the host cell chromosome, resulting in a 5’ viral CA base pair overhang 
and a cellular DNA five base gap on each side of the inserted viral genome. These 
overhangs and gaps are believed to be repaired by cellular DNA repair enzymes.
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1-4 Anti-HIV chemotherapy
14.1 The basic principles of anti-HIV chemotherapy
The current strategy used with anti-HIV therapy is to use drugs to target and inhibit 
critical stages in the HIV replication process, thus preventing more HIV from being 
produced (Figure 1.5).
The immediate goals of anti-HIV therapy are to cause the greatest possible reduction 
in viral load and to prevent further virus-induced damage to the host immune system. 
When successful, these factors help bring about anti-HIV therapy’s ultimate goals; 
immune system reconstitution and an increase in both the length and quality of the 
HIV-infected person’s life. From an epidemiological viewpoint, anti-HIV therapy 
and the subsequent reduction in viral load reduce the risk of transmitting the virus to 
non-infected individuals and children born to HIV-positive mothers (Stmt et al., 
2010).
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Figure 1.5. The main classes of antiretroviral drugs and how they inhibit the HIV 
replication cycle.
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1-4.2 Drugs used in anti-HIV chemotherapy
There are currently 25 anti-HIV drugs approved by the FDA and several more in 
various stages of development. Table 1.2 gives a list of the currently approved drugs, 
where each drug is classified by its mechanism of action. Details of the mechanism 
of action and general characteristics of each drug class are detailed below and 
examples from drug classes are shown in Figure 1.6.
Type Drug Abbrev. Trade Name Manufacturer
NRTIs Emtricitabine FTC Emtriva™ Gilead
Lamivudine 3TC Epivir™ GSK
Zidovudine AZT Retrovir™ GSK
Didanosine ddl Videx™ BMS
Tenofovir TFV/TDF Viread™ Gilead
Stavudine d4T Zerit™ BMS
Abacavir ABC Ziagen™ GSK
NNRTIs Delavirdine DLV Rescriptor™ Pfizer
Efavirenz EFV Sustiva™ BMS/MSD
Nevirapine NVP Viramune™ Boehringer Ingelheim
Etravirine ETR Intelence™ Tibotec
Rilpivirine RPV Edurant™ Tibotec
Pis Tipranavir TPV Aptivus™ Boehringer Ingelheim
Amprenavir APV Agenerase™ GSK
Darunavir DRV Prezista™ Tibotec
Indinavir IDV Crixivan™ MSD
Saquinavir SQV Invirase 500™ Roche
Lopinavir/ritonvir LPV Kaletra™ Abbott
Ritonavir RTV Norvir™ Abbott
Atazanavir ATV Reyataz™ BMS
Fosamprenivir FPV Telzir™ GSK
Nelfinavir NFV Viracept™ Roche/Pfizer
FIs Enfuvirtide T-20 Fuzeon Roche
AIs Maraviroc MVC Celsentri™ Pfizer
INIs Raitegravir RAL Isentress™ MSD
Table 1.2. Current anti-HIV drugs approved by the FDA. NRTIs = nucleoside and 
nucleotide reverse transcriptase inhibitors; NNRTIs = non-nucleoside reverse 
transcriptase inhibitors; Pis = protease inhibitors; FIs — fusion inhibitors; AIs = 
attachment inhibitors; INIs = integrase inhibitors.
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A) B)
Figure 1.6. Examples of drugs from the major anti-HIV drug classes. The NNRTI 
efavirenz (A) is highly lipophilic (logP of 4.46) and blocks the hydrophobic pocket 
within the polymerase domain of the p66 HIV reverse transcriptase subunit. The 
NRTI lamivudine (B) resembles a deoxynucleotide and arrest HIV DNA synthesis. 
The PI darunavir (C) contains polypeptide-like regions and blocks the active site of 
HIV protease. The attachment inhibitor maraviroc (D) resembles HIV gp41 and
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prevents the binding of gp41 with the cellular chemokine CCR5. The structure of 
raltegravir, the only integrase inhibitor currently used in anti-HIV therapy, is shown 
in Section 1.6.1.
1.4.3 Nucleoside and nucleotide reverse transcriptase 
inhibitors
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs, 
respectively) are analogues of the naturally occurring deoxynucleotides needed to 
synthesize the viral DNA. They compete with the natural deoxynucleotides for 
incorporation into the growing viral DNA chain but lack a 3’-hydroxyl group and 
therefore arrest the viral DNA synthesis once incorporated. The different NRTIs 
mimic only one of the four nucleotides used in DNA synthesis; adenine, thymine, 
cytosine or guanine. When co-administering different NRTIs to HIV patients, it is 
essential to use NRTIs that mimic different nucleotides to avoid cross-resistance.
1.4.4 Non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) work in a non-competitive 
manner by binding to reverse transcriptase at a location other than the enzyme’s 
active site. Specifically, the drugs block the hydrophobic pocket within the 
polymerase domain of the p66 RT subunit (Waters et cil, 2007). A hypersensitivity 
rash can result from the use of NNRTIs Mid hepatitis can occur in patients with a 
high CD4+ T-cell count (van Leth et ah, 2005). Once these immune system 
responses have been observed, the NNRTI cannot be used further in the patient’s 
treatment.
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1.4.5 Protease inhibitors
Protease inhibitors (Pis) act by blocking HIV protease, a viral enzyme that cleaves 
the HIV-1 gag and gag-pol polyprotein backbone at nine specific cleavage sites to 
produce shorter, functional proteins. The crystal structure of protease (Navia et al, 
1989) was used to develop compounds which would fit directly into the enzyme’s 
active site. The previously released drugs inhibited reverse transcriptase so the 
discovery of Pis was a major boost in the management of HIV infection and led to 
the development of Highly Active AntiRetroviral Therapy (HAART; Section 1.4.9). 
Unfortunately, most of the Pis developed so far exhibit adverse effects and can 
interact with other medications via inhibiting or inducing drug metabolising enzymes 
and drug transporters (Profit et al, 1999) (Granfors et al, 2006). The PI ritonavir is a 
particularly potent inhibitor of cytochrome P450 (CYP) 3A4, resulting in increased 
exposure of drugs metabolized by this enzyme (Kharasch et al, 2008) (Decker et al, 
1998). This property has been utilised to augment the bioavailability of Pis (CYP3A4 
substrates) and ritonavir-mediated “boosting” is used for currently licensed PI- 
containing HAART regimens (Merry et al, 1997). Cobicistat, a potent and selective 
inhibitor of human CYP3A4 which displays no anti-HIV activity, is currently under 
investigation for use as a replacement for ritonavir in Pi-containing HAART 
(Mathias et al, 2010). Pis are generally highly bound to plasma protein and 
therefore show poor passage into compartments such as cerebrospinal fluid (Kim et 
al, 1998), potentially resulting in the creation of sanctuary sites for HIV-1 
replication.
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1.4.6 Fusion inhibitors
Fusion inhibitors prevent fusion of the HIV virion with the host cell membrane and 
therefore prevent release of the nucleocapsid into the target cell. Currently, the 
polypeptide drug enfuvirtide is the only licensed fusion inhibitor available for HIV 
treatment. Enfuvirtide acts by binding to the HR1 region of gp41, preventing the 
fusion of the virion with the cell surface (Joly et al.t 2010). The large size and 
protein-like characteristics of enfuvirtide mean that the drug cannot be orally 
administered due to enzymatic degradation in the intestine. Therefore, enfuvirtide 
must be administered parenterally. This, coupled with high costs, has limited the use 
of the drug to “salvage” therapies for patients with multi-drug resistant HIV 
infection.
1.4.7 Attachment inhibitors
Attachment inhibitors prevent the HIV virion from binding to the target cell. 
Maraviroc is the only licensed attachment inhibitor and works by binding to the 
cellular chemokine receptor CCR5, blocking its interaction with HIV gp41 without 
activating the receptor (Corbeau et cil, 2009). CXCR4-tropic HIV, which is not 
susceptible to maraviroc treatment, is more lytic to T cells in vitro and is temporally 
associated with the development of AIDS (Daar et al., 2007). Therefore, patients 
require a HIV tropism test prior to stalling therapy with maraviroc to ensure they 
don’t harbour CXCR4-tropic HIV. The cost and time required to conduct the tropism 
test has limited the widespread use of this drug.
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1.4.8 Integrase inhibitors
Integrase inhibitors act by targeting and disrupting the function of the viral integrase 
enzyme (Pommier et ctl., 2005). The term “integrase inhibitors” currently covers a 
broad range of compounds which all inhibit the ability of integrase to function but 
which have different mechanisms of action (Ingale et cil, 2011). The recently 
approved drug, raltegravir, inhibits integrase strand transfer (Section 1.3.1), but there 
are also various 3’-processing and multimerisation inhibitors which are currently in 
development. A more complete discussion on the mechanism of action and drug 
properties of raltegravir is continued in Section 1.5.
1.4.9 The concepts of highiy active antiretroviral therapy and 
therapeutic drug monitoring
Despite huge successes in the treatment of HIV infection, it is now accepted that 
current HIV drugs cannot eradicate the virus from the body (Eisele et al.9 2012). This 
means that, unless more advanced treatments are developed, HIV-positive patients 
must continue taking anti-HIV therapy for life. This presents serious problems 
because patients must remain adherent to the drugs to prevent emergence of 
resistance and are also at risk of experiencing adverse drug reactions. All currently 
licensed anti-HIV drugs are associated with some form of adverse drug reaction but 
toxicities are more common and/or severe with some drug classes than with others.
Due to the high replication rate of the virus and the inefficient proof-reading ability 
of reverse transcriptase, HIV is able to rapidly become resistant to anti-HIV drugs 
via genetic mutation. This has led to the simultaneous use of multiple anti-HIV drugs
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with HAART. This limits the virus’s ability to become resistant to the treatment 
because resistance would require simultaneous mutation of all drug targets. The use 
of HAART has been extremely successful in reducing the occurrence of drug- 
resistant HIV in patients (Lehman et aL, 2009). However, resistance can still emerge 
when plasma exposure to one or more of the drugs within a regimen falls below the 
minimum therapeutic concentrations. Currently, WHO guidelines recommend first- 
line HAART should consist of the NRTIs tenofovir and emtricitabine and also a third 
drug of a different drug class (www.who.com). The third drug in first-line HAART 
can be the NNRTI efavirenz, the integrase inhibitor raltegravir or the ritonavir- 
boosted Pis atazanavir or danmavir.
The issues surrounding adverse drug reactions (particularly concentration-dependent 
toxicities) and drug resistance have led to the implementation of therapeutic drug 
monitoring (TDM) in some settings (Back et al., 2001). TDM involves measuring 
anti-HIV drug concentrations in the blood plasma of the patient during treatment and 
using that information to help understand key issues such as viral load, development 
of drug resistance, and drug-induced patient toxicity. TDM is a useful surrogate for 
physicians to assess whether their patients are adherent to their regimens.
An example of a typical drug concentration profile from human plasma is shown in 
Figure 1.7. There exists a minimum inhibitory concentration (MIC) for each drug, 
determined in vitro and confirmed in patients, which is the lowest drug concentration 
that completely suppresses viral replication. There is also a range of drug 
concentrations in the plasma below the MIC where only partial viral suppression is 
achieved, resulting in positive selection of drug-resistant virus. The range of drug
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concentrations between the MIC and the maximum concentration before host toxicity 
is called the “therapeutic window” of the drug. The maximum tolerated 
concentration before host toxicity (MTC) divided by the MIC is the drug’s 
therapeutic index. Drugs with a high therapeutic index are often favoured in drug 
development, as the drugs are generally safer to use.
There are standard pharmacokinetic (PK) parameters that are determined from 
concentration time plots, such as Cmax (the maximum concentration of drug achieved 
during the dose interval), Chough (the concentration of drug just before taking another 
dose) and Area Under the Curve (AUC, the area under the plot of plasma 
concentration of drug against time after drug administration). The CmaK and AUC 
values are often used to predict host toxicity (Forni et al, 2010) and the Qrough value 
is important in relation to the emergence of drug resistance during HAART (Rizk et 
al., 2012), The values of these PK parameters vary from patient to patient (inter­
patient variability) and also in the same patient over time (intra-patient variability). 
These variations result from multiple factors, such as age, genetics, disease and 
interactions with other substances, which can impact the Absoiption, Distribution, 
Metabolism and Excretion (ADME) of a drug.
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Figure 1.7. A typical drug concentration profile from human plasma. Shown is the 
minimum inhibitory concentration (MIC), the lowest drug concentration required to 
completely inhibit viral replication and prevent drug resistance selection.
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1.5 Pharmacological factors relevant to HIV therapy
As described in Section 1.4.9, the desirable and undesirable effects of a drug are 
often linked to the concentration of drug at the site of action and in the various 
compartments of the body. Drug exposure in the body is the result of the interplay of 
several individual factors which are encompassed in the ADME properties of a drug. 
Elimination of a drug is determined by drug metabolism (usually in the liver or gut) 
and drug excretion (usually by the liver or kidney). A major determinant of the 
ADME properties of a drug is its affinity for drug metabolism enzymes and drug 
transporters.
1.5.1 Drug-metabolising enzymes
Drug metabolism is the biochemical modification of pharmaceutical compounds 
through specialized enzymatic systems, usually with the goal of converting lipophilic 
compounds to more hydrophilic metabolites. These metabolites are usually more 
soluble and as such are more readily cleared from the body, usually via biliary 
excretion or via the kidneys. The principle site of drug metabolism is usually the 
liver, although drug metabolism enzymes are also expressed at various levels in other 
tissues, including the gastrointestinal (GI) tract, kidney, lung, brain and skin (Krishna 
et cd., 1994). Drug-metabolising enzyme reactions can be separated into two distinct 
groups: phase I (nonsynthetic) reactions and phase II (synthetic) reactions.
Phase I reactions include hydrolysis, reduction and oxidation of a drug and occur in 
the cellular endoplasmic reticulum membrane. The most intensively studied group of
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phase I enzymes are the CYP450 enzymes, which are involved in the metabolism of 
the majority of drugs used in HAART (with the exception of NtRTIs and raltegravir). 
Phase II reactions include glucuronidation, glycosidation, sulfation, methylation, 
acetylation, amino acid conjugation and glutathione conjugation and occur in the cell 
cytosol.
1.5.2 Drug transporters
Membrane-bound drug transporters are classified into two groups; the ATP-binding 
cassette (ABC) and solute-carrier (SLC) protein families (Rees et al, 2009; Roth et 
a/., 2012). Both families of drugs require ATP to function, although SLC transporters 
do not use ATP directly and instead utilise a proton gradient created by separate 
ATP-consuming proton pmnps.
Drug transporting proteins are located on both the celfs plasma membrane and the 
membranes of internalised compartments such as the mitochondria (Leung et aL, 
2007). The proteins function by transporting endogenous and xenobiotic molecules 
across membranes, often against a concentration gradient. Generally, ABC 
transporters move drugs out of the cell (efflux transporters) and SLC transporters 
concentrate drugs into the cell (influx transporters), although certain transporters, 
such as human equilibrative nucleoside transporter family (SLC29), are capable of 
moving substrates in both directions (Young et al., 2008). Cells in different tissues 
often express distinct and/or varying levels of drug transporters (Bleasby et al, 2006) 
and this can lead to directed drug distribution and an increased concentration of drug 
in different organs and compartments in the body (Table 1.3).
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Gene Protein Aliases Tissue in humans
ABCB1 ABCB1
P-gP,
MDR1
Intestine, liver, kidney, brain, 
placenta, adrenal gland, testes
ABCB4 ABCB4 MDR3 Liver
ACB11 ACB11 BSEP Liver
ABCC1 ABCC1 MRP1 Intestine, liver, kidney, brain
ABCC2 ABCC2 MRP2 Intestine, liver, kidney, brain
ABCG2 ABCG2 BCRP
Intestine, liver, breast, 
placenta
SLC01A2 SLC01A2
OATP1A2,
OATPA Brain
SLC02B1 SLC02B1 OATPB Intestine, liver, kidney, brain
SLC01B1 SLC01B1
OATP1B1,
OATPC Liver
SLC01B3 SLC01B3
OATP1B3,
OATP8 Liver
SLC10A1 SLC10A1 NTCP Liver, pancreas
SLC15A1 SLC15A1 PEPT1 Intestine, kidney
SLC15A2 SLC15A2 PEPT2 Kidney
SLC22A1 SLC22A1 OCT1 Liver
SLC22A2 SLC22A2 OCT2 Kidney, brain
SLC22A3 SLC22A3 OCT3
Skeletal muscle, liver, 
placenta, kidney, heart
SLC22A6 SLC22A6 OAT1 Kidney, brain
SLC22A7 SLC22A7 OAT2 Liver, kidney
SLC22A8 SLC22A8 OAT3 Kidney, brain
Table 1.3. Major drug transporters expressed in humans.
A possible misunderstanding when discussing drug transporters is the assumption 
that efflux transporters are associated with removal of drug from the body and influx 
transporters with the accumulation/maintenance of drug in the body. This 
relationship is not always correct, as the effect of a transporter on drug disposition 
will depend on which cellular' surface the transporter is located. As an example, 
enterocyte cells in the small intestine provide a controlling barrier for drug 
absorption from the gut (Figure 1.8). Efflux transporters on the apical (lumen-facing)
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surface (ABCB1, ABCC2, ABCC4, and ABCG2) decrease substrate absorption from 
the lumen, whereas efflux transporters on the basolateral (blood-facing) surface 
(ABCC1, ABCC3 and ABCC5) increase substrate absorption. Similarly, influx 
transporters on the apical (SLC01A2, SLC02B1, SLC22A3) and basolateral 
(SLC22A1, SLC22A2, SLC22A7) surface work to increase and decrease luminal 
substrate absorption, respectively (Kis et ai, 2010a).
ABCBl
ABCC1
ABCC2
1 (D ■“ ABCC3
ABCC4
ABCC5
ABCG2
M SLC22A1
SLC01A2
SLC22A2
SLC02B1
SLC22A7
SLC22A3
Figure 1.8. The expression and location of several drug-transporting proteins in 
enterocyte cells.
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It is increasingly accepted that drug transporters play a major role in the disposition 
of several antiretroviral drugs (Kis et ah, 2010a). The impact of drug transporters on 
raltegravir disposition is integral to the work in this thesis and the topic is covered in 
detail in the experimental Chapters 2, 3 and 4.
1.5.3 Drug interactions
Due to the life-long nature of HAART (Section 1.4.9) and the high likelihood of 
HIV-positive patients using drugs to treat co-morbidities, the amount and variety of 
drugs that a HIV-positive patient must take during their life is high. This increases 
the risk of the patient experiencing a drug interaction, some of which can be serious 
and even life-threatening.
A drug interaction is defined as an interaction between a drug and another co­
administered substance which alters the pharmacokinetic or pharmacodynamic 
characteristics of the drug. The drug can be described as the “perpetrator” (causes the 
interaction) or the “victim” (effected by the interaction), although interactions are 
often more complicated and both substances can affect each other.
The definition “drug interaction” is applied to interactions of the drug with another 
drug (drug-drug interaction), ingested food or liquid, or any other substance. The 
substance can interact directly (direct binding to the drug; displacing drug from 
plasma protein; etc) or indirectly (altering metabolism enzyme and transporter 
protein expression levels or activity; altering GI pH, fat content or emptying time; 
etc).
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Inhibition of drug-metabolising enzymes and drug transporters
Substances that can directly inhibit the activity of drug-metabolising enzymes and 
drug transporters are potentially capable of altering the PK. of substrates for these 
proteins. Inhibition is usually described as reversible or irreversible (Lin et al., 
1998). Reversible inhibition usually involves direct competition for the 
enzyme/transporter and does not normally damage the protein. Irreversible inhibition 
involves permanent or semi-permanent reduction in enzyme/protein activity and can 
result from non-competitive binding of inhibitor (binding at a location other than the 
enzyme/transporter active site). As an example, tariquidar is not a substrate of 
ABCB1 but is able to potently and irreversibly inhibit the ATPase activity of the 
transporter (Fox et al, 2007).
As discussed in Section 1.4.5, inhibition of drug metabolising enzymes can actually 
be used as a treatment strategy to increase concentrations of CYP3A4-metabolised 
drugs, such as the use of ritonavir in HAART to decrease the clearance rate of Pis 
(Merry et al, 1997). However, the usual goal in drug discovery is to avoid inhibiting 
major drug-metabolising enzymes and drug transporters and therefore reduce the 
chance of causing drug interactions.
Induction of drug-metabolising enzymes and drug transporters
Substances that can induce the expression level of drug-metabolising enzymes and 
drug transporters are potentially capable of altering the PK of substrates for these 
proteins. Expression of metabolism enzymes and drug transporters are regulated by
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nuclear receptors, ligand-activated transcription factors such as the pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR), which are important in 
the context of induction. As an example, the antibiotic rifampin is able to induce 
expression of CYP3A4 via activation of PXR (Li et al, 2006) and this can result in 
increased clearance of CYP3A4 substrates such as lopinavir (Decloedt et al, 2011), 
where rifampin treatment caused a 4.8-fold decrease in median plasma concentration.
The induction potential of drugs is often not detected during in vitro drug discovery 
as induction is “indirect” and often requires extended time periods to allow for 
protein expression. Furthermore, the correlation between in vitro induction data and 
in vivo reality is often not clear', with varying concentrations of drug in different 
tissues resulting in localised induction effects. For example, 10 pM nelfmavir 
induced ABCB1 mRNA 4-fold in isolated human hepatocytes (Dixit et al, 2007). 
However, ABCB1 protein induction was not detected in the liver of rats dosed with 
175 mg/kg/day nelfmavir after 14 days treatment (Huang et al, 2001), although 
expression of ABCB1 protein was increased 83% in rat intestine. The absence of 
ABCB1 induction in rat liver may be explained by lower nelfmavir concentrations 
being reached in the liver compared to in the lumen. In the same study, amprenavir 
450 mg/kg/day caused an increase in hepatic CYP3A4 of 151% but did not alter 
intestinal CYP3A4 protein levels.
Displacement of highly protein-bound drugs
Plasma protein binding is a major determinant and a potential limiting factor in the 
metabolism and excretion of highly protein-bound drugs (Boffito et al, 2003). Both
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drug metabolism and drug transport is prevented by drug-protein binding (Bow et al., 
2006). Any administered xenobiotic which inhibits the binding of a drug to plasma 
protein has the potential to increase the volume of distribution (redistribution of drug 
into tissues). However, several drug interactions originally believed to be controlled 
by plasma protein displacement, such as the increase in free phenytoin 
concentrations in plasma when co-administered with valproic acid (Tsanaclis et al, 
1984), are likely to also involve other mechanisms such as inhibition of drug 
metabolism (Rolan, 1994).
Alteration of gastrointestinal pH
The pH of the GI tract is an important factor in the absorption of many drugs, 
potentially altering drug release, solubility, chemical stability, charge state and/or 
intestinal permeability (Charman et al, 1997). Ionic drugs with a pKa within the 
physiological pH range are susceptible to alterations in GI pH because drugs with an 
ionic charge are less able to permeate the intestinal wall without active transport. 
Any drug or substance which alters the pH of the GI tract is therefore capable of 
causing drug interactions of susceptible drugs. As an example, the anti-HIV drug 
atazanavir is a weak base with a pKa of 4.3 (Kis et al, 2010b) and shows reduced 
solubility at higher pH. The gastric pH-reducing drugs omeprazole and famotidine 
decreased the bioavailability of atazanavir by 48% and 62%, respectively (Klein et 
al, 2008). The effect of pH on drug disposition is integral to the investigations in this 
thesis and is discussed in more detail in Chapters 5 and 6.
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The binding of drugs to metal ions
Metal ions are present in ingested food, liquids, multivitamin tablets and certain 
antacid treatments. There are known drug interactions where the presence of certain 
metal ions in the gastrointestinal tract alters the usual absorption profile of a drug 
(Lober et al, 1999) (Patel et al, 2011), presumably by binding of the metal ion to the 
ding and formation of a drug-metal complex which is less able to cross the intestinal 
epithelium. Binding of the metal ion to the drug can also reduce the activity of drugs 
and this interaction is characteristic of several antibiotics (Seedher et al, 2010). The 
effect of metal binding on drug disposition is integral to the investigations in this 
thesis and is discussed in more detail in Chapters 5 and 6.
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1-6 Raltegravir and other integrase inhibitors
Raltegravir (Isentress®), previously known as MK-0518, is an integrase inhibitor 
used in the treatment of HIV-infected patients (Okeke et al, 2011). The drug was 
given an accelerated release approval by the FDA in October 2007 to be used as part 
of HAART for treatment-experienced patients with multidrug resistant HIV-1. 
However, it is now also used in treatment-naive patients (Markowitz et al, 2009). 
Raltegravir is also effective at preventing HIV-2 viral replication (Smith et a/., 2011) 
and this allows it to be used as a part of treatment in HIV-2 infected patients.
1.6.1 Raltegravir chemistry and physicochemical properties
Raltegravir is formulated for HIV treatment as a potassium salt and has a molecular 
weight of 482.51 for the salt form and 444.42 for the free drug. The empirical 
formula of raltegravir potassium is C20H20FKN6O5 and the structural formula is 
shown in Figure 1.9. The full chemical name of raltegravir potassium is N-[(4- 
fluorophenyl)methyl] -1,6-dihydro-5-hydroxy-1 -methyl-2- [ 1 -methyl-1 - [ [(5 -methyl- 
l,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4~pyrimidinecarboxamide mono­
potassium salt.
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Figure 1.9. Structural formula of raltegravir potassium salt.
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The raltegravir potassium salt is an off-white powder with hydrophilic properties. 
The drug is soluble in water, somewhat soluble in methanol, very slightly soluble in 
acetonitrile and ethanol and insoluble in isopropanol. Raltegravir is moderately 
bound to human plasma at 83%. Outside of our investigations, the logP or logD of 
raltegravir has not been reported.
Further information on the physicochemical properties of raltegravir has been 
discovered during investigations for this thesis. These investigations are detailed in 
Chapter 5.
1.6.2 Raltegravir pharmacodynamics
Raltegravir inhibits the catalytic activity of HIV integrase by blocking the integration 
of HIV-1 cDNA into the host cell genome (Figure 1.5). Integration of viral cDNA is 
essential for HIV replication and the action of raltegravir effectively terminates the 
HIV life cycle. There is no known homologue of integrase expressed in humans, 
which reduces the risk of raltegravir-induced cellular toxicity.
Raltegravir can only bind to integrase once the enzyme is both bound to HIV DNA 
and has performed 3’ processing on the HIV DNA (Section 1.3.1) (Pommier et al, 
2005). 3’-processing of HIV DNA occurs inside the infected cell and this strongly 
suggests that intracellular permeation of raltegravir is a prerequisite for effective 
inhibition of integrase. Therefore, factors which dictate intracellular drug 
concentrations of raltegravir, such as cell membrane permeability and the actions of
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drug transporters, could play a crucial role in raltegravir pharmacokinetics and 
pharmacodynamics.
The mechanism of action of raltegravir is distinct from all other antiretrovirals and 
displays synergistic activity when combined in HAART treatment (Hicks el al, 
2009). Furthermore, an investigation into the effect of raltegravir on HIV decay 
kinetics (the speed at which HIV viral load decreases following initiation of therapy) 
showed raltegravir monotherapy reduced HIV viral load more rapidly compared with 
efavirenz monotherapy over the 10-day trial (Murray et al.t 2007). This suggests that 
raltegravir could be useful in initial therapy to treat patients with an extremely high 
HIV viral load.
The inhibitory action of raltegravir is observed at very low concentrations of drug. 
The IC5o of raltegravir in vitro was 2-7 nM (Temesgen et al, 2008) and the IC95 of 
raltegravir in cell cultures was 19 nM and 33 nM using 10% foetal bovine serum or 
50% human serum, respectively. Several completed or ongoing phase II and phase 
III trials have shown raltegravir to be a potent inhibitor of HIV-1 replication with an 
impressive safety profile (Grinsztejn et al, 2007) (Markowitz et al, 2007) 
(Steigbigel et al, 2008). Moreover, raltegravir has shown non-inferiority to the 
NNRTI efavirenz in combination therapy (Lennox et al, 2009).
As is seen with all other antiretroviral drugs, mutations in the HIV genome have been 
identified which confer resistance to raltegravir. The major mutation pathways 
G140S/Q148H and N155H confer around 8-fold and 14-fold raltegravir resistance, 
respectively, using purified integrase in vitro (Malet et al, 2008). Crossover
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resistance between raltegravir and NRTIs, NNRTIs and Pis have not been observed, 
although cross resistance with other integrase inhibitors in clinical development, such 
as elvitegravir, have been demonstrated (Hazuda, 2010).
1.6.3 Raltegravir metabolism and transport
The metabolism of raltegravir has been extensively studied in vitro (Kassahun et al., 
2007) (Iwamoto et al, 2008a). The main route of raltegravir metabolism is 
glucuronidation via uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1 and to 
a lesser extent by UGT1A9 and UGT1A3. All other UGT enzymes screened showed 
no contribution to raltegravir metabolism. Raltegravir was not a substrate or an 
inhibitor of cytochrome P450 enzymes 1A2, 2C9, 2D6, 2C19, 3A4, 2C8 and 2B6 
and did not induce CYP3A4 expression in primary human hepatocytes. These results 
suggest that drug-drug interactions between cytochrome P450 substrates/inhibitors 
and raltegravir is unlikely.
The oral bioavailability of raltegravir is estimated to be at least 32%, based on the 
fraction of drug excreted in the urine (Kassahun et al, 2007). PK studies in healthy 
volunteers showed that radioactively labelled raltegravir was excreted in the faeces 
(61.4% of total excreted drug) and the urine (38.6% total excreted drug). Raltegravir 
and its inactive glucuronide, named M2, constituted 28% and 72% of the dose 
excreted in urine, respectively. The dose excreted in faeces was wholly in the form of 
parent raltegravir.
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Interestingly, a study in rats showed that raltegravir is the only product excreted in 
the rat faeces, whereas a parallel study using bile duct-cannulated rats showed that 
the majority of dose in the bile was in the M2 glucuronide form (Kassahun et al.t 
2007), This suggests that the majority of the dose eliminated via the liver in rats is 
being glucuronidated but that this glucuronide undergoes subsequent hydrolysis in 
the gut to form the parent compound. This raises the possibility that raltegravir 
undergoes enterohepatic recirculation in rats but this has not been conclusively 
demonstrated in vivo.
Outside of the investigations in this project, there have been little published data on 
the interaction between raltegravir and drug transporters and only ABCB1 has been 
investigated in any detail. In a directional transport study conducted by Merck 
(unpublished data), raltegravir yielded efflux ratios (B-to-A / A-to-B) of 11.1, 7.1 
and 9.4 in LLC-PK1 cells expressing human, mouse and rat ABCB1, respectively. 
The non-expressing control LLC-PK1 cells showed no directional transport and the 
positive control drug verapamil gave efflux ratios in ABCBl-overexpressing cells of 
5.2 (human), 5.1 (mouse), and 4.1 (rat). These data indicate that raltegravir is a 
substrate of ABCB1 in the three species, although this was determined in only one 
experimental system and used an ABCBl-overexpressing cell line. Transport of 
raltegravir by ABCB1 at more physiological levels has not previously been 
determined but is investigated in this thesis.
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1-6.4 The effect of demographic factors and special 
populations on raltegravir PK
Demographic factors
There have been no confirmed relationships established between raltegravir PK and 
demographic factors sex, age, race or body mass index (Brainard et cil, 2011c; 
Iwamoto et alt 2008d). A significant decrease in raltegravir Ci2hr in females 
compared to males (24.7 ng/mL versus 58.0 ng/mL, p = 0.007) seen by Iwamoto et 
al has not been repeated in subsequent studies and was possibly due to the small 
female sample size of 6 subjects. In a study using HIV-infected patients, Siccardi et 
al (2012) found no significant difference in Qrough levels between females and males 
(median, 288 ng/mL versus 243 ng/mL, p = 0.45) and neither age (p = 0.78) or body 
weight (p = 0.36) were correlated to raltegravir concentrations (Siccardi et al, 
2012a).
Hepatic and renal impairment
The primary route of raltegravir elimination is glucuronidation via the liver 
(Kassahun et al., 2007) and the impact of moderate hepatic impairment on raltegravir 
PK has been evaluated (Iwamoto et al, 2009a). The effect of severe renal 
impairment on raltegravir PK was also assessed in the same study. There was no 
clinically significant effect of moderate hepatic impairment or severe renal 
impairment on raltegravir PK, meaning that the drug can be taken by these special 
populations without dose adjustments. However, raltegravir PK in subjects with 
severe hepatic impairment has not been investigated.
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UGT1A1 and UGT1A9 polymorphisms
Raltegravir is a UGT1A1 substrate and the primary route of raltegravir metabolism 
in humans is believed to be via this enzyme. There are known polymorphisms 
associated with UGT1A1 which reduce enzyme activity. Therefore, there is the 
potential that genetic polymorphisms in UGT1A1 could affect raltegravir PK or PD 
properties.
The impact of the homozygous UGT1A1*28 polymorphism (rs8175347) on single 
dose 400mg raltegravir PK was determined in healthy subjects (Wenning et al, 
2009b). When comparing homozygous UGT1A1*28 versus wild type UGT1A1*1, 
the geometric mean ratio (GMR) (90% Cl) of the AUC0^, Cmm and Ci2hr was 
1.41(0.96, 2.09), 1.40 (0.86, 2.28) and 1.91 (1.43, 2.55), respectively. A separate 
study assessed the impact of UGTIAI^S and UGT1A1*6 (rs4148323) 
polymorphisms on raltegravir PK in HIV-infected Japanese patients and found no 
association (Hirano et al, 2011).
Raltegravir is also metabolised by UGT1A9, although the rate of metabolism was 
less than half that seen using UGT1A1 in vitro (Kassahun et al, 2007). A clinical 
study assessed the impact of 102 single nucleotide polymorphisms (SNPs) on 
raltegravir PK in HIV patients, which included SNPs in UGT1A1 and UGT1A9 
(Arab-Alameddine et al, 2012). A SNP in UGT1A9 (rs72551330, UGT1A9*3), when 
present a homozygous mutation, showed a study-wide association with increased 
raltegravir bioavailability. However, the homozygous UGT1A9*3 mutation was only 
found in a single individual Rom the 219 HIV infected patients screened and
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statistical significance could not be confirmed. Furthermore, the rarity of this SNP 
reduces its usefulness in predicting raltegravir PK.
1.6.5 Raltegravir tissue distribution
The distribution of raltegravir into various tissues in the body is an important factor 
to understand, as insufficient concentrations of drug in HIV sanctuary sites such as 
cerebrospinal fluid, genital tract and the gut could lead to drug resistance. There have 
been studies determining tissue distribution of raltegravir, which are detailed below.
Penetration of raltegravir into the male genital tract has been assessed in 10 HIV- 
infected men (Barau el cil, 2010). Patients were taking raltegravir 400 mg twice- 
daily for 24 weeks before samples were taken. Five hours post-dose, median 
raltegravir concentrations in semen and blood plasma were 345 (range, 83-707) 
ng/mL and 206 (106-986) ng/mL, respectively, with a semen/blood plasma ratio of 
1.42 (0.5 to 6.7). This suggested that the raltegravir concentration in semen was 
generally comparable to the concentration in blood plasma, although variability in 
both compartments was high.
Another study using 10 HIV-infected men investigated the concentration of 
raltegravir in seminal fluid (Hasan et al, 2012). Patients were taking raltegravir 400 
mg twice-daily as part of HAART and a full concentration time curve was obtained 
in both blood plasma and semen. The GMR (CV%) semen/blood plasma ratio was 
3.19(41%).
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Penetration of raltegravir into the female genital tract has been assessed in 14 HIV- 
infected women using raltegravir 400 mg twice-daily as part of HAART (Clavel et 
al, 2011). Median raltegravir concentrations in cervicovaginal fluid and blood 
plasma were 235 (IQR, 135-775) ng/mL and 93 (48-167) ng/mL, respectively, with a 
cervicovaginal fluid/blood plasma ratio of 2.3 (1.4 to 4.1).
Penetration of raltegravir into the cerebrospinal fluid has been assessed in 16 HIV- 
infected individuals using raltegravir 400 mg twice-daily as part of HAART (Yilmaz 
et al, 2009). Median raltegravir concentrations in cerebrospinal fluid and blood 
plasma were 18.4 (range, <2-126.0) ng/mL and 448 (37-5180) ng/mL, respectively, 
with a cerebrospinal fluid/blood plasma ratio of 0.03 (0.01 to 0.61). Importantly, 
raltegravir cerebrospinal fluid concentrations were lower than the IC95 determined 
for raltegravir in vitro (15.9 ng/mL) (Iwamoto et al, 2008d) in around 50% of 
patients.
The concentration of raltegravir in maternal blood, cord blood and infant blood was 
determined in a study using 8 HIV-infected pregnant females during delivery (Clarke 
et al, 2012). Each female had received at least two weeks of raltegravir 400 mg 
twice-daily prior to delivery. Samples were taken one hour post-delivery for maternal 
and cord blood and 23 hours post-delivery for infant blood. The geometric mean 
(CV%) maternal, cord and infant raltegravir concentrations were 1270 (108%), 1284 
(70.5%) and 424 (76.7%), respectively. No adverse effects were noted in infants 
which could be attributed to raltegravir. These results suggest raltegravir could be a 
candidate for use during late pregnancy and during delivery, as the drug showed 
good placenta banier penetration and no obvious detrimental effects on the infant.
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The concentration of raltegravir in gut-associated lymphoid tissue (GALT) was 
determined in 14 healthy male volunteers given raltegravir 400 mg for seven days 
(Patterson et al, 2012). Analysis of PK data showed that raltegravir AUC was 99- 
fold higher in the terminal ileum compared to blood plasma. The authors suggested 
that raltegravir was concentrating in the GALT following drug absorption and 
therefore raltegravir could be beneficial for use in pre-exposure prophylaxis. 
However, the high drug concentrations taken with the terminal ileum samples could 
have been unabsorbed drug which had travelled through the intestine and further 
investigation is needed to confirm the hypothesis given by the author.
1.6.6 Raltegravir drug-drug interactions
A summary of clinical drug interaction studies investigating the impact of co­
administered drugs on raltegravir PK (Table 1.4) and the impact of raltegravir on co­
administered drugs (Table 1.5) is given.
There have been a number of studies undertaken to evaluate the PK interactions 
between raltegravir and co-administered drugs. Several of these studies have shown 
raltegravir metabolism and disposition to be largely unaffected. For example, 
boceprevir (da Silva et al, 2010), etravirine (Anderson et aL, 2008a), lopinavir (Rhame 
et al, 2008), darunavir (Anderson et al, 2008c) and rifabutin (Brainard et al, 2009) 
did not significantly alter raltegravir plasma concentrations. In addition, despite 
ritonavir being an inducer of both ABCB1 (Dixit et al, 2007) and UGT1A1 (Foisy et 
al, 2008), the drug did not cause a significant reduction in raltegravir plasma
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concentration (Iwamoto et al., 2008c). However, there are interactions with other co­
administered drugs that have a more marked effect on raltegravir disposition.
Raltegravir is a substrate for UGT1A1 and therefore co-administered compounds 
which alter UGT1A1 functionality have the potential to alter raltegravir PK. 
Atazanavir is an inhibitor of UGT1A1 (Zhang et al, 2005) and co-administration of 
atazanavir (400 mg once-daily) with raltegravir (100 mg single dose) resulted in an 
increase in raltegravir plasma AUC, Cmax and Crain of 72%, 53% and 95%, 
respectively (Iwamoto et al, 2008b). This interaction was also confirmed in a 
separate study (Zhu et al, 2009). Efavirenz and rifampin are inducers of UGT1A1 
expression (Hariparsad et al, 2004; Xie et al, 2003) and have been shown to 
decrease raltegravir plasma exposure (Iwamoto et al, 2008c; Wenning et al, 2009a).
Omeprazole (Iwamoto et al, 2009b) and famotidine (Rhame et al, 2009) are 
treatments used to increase gastric pH and both increased raltegravir exposure. 
However, Maalox antacid, which also increases gastric pH, caused a reduction in 
raltegravir Cnhr (Kiser et al, 2010). Therefore, it was not completely clear if 
increasing gastric pH was leading to an increase or decrease in raltegravir exposure. 
These interactions are discussed and investigated further in Chapter 5.
Several interactions affecting raltegravir exposure have no clear explanation. For 
example, fosamprenavir (Tuber et al, 2009), pravastatin (van Luin et al, 2010) and 
maraviroc (Andrews et al, 2010) all decreased raltegravir exposure and all are not 
known to induce UGT1A1. One intriguing interaction is that of tenofovir disoproxil 
lumarate (tenofovir DF) causing a moderate increase in raltegravir AUC and Cmax by
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49% and 64%, respectively (Wenning et al, 2008). Although the increase in 
raltegravir plasma concentration is unlikely to have any important clinical 
significance (no increase in toxicity is expected) the mechanism of the interaction 
was unexplained at the outset of this thesis. Interestingly, tenofovir is an anionic 
compound when charged and is therefore a substrate of organic anion uptake 
transporters SLC22A6 and SLC22A8 (Uwai et at, 2007) and this led to the 
investigations detailed in Chapter 4.
Raltegravir does not inhibit cytochrome P450 enzymes or induce CYP3A4 
expression, therefore the potential of raltegravir to alter another drug’s exposure is 
believed to be low. However, raltegravir has been shown to decrease the exposure of 
atazanavir (Iwamoto et al, 2008b), fosamprenavir (Luber et alt 2009), maraviroc 
(Andrews et al., 2010), and tenofovir (Wenning et al, 2008), and to increase the 
exposure of rilpivirine (Crauwels et al, 2012). The mechanisms controlling these 
interactions are not known.
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GMR (90% Cl) of raltegravir PK parameter 
values with/without co-administered drug
Co-administered 
drug/dose and 
schedule
Raltegravir 
dose and 
schedule
Overall 
effect on 
raltegravir AUC* Cmax ClZh Reference
Maalox antacid
30 ml single dose
400 mg single 
dose Decrease 0.96 (0.62-1.50) 1.53 (0.90-2.60) 0.33 (0.26-0.42)
(Kiser et at.,
2010)
Atazanavir 400 mg 
qd
100 mg single 
dose Increase 1.72 (1.47-2.02) 1.53 (.111-2.12) 1.95 (1.30-2.92)
(Iwamoto eta!., 
2008b)
Atazanavir 300 mg 
bid 400 mg bid Increase 1.54(1.14-2.08) 1.39 (0.99-1.96) 1.48 (1.08-2.02)
(Zhu et at.,
2010)
Atazanavir/ritonavir 
300/100 mg qd 400mg bid Increase 1.41 (1.12-1.78) 1.24 (0.87-1.77) 1.77 (1.39-2.25)
(Iwamoto etc/,, 
2008b)
Boceprevir800 mg 
tid
400 mg single 
dose No change 1.01 (0.85-1.20) 1.09 (0.89-1.33) ND
(da Silva etal., 
2010)
Darunavir/ritonavir 
600/100 mg bid 400 mg bid No change 0.71 (0.38-1.33) 0.67 (0.33-1.37) 1.38 (0.16-12.1)
(Anderson et 
at., 2008b)
Efavirenz 600 mg qd
400 mg single 
dose Decrease 0.64 (0.52-0.80) 0.64 (0.41-0.98) 0.79 (0.49-1.28)
(Iwamoto etal., 
2008c)
Etravirine 200 mg 
bid 400 mg bid No change 0.90 (0.68-1.18) 0.89 (0.68-1.15) 0.66 (0.34-1.26)
(Anderson et 
at., 2008a)
Famotidine 20 mg 
single doset 400 mg bid Increase 1.45 (1.09-1.93) 1.60(1.11-2.30) 1.06 (0.84-1.35)
(Rhame et at., 
2009}
Fosamprenavir
1400 mg qd 400 mg bid Decrease 0.63 (0.40-0.99) 0.72 (0.41-1.26) 0.62 (0.43-0.89)
(Luber etc?/.,
2009)
Lopinavir/ritonavir 
200/50 mg bid 400 mg bid No change 1.03 (0.64-1.64) 0.99 (0.56-1.76) 0.70 (0.53-091)
(Rhame et at., 
2008)
Maraviroc 300 mg 
bid 400 mg bid Decrease 0.63 (0.44-0.90) 0.67 (0.41-1.08) 0.72 (0.58-0.91)
(Andrews et at., 
2010)
Omeprazole 20 mg 
qd
400 mg single 
dose Increase 3.12 (2.13-4.56) 4.15 (2.82-6.10) 1.46(1.10-1.93)
(Iwamoto et at., 
2009b)
Pravastatin 40 mg 
qd 400 mg bid Decrease 1.13 (0.77-1.65) 1.31(0.81-2.13) 0.59 (0.39-0.88)
(van Luin et at., 
2010)
Rifabutin 300 mg qd 400 mg bid No change 1.19 (0.86-1.63) 1.39 (0.87-2.21) 0.80 (0.68-0.94)
(Brainard et at., 
2011b)
Rifampin 600 mg qd
400 mg single 
dose Decrease 0.60 (0.39-0.91) 0.62 (0.37-1.04) 0.39 (0.30-0.51)
(Wenning et at., 
2009a)
Rifampin 600 mg qd 800 mg bid Decrease 1.27 (0.94-1.71) 1.62 (1.12-2.33) 0.47 (0.36-0.61)
(Wenning et at., 
2009a)
Rilpivirine 25 mg 
qdt 400 mg bid Increase 1.09 (0.81-1.47) 1.10 (0.77-1.58) 1.27 (1.01-1.60)
(Crauwels etal., 
2012)
Ritonavir 100 mg 
bid
400 mg single 
dose No change 0.84 (0.70-1.01) 0.76 (0.55-1.04) 0.99 (0.70-1.40)
(Iwamoto etal., 
2008c)
Tenofovir 300 mg 
qd 400 mg bid Increase 1.49 (1.15-1.94) 1.64 (1.16-2.32) 1.03 (0.73-1.45)
(Wenning et at., 
2008)
Tipranavir/ritonavir 
500/200 mg bid 400 mg bid Decrease 0.76 (0.49-1.19) 0.82 (0.46-1.46) 0.45 (0.31-0.66)
(Hanley et at., 
2009)
Table 1.4. Effect of co-administered agents on raltegravir pharmacokinetics in 
healthy subjects (unless otherwise stated), qd = once-daily, bid - twice-daily, tid ~ 
three times-daily. * AUCo-mr for multiple dose raltegravir, AUCo-00 for single dose 
raltegravir. f HIV-infected patients used in the study.
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GMR (90% Cl) of co-administered drug PK 
parameter values with/without raltegravir
Co-administered 
drug/dose and 
schedule
Raltegravir 
dose and 
schedule
Overall effect
on co­
administered 
drug AUC* Onax Reference
Abacavir 600 mg qd+ 400 mg bid No change 1.03 (0.95-1.12) 1.06 (0.96-1.18) 0.83 (0.66-1.10)
(Jackson et ah, 
2009)
AtazanavirBOO mg 
bid 400 mg bid Decrease 0.83 (0.78-0.89) 0.89 (0.84-0.94) 0.71 (0.65-0.78)
(Iwamoto etah, 
2008b)
Etravirine 200 mg bid 400 mg bid No change 1.10(1.03-1.16) 1.04 (0.97-1.12) 1.17 (0.65-0.78)
(Anderson et 
ah, 2008a)
Fosamprenavir 1400 
mg bid 400 mg bid Decrease 0.64 (0.47-0.88) 0.73 (0.53-1.01) 0.57 (0.43-0.76)
(Luber etah,
2009)
Lamotrigine 100 mg 
single dose 400 mg bid No change 0.99 (0.96-1.01) 0.94 (0.89-0.99) ND
(van Luin etah, 
2009)
Lopinavir/ritonavir 
200/50 mg bid 400 mg bid No change 0.99 (0.87-1.12) 0.97 (0.87-1.08) 1.04 (0.73-1.46)
(Rhame etah, 
2008)
Maraviroc 300 mg bid 400 mg bid Decrease 0.86 (0.80-0.92) 0.80 (0.67-0.94) 0.90 (0.85-0.96)
(Andrews et ah, 
2010)
Methadone 40-60 mg 
qd 400 mg bid No change 1.00 (0.93-1.09) 1.00 (0.94-1.07) ND
(Anderson et 
ah, 2010)
Midazolam 2 mg 
single dose 400 mg bid No change 0.92 (0.82-1.03) 1.03 (0.87-1.22) ND
(Iwamoto etah, 
2008a)
Pravastatin 40 mg qd 400 mg bid No change 0.96 (0.83-1.11) 1.04 (0.85-1.26) ND
(van Luin etah, 
2010)
Rilpivirine 25 mg qdt 400 mg bid Increase 1.12(1.05-1.19) 1.12 (1.04-1.20) 1.03 (0.96-1.12)
(Crauwels et ah, 
2012)
Tenofovir 300 mg qd 400 mg bid Decrease 0.90 (0.82-0.99) 0.77 (0.69-0.85) 0.87 (0.74-1.02)
(Wenning etah, 
2008)
Table 1.5. Effect of raltegravir on co-administered drag pharmacokinetics in healthy 
subjects (unless otherwise stated), qd = once-daily, bid = twice-daily. * AUCo-mr for 
twice-daily dose drag, AUC0.24hr for once-daily dose drag, AUCo^ghr for lamotrigine 
and AUCo-oo for raltegravir single dose. J Ctrough is Ci2hr for twice-daily drags and 
C24hr for once-daily drags, f HIV-infected patients used in the study.
1.6.7 Other integrase inhibitors in deveiopment
Raltegravir is currently the only integrase inhibitor available for use in anti-HIV 
therapy. However, there are several integrase inhibitors in pre-clinical and clinical 
development which may become an important part of future HAART. Drags that
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inhibit the 35-processing activity of integrase, such as the styrylquinoline 
carboxamides (Langford et al, 2008), have been investigated. However, interest in 
3’-processing inhibitors has diminished following the success of the less toxic strand 
transfer inhibitors. Recent investigations have introduced a new class of integrase 
inhibitor which prevents the binding of LEDGF/p75, an important co-factor in the 
pre-integration complex (Cherepanov et al, 2003), to integrase (Christ et al, 2010). 
Initial efficacy data for LEDGF/p75-integrase binding inhibitors is promising, 
although these drugs are only in the early stages of development. The most 
developed and most promising of the new integrase inhibitors are based on the 
mechanism of action of raltegravir and are elvitegravir and dolutegravir.
Elvitegravir
Elvitegravir is a potent HIV integrase inhibitor currently in late-stage clinical 
development. Similarly to raltegravir, elvitegravir contains a P-hydroxy-ketone 
structural motif and shows specific inhibition of strand transfer (Shimura et al, 
2009). Despite having similar mechanisms of action and sharing certain elements of 
chemical structure, the physicochemical properties of elvitegravir are noticeably 
different from raltegravir. Elvitegravir is highly lipophilic (logD of 4.5 at pH 6.8) 
and is extremely highly bound to human plasma protein (99.4% bound).
The drug shows potent inhibition of HIV-1 (mean IC5o of 0.04-0.55 ng/mL) and 
HIV-2 (mean IC50 of 0.61-1.2 ng/mL) replication in vitro and this effect is 
synergistic when used in combination with other antiretroviral classes (Ledford et al, 
2007). There is significant cross-over in resistance mutations for elvitegravir and
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raltegravir (Van Wesenbeeck et al., 2011) which limits the use of elvitegravir in 
HIV-positive patients resistant to raltegravir.
The metabolism of elvitegravir and raltegravir are noticeably different. Elvitegravir 
is primarily metabolised by CYP3A4 and shows minor (less than 10%) metabolism 
by UGT1A1 (Ramanathan et al, 2007b). The extent of CYP3A4 metabolism is so 
great that it is necessary to co-administer the drug with ritonavir, in a similar 
procedm-e to that used with the HIV protease inhibitors (Section 1.4.5). The co­
administered ritonavir inhibits CYP3A4 and causes a reduction in elvitegravir 
clearance, resulting in greatly increased bioavailability and drug exposure. When co­
administered with 100 mg ritonavir, 50 mg elvitegravir once-daily caused a 1.99 log 
reduction in HIV-1 RNA load in HIV-infected HAART-naive patients over a ten-day 
treatment course, whereas 800 mg elvitegravir twice-daily taken without ritonavir 
caused a 1.91 log reduction (DeJesus et al, 2006).
A large-scale non-inferiority study in HIV-positive treatment-experienced patients 
confirmed that ritonavir-boosted elvitegravir had a similar efficacy and safety profile 
to raltegravir (Molina et al, 2012). Considering that elvitegravir is given once-daily 
and raltegravir is given twice-daily, the authors suggest that replacing raltegravir 
with elvitegravir in HA ART regimens may increase patient adherence. However, 
raltegravir does not require ritonavir boosting and therefore avoids the risk of 
ritonavir-related adverse drug reactions.
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Dohitegravir
Dolutegravir is a strand transfer inhibitor in late-stage clinical development. The 
drug has a similar mechanism of action to elvitegravir and raltegravir, shows a 
superior binding affinity for the integrase enzyme active site (Hightower et a/., 2011) 
and has displayed high anti-HIV activity in vitro (Kobayashi et a/., 2011) and in vivo 
(van Lunzen et al, 2012).
The major advantage of dolutegravir is that current treatment used in trials is based 
on a once-daily dosing regimen without the requirement for ritonavir boosting. Also, 
dolutegravir has demonstrated activity in vivo against HIV which is resistant to 
raltegravir (Song et al, 2010).
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1.7 Raltegravir pharmacokinetics issues requiring 
investigation
This thesis aimed to use in vitro techniques to investigate the factors involved in 
determination of raltegravir cellular' exposure, thus increasing our understanding of 
the mechanisms that control raltegravir PK in the body. The issues of interest 
discussed in this section are investigated in more detail throughout the thesis and 
therefore are given here only as a brief introduction.
1.7.1 High variability in raltegravir PK
Raltegravir plasma PK profiles are characterised by their high variability. Table 1.6 
shows a selection of trials using healthy, fasted subjects taking a single 400 mg 
raltegravir dose. In this table the Cmax, AUCo-oo and Qrough vary with a range of 5.4- 
fold, 3.9-fold and 4.1-fold, respectively. This variability is observed between patients 
and also within patients over multiple doses (Cattaneo et al, 2012). For example, a 
study determining raltegravir plasma concentrations obtained results with an inter­
patient coefficient of variation percentage (CV%) for AUC, Cmax and Chough of 160%, 
166% and 290%, respectively (Fayet Mello et al., 2011). Another study measuring 
raltegravir PK variability found Chough levels had an inter-patient CV% of 110% and 
an intra-patient CV% of 245%, suggesting in this case an even higher variability in 
the same patient compared to between patients (Siccardi et al, 2012a). The causes of 
such high variability in raltegravir PK are not fully understood but a reduction in 
variability was seen when raltegravir was taken with treatments which increased gut 
pH (Iwamoto et al, 2009b).
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Understanding what causes high variability in raltegravir PK has been a primary goal 
during the author’s investigations. The failure rate of raltegravir therapy in HIV- 
infected patients is low, although drug failure does occur. Furthermore, drug failure 
is not always associated with a genetic drug resistance development. Over half (141 
of 255) of HIV-infected patients who failed raltegravir therapy in a recent 
multicenter drug study had HIV with no detectable integrase resistance mutations 
(Geretti et al., 2012), and a smaller study found that 18% (2 of 11) of patients who 
failed raltegravir therapy had no evidence of HIV integrase mutations (da Silva et al, 
2010). High variability in raltegravir PK has led to difficulty in establishing a reliable 
pharmacokinetic-pharmacodynamic (PK-PD) relationship for raltegravir, it is 
important that investigations are undertaken so that this variability can be explained 
and appropriate clinical strategies can be developed.
Trial conditions Geometric mean PK data
Dose regimen Subject number Sex t-max (uM) AUC (uM/hr) ^trouEh (nM) Reference
400 mg single dose 12 Male 10.63 24.61 81.3
(Iwamoto et 
al., 2008d)
400 mg single dose 6 Male 2.25 10.78 338.7
(Wang et al., 
2011)
400 mg single dose 14 Mixed 2.88 11 80.6
(Iwamoto et 
al., 2009b)
400 mg single dose 12 Mixed 1.96 6.3 76.7
(Kiser et al., 
2010)
Table 1.6. Examples of raltegravir PK parameters from studies using healthy, fasted 
subjects.
1.7.2 Unexplained drug-drug interactions
Raltegravir is metabolised primarily by UGT1A1 (Kassahun et al, 2007) and the 
induction or inhibition of UGT1A1 is assumed to be the cause of certain drug-drug
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interactions affecting raltegravir PK. However, several interactions between 
raltegravir and concomitant drugs have been discovered which cannot be explained 
by the involvement of UGT1A1 (Section 1.6.6). Furthermore, it is not understood 
how raltegravir alters the exposure of certain co-administered drugs. A clearer 
understanding of the factors influencing raltegravir PK may help to explain these 
moderate drug interactions.
1.7.3 Raltegravir and drug transporters
Previous investigations have confirmed the route of metabolism of raltegravir 
(Section 1.6.3). However, the involvement of human drug transporters in raltegravir 
absorption, disposition and excretion had not been rigorously investigated at the 
outset of this thesis. An in-house bidirectional transport investigation by Merck 
suggested that raltegravir was substrate of the efflux transporter ABCB1, yielding 
efflux ratios of 11.1 in ABCB1-over-expressing LLC-PK1 cells (Section 1.6.3). 
However, human drug trials do not support this hypothesis. For example, ritonavir, a 
potent ABCB1 inhibitor, had only a minimal effect on raltegravir PK (Iwamoto et 
al, 2008c). Further investigations into the transport of raltegravir by ABCB1 are 
clearly justified. Also, the effects that influx transporters have on raltegravir 
disposition are unknown and may aid our understanding of raltegravir PK in patients. 
The impact of drug transporters on raltegravir disposition is a key area of 
investigation in this thesis and is explored further in Chapters 2, 3 and 4.
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1.7.4 The effects of food, metal cations and gastrointestinal 
pH on raltegravir exposure
It has become clear from clinical studies that raltegravir PK can be affected by food 
intake (Brainard et al., 2011a), pH-altering agents (Iwamoto et al., 2009b), and metal 
cation-containing products (Kiser et al, 2010) and these studies are reviewed in 
detail in Chapter 5. Environmental factors such as these are more likely than genetic 
factors to explain raltegravir intra-patient PK variability. The impact of pH and metal 
cations on raltegravir disposition are investigated further in Chapters 5 and 6.
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1.8 Aims of the thesis
Chapter 2 confirmed whether raltegravir is transported by the drug efflux transporter 
ABCB1 in vitro, and whether raltegravir is able to inhibit or induce ABCB1 activity. 
Cellular toxicity of raltegravir was also assessed.
Chapter 3 investigated the ability of influx transporters to transport raltegravir and 
other anti-HIV drugs in vitro using the Xenopus laevis oocyte expression system. The 
ability of raltegravir and other anti-HIV drugs to inhibit influx transporter SLC22A1 
was also assessed.
Chapter 4 investigated in more detail the transport of raltegravir by influx transporter 
SLC22A6. Kinetic parameters Km and Vmax were also determined. The competition 
between tenofovir and raltegravir for SLC22A6 transport was assessed and results 
were used to calculate IC50 values.
Chapter 5 moved away from the impact of drug transporters and investigated the 
effect of pH on raltegravir lipophilicity, solubility and cell membrane permeation. 
Raltegravir pKa was also determined. The effect of metal cations on raltegravir 
Caco-2 cell membrane permeation was also assessed.
Chapter 6 used the PK simulation modelling program Simcyp to help explain and 
predict the effects of food, pH-altering agents and divalent metal cation-containing 
products on raltegravir PK. The in vitro data from Chapter 5 was added to this 
model.
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Chapter 7 briefly summarised the investigations in Chapters 2 to 6 and discussed 
how the data have improved our understanding of the factors and mechanisms which 
determine raltegravir cellular exposure. Suggestions are given about how these 
investigations can be continued.
73
Chapter 2
Interactions between raltegravir and drug efflux 
transporter ABCB1
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2.1 INTRODUCTION
The US Food and Drug Administration (FDA) request that potential commercial 
drugs are screened for their substrate affinity and inhibitory potential of drug efflux 
transporter ABCB1 (Huang et al, 2007). ABCB1 is a cell membrane-bound ATP- 
binding cassette (ABC) transporter which utilizes energy (from ATP hydrolysis) to 
actively transport xenobiotics out of the cell (Leschziner et al., 2007). The protein 
contains two connected six-transmembrane-spanning domains and two nucleotide 
binding domains. ATP is dephosphorylated to produce energy, allowing for the 
active transport of substrates from the cytoplasm, through the cell membrane and into 
the extracellular' domain (Figure 2.1). In doing this, ABCB1 can influence xenobiotic 
absorption through the gut and aid xenobiotic elimination via the liver and kidney, 
potentially averting xenobiotic-induced cellular toxicity. This protective function of 
ABCB1 may have originated as a physiological defence mechanism against 
xenotoxins of natural origin from plants, fungi and bacteria (Ames et al, 1990).
ABCB1 is expressed in several pharmacologically-important tissues which determine 
drug ADME properties, such as the mucosal surface epithelial cells in the intestine 
(Lindell et al, 2003), the biliary canalicular surface of hepatocytes in the liver 
(Thiebaut et al, 1987) and the brush border membrane of renal proximal tubular- 
cells in the kidney (Ernest et al, 1997). Generally, drug elimination is aided by the 
activity of ABCB1, as drug is prevented from being absorbed in the gut or removed 
from the blood into bile and/or urine for excretion.
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Figure 2.1. Xenobiotic efflux transporter ABCB1.
Importantly, ABCB1 is expressed in several tissues believed to be important 
sanctuary sites for HIV replication, such as the placenta trophoblast (Nakamura et 
al., 1997), the endothelial cells in the testes (Cordon-Cardo et al, 1989) and the 
luminal membrane of capilliary endothelial cells in the brain (Schinkel, 1999). It is 
hypothesised that the action of ABCB1 prevents certain antiretroviral drugs from 
sufficiently penetrating these tissues (Choo et al, 2000), therefore providing a 
location where HIV is able to replicate and develop drug resistance.
ABCB1 is also expressed at varying levels in CD4+ T-cells and 
monocytes/macrophages (Drach et al, 1992), both of which are viral targets for HIV 
(Fauci et al, 1998) and are therefore important targets for antiretroviral drugs.
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Antiretroviral drugs (with the exception of enfuvirtide and maraviroc) require 
intracellular access to their targets to elicit their inhibitory effects (Khoo et at., 2002) 
and low intracellular drug concentrations in these cells may lead to incomplete viral 
suppression and subsequent resistance development by HIV (Jones et ah, 2001).
ABCB1 is believed to play a key role in the disposition and drug interaction profiles 
of many antiretroviral compounds. ABCB1 is able to transport the Pis saquinavir 
(Janneh et ah, 2005), ritonavir (Kim et ah, 1998), indinavir (Lee et ah, 1998), 
nelflnavir (Choo et ah, 2000), amprenavir (Choo et ah, 2000), lopinavir (Janneh et 
ah, 2007), atazanavir (Bousquet et ah, 2008), tipranavir (Orman et ah, 2008) and 
darunavir (Kwan et ah, 2009) in vitro. Lower intracellular accumulation of protease 
inhibitors has been seen in peripheral blood mononuclear cells (PBMCs) with higher 
levels of ABCB1 expression (Meaden et ah, 2002). As a drug class, the Pis show 
varying levels of inhibition and induction of ABCB1, with the most potent inhibitor 
being ritonavir (Sankatsing et ah, 2004). The NNRTIs efavirenz, nevirapine, 
delavirdine and etravirine are not substrates for ABCB1 in vitro (Janneh et ah, 2009; 
Scholler-Gyure et ah, 2009; Stormer et at, 2002) but efavirenz, nevirapine and 
delavirdine appear to cause varying levels of inhibition (Storch et ah, 2007) and 
induction (Stormer et ah, 2002; Weiss et ah, 2008) of ABCB1 in vitro. Generally, 
NRTIs are not known to be potent ABCB1 substrates, inhibitors (Storch et ah, 2007) 
or inducers (Weiss et ah, 2008), although abacavir (Shaik et ah, 2007) and the 
prodrug tenofovir disoproxil fumarate (van Gelder et ah, 2002) appeal' to be ABCB1 
substrates in vitro. The CCR5 receptor antagonist maraviroc is also transported by 
ABCB1 in vitro (Zembruski et al., 2011).
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The interactions between ABCB1 and HIV integrase inhibitors do not appear to be as 
uniform as with other antiretroviral classes (generally. Pis are ABCB1 substrates, 
NNRTIs are not, etc) and investigations detailing these interactions are still ongoing. 
The integrase inhibitor elvitegravir has been determined as a substrate of ABCB1 
and an inhibitor of ABCB1 and ABCG2 in vitro (Zembruski el al, 2011). 
Elvitegravir has also been shown to induce the production of mRNA coding for 
ABCB1 as well as mRNA for ABCC3, ABCG2, influx transporter SLC01B1 and 
metabolism enzymes CYP3A4 and CYP2B6 in LSI80 cells in vitro (Zembruski et 
al, 2011). It is unclear whether ABCB1 plays an important role in elvitegravir 
disposition in vivo. The interactions between ABCB1 and dolutegravir have not been 
published.
Previous review papers have claimed that raltegravir is an ABCB1 substrate 
(Cocohoba et al, 2008), referencing ultimately to the drug package insert. However, 
to the author’s knowledge no published work had described an investigation of 
raltegravir transport by ABCB1 prior to the work published from this thesis.
One study showed that several lead-compound strand transfer inhibitors were able to 
inhibit ABCB1 activity and induce ABCB1 protein expression in vitro> although 
raltegravir was not tested (Cianfriglia et al, 2007). Nine quinolonyl diketo acid 
derivatives were found to inhibit ABCB 1-mediated doxorubicin efflux from KB-V1 
MDR cells and to induce ABCB1 protein expression in CEM cells, evaluated by the 
modulation of anti-ABCBl UIC2 monoclonal antibody binding. The chemical 
structures of the quinolonyl diketo acid derivatives were not provided, although both 
these compounds and raltegravir share the same mechanism of action by preventing
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HIV integrase strand transfer. Therefore, it is possible that raltegravir shares the 
same “off-target” effects as the quinolonyl diketo acid derivatives and is able to 
inhibit and/or induce ABCB1.
The work in this chapter investigated the extent of raltegravir transport by ABCB1 in 
vitro in T-lymphoblastoid and gut cell lines and ex vivo in PBMCs. A cellular 
toxicity assay was utilized to select non-cytotoxic concentrations of raltegravir for 
use in these experiments. Additionally, ABCB1-mediated transport of rilpivirine, an 
NNRTI which has recently been licensed for use in HAART, has not been fully 
investigated. Therefore, rilpivirine was also investigated in this study.
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2.2 METHODS
2.2.1 Materials
CEM and CEMvblioo cells were donated by Ross Davey, Bill Walsh Cancer 
Research Laboratories (St* Leonards^ Australia). Caco-2 cells were purchased from 
the European Collection of Cell Cultures (Salisbury, UK). CellFix was purchased 
from Becton Dickinson (Oxford, UK). UIC2 (anti-ABCBl) antibody was purchased 
from Immunotech (Marseilles, France). IgG2a and IgGl negative control antibodies 
and goat anti-mouse IgG2a:RPE were purchased from Serotech Ltd. (Oxford, UK). 
QCLR-1 (anti-MRPl) antibody was purchased from Merck (New Jersey, USA). 
Goat anti-mouse IgG:FITC was purchased from Sigma (Poole, UK). [3H]Raltegravir 
(specific activity = 32.85 Ci/mmol) and non-radiolabeled raltegravir sodium salt 
were gifts from Merck (New Jersey, USA). [3H]Digoxin (specific activity = 0.039 
Ci/mmol) was purchased from Perkin Elmer (Massachusetts, USA). [3H]Saquinavir 
(specific activity = 1 Ci/mmol) and [3H]lopinavir (specific activity, 5 Ci/mmol) were 
purchased from Moravek Biochemicals (California, USA). [14C]Mannitol was 
purchased from American Radiolabelled Chemicals (Missouri, USA). Saquinavir 
was a gift from Roche (Sussex, UK). [3H]Rilpivirine (specific activity = 20 
mCi/mmol) and non-radiolabelled rilpivirine were gifts from Tibotec (Mechelen, 
Belgium). Lopinavir was a gift from Abbott (Illinois, USA). Tariquidar (XR9576) 
was purchased from Xenova (Sloane, UK). Ficoll-Paque PLUS was purchased from 
GE Healthcare (Buckinghamshire, UK). Ultima Gold scintillation fluid was 
pm*chased from Perkin Elmer (Boston, USA). All other drugs and reagents were 
obtained from Sigma (Poole, UK).
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2.2.2 Cell culture
2.2.2.1 Culture of CEM and CEMvblioo T-cells
CEM and CEMvblioo cells were maintained in cell culture medium (Roswell Park 
Memorial Institute medium (RPMI), 10% [vol/vol] PCS) prior to the experiment in a 
CO2 incubator (37 °C, 5% CO2). CEM cells are a wild type T-lymphoblastoid cell 
line. CEMvblioo cells are CEM cells which have increased ABCB1 expression. All 
cell culture procedures were performed in a sterile environment.
2.2.2.2 Troatmont of CEM and CEMvblioo Is
High expression of ABCB1 in CEMvblioo was maintained by incubating cells with 
100 ng/mL vinblastine (RPMI, 10% [vol/vol] PCS) for 72 hours (37 °C, 5% C02). 
Vinblastine is toxic to CEM cells and is also a substrate for ABCB1, therefore 
incubation of cells with vinblastine leads to the selection of cells with higher ABCB1 
expression. This treatment was repeated every eight weeks to maintain high ABCB1 
expression.
2.2.2.3 Freezing and thawing of CEM and CEMvblioo cell stocks
CEM and CEMvblioo cells were maintained in cell culture medium (RPMI, 10% 
[vol/vol] PCS) prior to establishing cryopreserved cell stocks. Cells were added to a 
50mL skirted tube and centrifuged (800 g, 4°C, 5 minutes). Supernatant fraction was 
replaced with cell freezing solution (RPMI, 10% [vol/vol] PCS, 10% [vol/vol]
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DMSO) to achieve a final cell density of 5 x 106 cells/mL. After gentle mixing, cell 
solutions were aliquoted into ice-cold cryovials and placed in a minus 20°C freezer 
for two hours. Following this, vials were transferred to a sealed styrofoam box (to 
avoid lysis associated with rapid freezing), placed in a minus 80°C freezer and left 
overnight. On the following morning, cells were transferred to a storage box in the 
minus 80°C freezer until required.
When removed from the minus 80°C freezer, cells were rapidly thawed by hand and 
added to 50 mL cell culture medium (RPMI, 10% [vol/vol] FCS) and centrifuged 
(800 g, 4°C, 5 minutes). Supernatant fraction was removed, cells were resuspended 
in fresh cell culture medium (RPMI, 10% [vol/vol] FCS) and used to begin a fresh 
cell culture.
2.2.2A Culture of Caco-2 cells
Caco-2 cells are human epithelial colorectal adenocarcinoma cells and are widely 
utilised in cell culture to represent the enterocyte cells of the small intestine. Cells 
were maintained in cell culture medium (Dulbecco's Modified Eagle Medium 
(DMEM), 15% [vol/vol] FCS) prior to the experiment. Once a cell confluence level 
of 70-80% was reached, Caco-2 cells were washed three times with Hank’s Balanced 
Salt Solution (HBSS, 37°C) and incubated with trypsin-EDTA solution (37°C, 5 
minutes). Flasks were gently tapped to remove Caco-2 cells and cell culture medium 
was added to neutralise the trypsin (DMEM, 15% [vol/vol] FCS). Cells were added 
to a 50mL skirted tube and centrifuged (800 g, 4°C, 5 minutes). Supernatant fraction 
was removed and replaced with fresh cell culture medium (DMEM, 15% [vol/vol]
84
FCS) to a final density of 5 x 105 cells/mL. Cells were seeded into new culture flasks 
at a density of 1 x 105 cells/cm2.
Cells were purchased at passage 18 and used to create frozen stocks (Section 
2.2.2.5). All cell culture procedures were performed in a sterile environment and all 
Caco-2 cells used in experiments were between passage numbers 20 to 30.
2.2.2.S Freezing and thawing of Caco-2 ceil stocks
Caco-2 cells were maintained in cell culture medium (DMEM, 15% [vol/vol] FCS) 
prior to the creation of frozen cell stocks. Once a cell confluence level of 70-80% 
was reached, Caco-2 cells were washed three times with BBSS (37°C) and incubated 
with trypsin-EDTA solution (37°C, 5 minutes). The flasks were gently tapped to 
remove Caco-2 cells and cell culture medium was added to neutralise the trypsin 
(DMEM, 15% [vol/vol] FCS). Cells were added to a 50 mL skirted tube and 
centrifuged (800 g, 4°C, 5 minutes). Supernatant fraction was replaced with Caco-2 
cell freezing solution (DMEM, 15% [vol/vol] FCS, 10% [vol/vol] DMSO) to achieve 
a final cell density of 5 x 106 cells/mL. After gentle mixing, cell solutions were 
aliquoted into ice-cold cryovials and placed in a minus 20°C freezer for two hours. 
Following this, vials were transferred to a sealed styrofoam box to avoid rapid 
freezing of cells, placed in a minus 80°C freezer and left overnight. On the following 
morning, cells were transferred to a storage box in the minus 80°C freezer until 
required.
85
When removed from the minus 80°C freezer, cells were rapidly thawed by hand and 
added to 50 mL cell culture medium (DMEM, 15% [vol/vol] PCS) and centrifuged 
(800 g, 4°C, 5 minutes). Supernatant fraction was discarded, cells were resuspended 
in fresh cell culture medium (DMEM, 15% [vol/vol] PCS) and used to begin a fresh 
Caco-2 cell culture.
2,2.3 Detection of ABCB1 and ABCC1 expression in OEM and 
CEMvblwo cells
CEM and CEMvblioo cells were diluted in 1:10 Cell Fix and incubated (1 x 106 
cells/mL, 30 minutes, 4°C). Cells were dispensed into vials (1 mL, 1 x 106 cells/mL, 
n = 2 replicates for each cell line) and centrifuged (800 g, 22°C, 5 minutes).
Following centrifugation, supernatant fraction was discarded and 1 mL 1 x PBS was 
added to each well. For ABCB1 detection, cells were centrifuged (800 g, 22°C, 5 
minutes), supernatant fraction was discarded and cells were resuspended in lOOpL 
primary ABCB1 antibody UIC2 or 100 pL isotype control IgG2a (2.5 pg/mL 
antibody dilution in 1 x PBS) and incubated in darkness (60 minutes, 22°C). For 
ABCC1 detection, cells were centrifuged (800 g, 22°C, 5 minutes), supernatant 
fraction was discarded and cells were resuspended in 100 pL primary ABCC1 
antibody QCLR-1 or 100 pL isotype control IgGl (2.5pg/mL antibody dilution in 
IxPBS) and incubated in darkness (60 minutes, 22°C). Cells were washed three 
times with 1 mL 1 x PBS and centrifuged (800 g, 22°C, 5 minutes). Supernatant 
fraction was discarded and cells were resuspended in 100 pL secondary antibody 
(2.5 pg/mL antibody dilution in 1 x PBS) and incubated in darkness (60 minutes, 
22°C). Cells were washed three times with 1 mL 1 x PBS and centrifuged (800 g,
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22°C, 5 minutes). A volume of 100 |uL 1:10 Cell Fix was added to each vial and the 
contents transferred to separate FACS tubes for analysis using a Coulter Epics XL- 
MCL flow cytometer. Data are presented as relative fluorescence units ± SD (RFU, 
median fluorescence minus that of the isotype control, n = 2).
2.2.4 Evaluation of the toxicity of raltegravir in Caco-2 and 
CEM cells
The cellular’ toxicity of raltegravir was determinate using the MTT assay, with 
modifications (Mosmann, 1983). CEM and Caco2 cells (100 pL, 2 x 105 cells/mL) 
were incubated in a 96-well Nunc flat-bottom plate (37°C, 5% CO2, 120 hour's) with 
0, 0.01, 0.1, 1, 10 and 100 pM raltegravir. To validate the study, the cytotoxic 
control compounds epimbicin and vinblastine were incubated (0, 0.1, 1, 10, 100 pM) 
with CEM and Caco-2 cells, respectively. The solvent vehicle used to dissolve the 
drugs was sterile water (1% [vol/vol] final concentration) and control cells were 
incubated with 1% sterile water to act as drug-free controls.
Following incubation, plates were centrifuged (800 g, 5 minutes, 22°C), the 
supernatant fraction discarded and replaced with a 3-(4,5-dimethylthiazol-2-Yl)-2,5- 
diphenyltetrazolium bromide (MTT) solution (1 mg/mL MTT, 100 pL, HESS). 
Plates were wrapped in metal foil and incubated (37°C, 5% CO2, 2 hour’s).
Following incubation, cell lysis buffer (50% [vol/vol] dimethylformamide in distilled 
water, 20% [wt/vol] SDS) was added to wells and plates were incubated on a 
mechanical shaker (60 rpm, 22°C, 2 hours) to allow the cells to lyse. Plates were 
loaded into a GENios Microplate Reader (TECAN®) and absorbance at 570 nm was
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determined. Data are expressed as percentage cell viability compared to vehicle 
control cells (n = 6 experimental replicates) ± SD. These data were used to determine 
the IC50 (concentration of drug needed to reduce absorbance by half) of raltegravir 
and the control drugs using Graphpad Prism 5.
2.2.5 Evaluation of the effects of tariquidar on raltegravir, 
saquinavir, lopinavir and rilpivirine accumulation in CEM and 
CEMvblioo cells
CEM and CEMvblioo cells of a constant cell density (1 mL, 2.5 x 106 cells/mL) were 
incubated (37°C, 5% CO2) for 30 minutes in cell culture medium (RPMI, 10% 
[vol/vol] PCS) containing either [3H]raltegravir (1 pM, 0.2 pCi/mL), [3H]saquanavir 
(1 pM, 0.2 pCi/mL), [3H]lopinavir (1 pM, 0.5 pCi/mL) or [3H]rilpivirine (25 pM, 
0.5 pCi/mL). A separate incubation was undertaken where CEMvblioo cells were 
preincubated prior to the substrate addition in cell culture medium containing the 
potent non-competitive ABCB1 inhibitor, tariquidar (RPMI, 10% [wt/vol] ECS, 300 
nM tariquidar', 30 minutes). Tariquidar was also included during the 30 minute 
substrate incubation. Following incubation, cells were centrifuged (800 g, 1°C, 1 
minute), 100 pL supernatant fraction aliquots were taken, added to scintillation vials 
and used to calculate extracellular drug concentrations. The remaining supernatant 
fraction was discarded and cells were washed with ice-cold HBSS and centrifuged 
(800 g, 1°C, 1 minute). This HBSS wash was repeated a total of three times, after 
which the HBSS was discarded and 100 pL tap water was added to lyse the cells. 
Cells were vortexed for five minutes and samples were added to scintillation vials. 
Four millilitres of scintillation fluid was added to scintillation vials, which were then 
loaded into a liquid scintillation analyzer (TRI-CARB®). Using supernatant fraction
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and intracellular radioactivity readings, cellular accumulation ratios (CAR; ratio of 
drug concentration in the cell pellet compared with drug concentration in the 
supernatant fraction ± SD, assuming 1 pL volume per cell) were calculated for drugs 
in each cell line.
2.2.6 The effect of tariquidar on the bidirectional transport of 
raltegravir and digoxin using a Caco-2 monolayer
Caco-2 monolayer experiments were performed as previously described (Hubatsch et 
al, 2007), with modifications. Figure 2.2 shows the layout of a cell monolayer 
grown on a polycarbonate transwell. When confluent, Caco-2 cells were removed 
from cell culture flasks (Section 2.2.2.4) and seeded onto polycarbonate membrane 
transwells at a density of 5 X 105 cells/cm2 (DMEM, 15% [vol/vol] FCS) and 
incubated (37°C, 5% CO2) for 24 hours. Following this incubation, media was 
replaced to remove dead cells and to prevent the formation of multiple layers of cells 
settling on the filter. Media was then changed every two to three days and plates 
were used in experiments after a total of 21 days from initial seeding. Monolayer 
integrity was checked using a MillicellERS instrument (Millipore) to determine the 
trans-epithelial electrical resistance (TEER) across the monolayer. A TEER of more 
than 600 gQ was deemed acceptable.
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Figure 2.2. An experimental set-up used in bidirectional drug transport assays. A 
Caco-2 cell monolayer is grown on a semi-permeable polycarbonate filter over 21 
days and drug permeability through the monolayer is determined in both directions.
On the day of the experiment, the TEER was assessed and the media in each plate 
was replaced with warm transport buffer (HBSS, 25 mM HEPES, 0.1% [wt/vol] 
bovine serum albumin, pH 7) and allowed to equilibrate (37°C, 30 minutes). For 
inhibition studies this transport buffer contained tariquidar (300 nM). The transport 
buffer in the apical (for apical-to-basolateral (A-to-B) transport) and basolateral (for 
basolateral-to-apical (B-to-A) transport) chambers was replaced with transport buffer 
containing either the test drug [3H]raltegravir or the control ABCB1 substrate 
[3H]digoxin (1 pM, 0.33 pCi/mL) with or without 300 nM tariquidar. Samples (50 
pL) were taken from the receiver compartment at 0, 30, 60, 90, 120 and 180 minutes 
and replaced with an equal volume of transport buffer. Samples were analysed using 
a liquid scintillation counter (TRI-CARB&). Data were used to determine apparent 
permeability (Papp, cm/s) for each direction and efflux ratio (ratio of basolateral to 
apical Papp compared with apical to basolateral Papp). Papp was calculated using the 
following equation as described previously (Elsby et al., 2008):
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Papp X HT6 = fdO / dtt x V
A x Co
dQ / dt is the change in drug concentration in the receiver chamber over time (nM/s); 
V is the volume in the receiver compartment (mL); A is the total surface area of the 
transwell membrane (cm2); Co is the initial drug concentration in the donor 
compartment (nM); and Papp is the apparent permeability (xlO'6 cm/s).
2.2.7 Isolation of peripheral blood mononuclear cells from 
human blood and the influence ofABCBI inhibition
Venous blood samples (60 mL) were obtained from healthy volunteers via 
venipuncture and mixed in heparin-containing blood sample tubes. Blood (10 mL) 
was carefully layered onto Ficoll reagent (5 mL) and centrifuged (800 g, 30 minutes, 
4°C, no brake on deceleration). Following centrifugation, plasma was discarded and 
the PBMC layer was carefully transferred to a sterile 50 mL skirted tube using a 
sterile plastic pipette. HBSS (25 mL) was added to PBMCs and tubes were 
centrifuged (800 g, 5 minutes, 4°C). Supernatant fraction was discarded and the wash 
procedure was repeated. PBMCs were resuspended in HBSS, ensuring that different 
patient samples were not mixed together. Cells were used immediately for cellular 
accumulation studies as described in Section 2.2.8.
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2.2.8 Accumulation of raltegravir in peripheral blood 
mononuclear cells
Accumulation of raltegravir in PBMCs was determined using the same method as 
used in Section 2.2.5, with slight modifications. Briefly, cells of a constant cell 
density (1 mL, 5 x 106 cells/mL) were incubated (37°C, 5% CO2) for 30 minutes in 
cell culture medium (RPMI, 10% [vol/vol] FCS) containing [3H]raltegravir (1 pM, 
0.2 p,Ci/mL). Separate incubations were undertaken where cells were preincubated 
prior to substrate addition with cell culture medium (10% [vol/vol] FCS) containing 
tariquidar (300 nM, 30 minutes). Tariquidar was again also included during the 30 
minute substrate incubation. Cells were washed and treated for analysis as described 
in Section 2.2.5. Using supernatant fraction and intracellular radioactivity readings, 
CARs were calculated for raltegravir as described in Section 2.2.5. Data are 
expressed as mean CAR (n = 4 biological replicates, n > 3 experimental replicates 
per biological replicate) ± SD.
2.2.9 Inhibition of ABC B1 by raltegravir, verapamil and 
tariquidar using CEM and CEMVBlioo cells
CEM and CEMvblioo cells of a constant cell density (1 mL, 2.5 x 106 cells/mL) were 
incubated (37°C, 5% CO2) for 30 minutes in cell culture medium (RPMI, 10% 
[vol/vol] FCS) containing control ABCB1 substrate [3H]digoxin (1 pM, 0.2 
pCi/mL). Separate incubations were undertaken where CEMvblioo cells were 
preincubated for 30 minutes prior to the substrate addition with RPMI 1640 medium 
(10% [vol/vol] FCS) containing either raltegravir (2.5 pM, 25 pM, or 250 pM), the 
non-specific transport inhibitor, verapamil (30 pM), or the potent non-competitive
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ABCB1 inhibitor, tariquidar (300 nM). Again, inhibitors were also included during 
the 30 minutes of substrate incubation. Cells were washed and treated for analysis as 
described in Section 2.2.5. Using supernatant fraction and intracellular radioactivity 
readings, CARs were calculated for digoxin as described in Section 2.2.5.
2.2.10 Modulation of vinblastine toxicity in CEMVBlioo cells by 
raltegravir
OEM and CEMvblioo cells of a constant cell density (100 pL, 2 x 105 cells/mL) were 
incubated in 96-well Nunc flat-bottom plates (37°C, 5% CO2, 120 hours) with cell 
culture medium (RPMI, 10% [vol/vol] FCS) containing a concentration range from 0 
to 2000 ng/mL of the cytotoxic compound, vinblastine. Separate incubations were 
undertaken where CEMvblioo cells were incubated in 96-well Nunc flat-bottom 
plates (37°C, 5% CO2, 120 hours) containing 0 to 2000 ng/mL vinblastine with the 
addition of raltegravir (1 pM, 10 pM, or 100 pM). The solvent vehicle used to 
dissolve the drugs was sterile water (1% [vol/vol] final concentration) and control 
cells were incubated with 1% water to act as drug-free controls. An MTT assay was 
conducted using the treated cells and results were determined using Graphpad Prism 
essentially as described in Section 2.2.4.
2.2.11 Induction ofABCBI by raltegravir in Caco~2 
monolayers
Caco-2 monolayers were created as described in Section 2.2.6, with modifications. 
During the last three days of the 21-day monolayer maturation, a selection of cells 
were incubated (DMEM, 15% [vol/vol] FCS) containing raltegravir (20 pM).
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Monolayer integrity was checked using a MillicellERS instrument (Millipore) to 
determine the TEER across the monolayer, A TEER of more than 600 piQ was 
deemed acceptable. In addition to TEER, [14C]Mannitol, which is not permeable 
through a cell membrane, was also added to each well during the experiment to 
confirm monolayer integrity.
On the day of the experiment, the TEER was assessed and the media in each plate 
was replaced with warm transport buffer (HBSS, 25 mM HEPES, 0.1% [wt/vol] 
bovine serum albumin, pH 7) and allowed to equilibrate (37°C, 30 minutes). The 
transport buffer in the apical (for A-to-B transport) and basolateral (for B-to-A 
transport) chambers was replaced with transport buffer containing the ABCB1 
substrate, [3H]lopinavir (1 pM, 0.5 pCi/mL), and [14C]mannitol (3.6 pM, 0.2 
pCi/mL). Samples (50 pL) were taken from the receiver compartment at 0 and 60 
minutes. Samples were analysed using a liquid scintillation counter (TRI-CARB®). 
Data were used to determine apparent permeability (Papp, cm/s) and efflux ratio (ratio 
of basolateral to apical Papp compared with apical to basolateral Papp) as described in 
Section 2.2.6.
2.2.12 Statistical analysis
Data were analysed using SPSS 15.0 for Windows. All data were tested for normality 
using the Shapiro-Wilk test. An independent t test was used to determine the 
significance of normally distributed data and the Mann Whitney U test was used for 
all other data. A two-tailed p value of < 0.05 was accepted as being statistically 
significant.
94
2.3 RESULTS
2.3.1 ABCB1 and ABCC1 expression levels in CEM and 
CEMvbuoo cells
Expression of ABCB1 (Figure 2.3) and ABCC1 (Figure 2.4) in CEM and CEMvbuoo 
cells were determined using flow cytometry. Data are presented as relative 
fluorescence units (RFU) ± SD. ABCB1 expression was 158-fold higher in 
CEMvbuoo cells compared to CEM cells (RFU of 158.0 ± 3.0 versus 1.0 ± 0.3, p < 
0.05). No difference in ABCC1 expression was seen between CEMvbuoo and CEM 
cells (RFU of 2.0 ±0.1 versus 2.1 ± 0.2, p = 1.00).
p < 0.05
Figure 2.3. Expression of ABCB1 in CEM and CEMvbuoo cells. Data are expressed 
as RFU (median fluorescence minus that of the isotype control, n = 2 experimental 
replicates) ± SD.
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Figure 2.4. Expression of ABCC1 in CEM and CEMvblioo cells. Data are expressed 
as RED (median fluorescence minus that of the isotype control, n = 2 experimental 
replicates) ± SD.
2.3.2 Cytotoxicity of raltegravir in CEM and Caco-2 cells
Raltegravir showed no cellular toxicity in Caco-2 (Figure 2.5) and CEM (Figure 2.6) 
cells at any concentration tested. Cell viability (percentage mean viability compared 
to drug-free control cells ± SD, n = 6 experimental replicates) appeared unaffected 
by raltegravir concentrations up to 100 pM in Caco-2 (104.9% ± 12.7) and CEM 
(113.9% ± 13.0) cells. Due to the absence of any raltegravir-induced cytotoxicity at 
the screened concentration range, an IC50 value could not be calculated from the 
slope. The cytotoxic compounds vinblastine and epirubicin were used at up to 
lOOpM concentration to significantly reduce cell viability in Caco-2 (13.2% ± 5.9 at 
100 pM, p = 0.04) and CEM (9.5% ± 2.7 at 100 pM, p = 0.04) cells, respectively. 
The calculated IC50 values for vinblastine and epirubicin were both 1.0 pM. The
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vehicle used to deliver drugs was sterile water (1% final concentration) which had no 
significant affect on cell viability.
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Figure 2.5. Cellular toxicity of raltegravir and vinblastine in Caco-2 cells. Data 
expressed as cell viability (percentage mean viability compared to drug-free control 
cells, n=6 experimental replicates) ± SD.
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Figure 2.6. Cellular toxicity of raltegravir and epirubicin in CEM cells. Data 
expressed as cell viability (percentage mean viability compared to drug-free control 
cells, n=6 experimental replicates) ± SD.
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2.3.3 The effect of tariquidar on raltegravir, saquinavir, 
lopinavir and rilpivirine accumulation in CEM and CEMVBlioo 
cells
The cellular accumulation of raltegravir (Figure 2.7), saquinavir (Figure 2.8), 
lopinavir (Figure 2.9) and rilpivirine (Figure 2.10) were determined using CEM cells 
and ABCB1-overexpressing CEMvblioo cells. The effect of the ABCB1 inhibitor 
tariquidar on cellular accumulation in CEMvblioo cells was also investigated. Data 
are expressed as mean CAR ± SD. Raltegravir CAR was significantly lower in 
ABCB1-expressing CEMvblioo cells compared to CEM cells (1.4 ± 0.2 versus 2.1 ± 
0.2, p = 0.02). Raltegravir CAR in CEMvblioo cells was significantly increased when 
cells were incubated with tariquidar (2.0 ± 0.4, p = 0.042).
The protease inhibitors saquinavir and lopinavir are confirmed ABCB1 substrates 
and were used to validate the experiment. Saquinavir CAR was significantly lower in 
ABCBl-overexpressing CEMvblioo cells compared to CEM cells (19.0 ± 5.6 versus 
37.5 ± 2.1, p = 0.021). Saquinavir CAR in CEMvblioo cells was significantly 
increased when cells were incubated with tariquidar (37.8 ± 8.5, p = 0.021). 
Lopinavir CAR was significantly lower in ABCB1-expressing CEMvblioo cells 
compared to CEM cells (8.4 ±1.3 versus 15.1 ± 2.6, p =0.021). Lopinavir CAR in 
CEMvblioo cells was significantly increased when cells were incubated with 
tariquidar (17.8 ± 0.9, p = 0.034).
The NNRTI rilpivirine has recently been accepted for use in HAART. Transport of
rilpivirine by ABCB1 has not been fully investigated and therefore the drug was
investigated in this study. Rilpivirine CAR was unchanged in ABCBl-
overexpressing CEMvblioo cells compared to CEM cells (74.4 ± 9.2 versus 70.9 ±
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5.5, p = 0.56). Rilpivirine CAR in CEMvbuoo ce^s was unchanged when cells were 
incubated with tariquidar (72.1 ± 7.2, p = 0.72).
p = 0.02 p = 0.042
Figure 2.7. Raltegravir (1 pM) accumulation in CEM, CEMvbuoo, and CEMvbuoo 
cells treated with 300 nM tariquidar (TAR). Data are expressed as mean CAR (n = 4 
biological replicates, n = 3 experimental replicates per biological replicate) ± SD.
99
p = 0.021 p = 0.021
•8 40-
8 10-
Figure 2.8. Saquinavir (1 qM) accumulation in CEM, CEMvblioo, and CEMvblioo 
cells treated with 300 nM tariquidar (TAR). Data are expressed as mean CAR (n = 4 
biological replicates, n = 3 experimental replicates per biological replicate) ± SD.
p = 0.021 p = 0.034
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Figure 2.9. Lopinavir (1 pM) accumulation in CEM, CEMvblioo, and CEMvblioo 
cells treated with 300 nM tariquidar (TAR). Data are expressed as mean CAR (n > 3 
experimental replicates) ± SD.
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Figure 2.10. Rilpivirine (25 pM) accumulation in CEM, CEMvblioo, and CEMvblioo 
cells treated with 300 nM tariquidar (TAR). Data are expressed as mean CAR (n > 3 
experimental replicates) ± SD.
2.3.4 The effect of tariquidar on the bidirectionai transport of 
raitegravir and digoxin using a Caco-2 monolayer
The amount of drug entering the receiver compartment over a 180 minute incubation 
period is shown for raitegravir without (Figure 2.11) and with (Figure 2.12) 
tariquidar-mediated ABCB1 inhibition. The same results are presented tor the 
positive control ABCB1 substrate, digoxin, without (Figure 2.13) and with (Figure 
2.14) ABCB1 inhibition. Data are expressed as mean drug amount in receiver well 
(pmol, n = 3 experimental replicates) ± SD.
The Papp values obtained for raitegravir and digoxin with and without tariquidar are 
given in Figure 2.15. Data are expressed as mean Papp (xlO'6 cm/s) ± SD and efflux 
ratios (B-to-A Papp / A-to-B Papp) were calculated. All calculations were made by
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using the samples taken after 120 minutes of incubation as sink conditions were 
maintained. Raltegravir showed significantly higher transport in the B-to-A direction 
(Papp = 13.4 ± 2.1) compared to the A-to-B direction (Papp = 7.3 ± 2.2, p = 0.02). The 
efflux ratio of raltegravir at 120 minutes was 1.9. The presence of tariquidar reduced 
the efflux ratio of raltegravir to 1.3, which removed the preference for B-to-A 
permeability (p = 0.30). The ABCB1 control substrate digoxin showed significantly 
higher transport in the B-to-A direction (Papp = 12.9 ± 0.6) compared to the A-to-B 
direction (Papp = 2.1 ± 0.3, p < 0.001). The efflux ratio of digoxin at 120 minutes was 
6.3. The presence of tariquidar reduced the efflux ratio of digoxin to 0.9 which 
removed the preference for B-to-A permeability (p = 0.58).
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Figure 2.11. Raltegravir (1 pM) transport across a Caco-2 monolayer, showing A-to- 
B (•) and B-to-A (■) directions. Data are expressed as mean drug amount in 
receiver well (pmol, n = 3 experimental replicates) ± SD.
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Figure 2.12. Raltegravir (1 pM) transport across a Caco-2 monolayer treated with 
300 nM tariquidar, showing A-to-B (•) and B-to-A (■) directions. Data are 
expressed as mean drug amount in receiver well (pmol, n = 3 experimental 
replicates) ± SD.
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Figure 2.13. Digoxin (1 pM) transport across a Caco-2 monolayer, showing A-to-B 
(•) and B-to-A (■) directions. Data are expressed as mean drug amount in receiver 
well (pmol, n = 3 experimental replicates) ± SD.
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Figure 2.14. Digoxin (1 pM) transport across a Caco-2 monolayer treated with 300 
nM tariquidar, showing A-to-B (•) and B-to-A (■) directions. Data are expressed as 
mean drug amount in receiver well (pmol, n = 3 experimental replicates) ± SD.
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Figure 2.15. Papp of raltegravir (RAL) and digoxin (DIG) in the A-to-B (■) and B- 
to-A (■) directions across a Caco-2 transwell membrane, with and without the 
presence of 300 nM tariquidar (TAR). Data are expressed as mean Papp (xlO'6 cm/s; n 
= 3 experimental replicates) ± SD.
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2.3.5 Accumulation of raltegravir in peripheral blood 
mononuclear cells and the influence of ABCB1 inhibition
Raltegravir accumulation in PBMCs from four human subjects was determined and 
tariquidar was used to determine the extent of raltegravir transport by ABCB1. Data 
are expressed as mean CAR ± SD and given in Figure 2.16. Raltegravir CAR was not 
significantly altered in tariquidar-treated cells compared to non-treated cells in 
subject 1 (3.76 ± 0.56 versus 3.78 ± 0.70, p = 0.83), subject 3 (2.52 ± 0.29 versus 
3.03 ± 0.97, p = 1.0) or subject 4 (2.86 ± 0.93 versus 2.15 ± 0.30, p = 0.51). 
Raltegravir CAR was significantly higher in tariquidar-treated cells compared to 
non-treated cells in subject 2 (5.98 ± 2.12 versus 3.13 ± 0.22, p = 0.02). When 
combining the average results from each subject, raltegravir CAR was not 
significantly different in tariquidar-treated cells compared to non-treated cells (3.78 ± 
1.56 versus 3.02 ± 0.67, p = 0.77).
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Subject 1 Subject 2
Figure 2.16. Raltegravir (1 |aM) accumulation in PBMCs (■) and PBMCs co­
incubated with 300 nM tariquidar (■). Data for subjects 1, 2, 3 and 4 are expressed 
as mean CAR (n > 3 experimental replicates) ± SD. Combined data are expressed as 
mean CAR (n = 4 biological replicates, n > 3 experimental replicates per biological
replicate) ± SD.
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2.3.6 Inhibition of ABCB1 by raltegravir, verapamil and 
tariquidar using CEM and CEMVBL100 cells
The ability of raltegravir to inhibit ABCB1-mediated drug transport was determined 
using CEM and CEMvblioo cells. The CAR of ABCB1 substrate digoxin was 
determined in CEM, CEMvblioo and CEMvblioo co-incubated with raltegravir (2.5 
pM, 25 pM or 250 pM), ABCB1 inhibitor tariquidar (300 nM) or non-specific 
transporter inhibitor verapamil (30 pM). Data are expressed as mean CAR (n = 3 
experimental replicates) ± SD and are given in Figure 2.17. Digoxin CAR was 
significantly lower in ABCB1-overexpressing CEMvblioo cells compared to CEM 
cells (0.49 ± 0.05 versus 1.19 ± 0.05, p = 0.046). Digoxin CAR in CEMvblioo was 
unchanged when cells were incubated with 2.5 pM raltegravir (0.56 ± 0.05, p = 
0.105), 25 pM raltegravir (0.46 ± 0.07, p = 0.268) or 250 pM raltegravir (0.52 ± 
0.05, p = 0.268) but was significantly increased when CEMvblioo cells were 
incubated with tariquidar (1.30 ± 0.24, p = 0.046) or verapamil (1.09 ± 0.09, p = 
0.046).
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Figure 2.17. Digoxin (1 |iM) accumulation in CEM, CEMvblioo and CEMvblioo co­
incubated with raltegravir (RAL; 2.5 |aM, 25 |aM or 250 (iM), ABCB1 inhibitor 
tariquidar (TAR; 300 nM) or non-specific transporter inhibitor verapamil (VER; 30 
pM). Data are expressed as mean CAR (n = 3 experimental replicates) ± SD.
2.3.7 Modulation of vinblastine toxicity in CEMVBL10o cells by 
raltegravir
CEMvblioo cells are resistant to vinblastine-induced toxicity due to greatly increased 
ABCBl expression. The ability of raltegravir to increase vinblastine-induced toxicity 
over five day s incubation was determined. Data are expressed as percentage cell 
viability (mean percentage viability compared to vinblastine-ffee control cell 
incubations) ± SD and results are given in Figure 2.18 and converted to log scale in
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Figure 2.19. Raltegravir did not appear to alter the susceptibility of CEMvblioo cells 
to vinblastine-mediated toxicity at any concentration tested.
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Figure 2.18. Cellular toxicity of vinblastine in CEM cells and CEMvblioo cells co- 
incubated with 0-100 pM raltegravir. Data expressed as cell viability (percentage 
mean viability compared to drug-free control cell incubations, n = 6 experimental
replicates) ± SD.
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Figure 2.19. Log scale plot of cellular toxicity of vinblastine in CEM cells and 
CEMvblioo cells co-incubated with 0-100 pM raltegravir. Data expressed as cell 
viability (percentage mean viability compared to drug-free control cells, n = 6 
experimental replicates) ± SD.
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2.3.8 Induction of ABCB1 by raltegravir in Caco-2 monolayers
The permeability of lopinavir, a confirmed ABCB1 substrate, through a Caco-2 
monolayer was determined using control cells and cells pre-incubated for three days 
prior to the experiment with 20 pM raltegravir. Data are given as efflux ratios (B-to- 
A Papp / A-to-B Papp, n = 3 experimental replicates) ± SD and are shown in Figure 
2.20. There was no significant difference in lopinavir efflux ratio between control 
cells (9.02 ± 0.85) and cells pre-incubated with raltegravir (8.81 ± 1.75, p = 1.0).
15
Inducer
Figure 2.20. Efflux ratios of lopinavir across a Caco-2 monolayer with (■) and 
without (■) pre-incubation for three days with 20 pM raltegravir. Data are expressed 
as mean efflux ratio (B-to-A Papp / A-to-B Papp, n = 3 experimental replicates) ± SD.
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2.4 DISCUSSION
After initially determining the toxicity of raltegravir in utilised cell lines, this chapter 
investigated how ABCB1 influences the cellular permeability and disposition of 
raltegravir. The ability of raltegravir to inhibit or induce ABCB1 activity was also 
investigated. Experiments utilised in vitro cell accumulation, permeability and 
toxicity models, as well as ex vivo models using isolated PBMCs.
The MTT assay (Mosmann, 1983) was modified and used to determine the toxicity 
of raltegravir in Caco-2 and CEM cell lines. Viable cells are able to convert yellow 
MTT, using mitochondrial reductase enzymes, to a dark blue formazan derivative. 
This process requires energy in the form of ATP and therefore non-viable cells are 
unable to convert MTT to formazan. Previous work in the Liverpool HIV 
pharmacology group has shown the Pis saquinavir, nelfinavir, indinavir, lopinavir, 
ritonavir and the NNRTI efavirenz caused toxicity in PBMCs at lOpM and higher 
concentrations (Chandler etal, 2003).
Raltegravir showed no toxicity after five days in either Caco-2 or CEM cell lines at 
the highest concentration tested (100 pM) and the IC5o value of raltegravir could not 
be determined from the slope in either cell lines. This apparent lack of raltegravir 
toxicity at high concentrations in vitro suggests that raltegravir-induced cell toxicity 
is unlikely to affect experiments in this and subsequent chapters.
The expression of ABCB1 and ABCC1 on CEM and CEMvblioo cell membranes 
was determined using specific monoclonal antibodies. Compared to CEM cells.
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CEMvblioo cells had 158-fold higher ABCB1 expression, confirming the use of 
CEMvblioo cells in experiments requiring an ABCB1-overexpressing cell line. The 
lack of increased ABCC1 expression on CEMvblioo cells suggests that vinblastine 
treatment has not increased expression of all drug transporters to the same degree as 
with ABCB1, although overexpression of an unchecked transporter cannot be ruled 
out. Drug accumulation studies in CEM and CEMvblioo cells showed a small but 
significant decrease in raltegravir CAR in the ABCB1 over-expressing CEMvblioo 
cells. The control ABCB1 substrates saquinavir and lopinavir showed a greater CAR 
decrease than was seen with raltegravir, suggesting that raltegravir is the weaker 
ABCB1 substrate. Raltegravir, saquinavir and lopinavir all showed increased CAR in 
CEMvblioo cells co-incubated with ABCB1 inhibitor tariquidar and this increased 
CAR was comparable to the CAR obtained in wild type CEM cells. This supported 
the hypothesis that raltegravir is being actively transported by ABCB1 out of 
CEMvblioo cells. The experiment was repeated four times to confirm the results.
In the bidirectional transport study using Caco-2 cells, the positive control substrate 
digoxin achieved an efflux ratio of 6.27 which was above the minimum efflux ratio 
of digoxin in Caco-2 monolayers suggested by the FDA (Huang et at, 2007). 
Raltegravir achieved an efflux ratio of 1.85, which was reduced to 1.33 in the 
presence of tariquidar. This supported the hypothesis that raltegravir is being actively 
transported by ABCB1 in the B-to-A direction. However, unlike digoxin, raltegravir 
still showed preferential transport in the B-to-A direction in the presence of 
tariquidar (Figure 2,12). This presents the possibility that either tariquidar was not 
totally effective at preventing ABCB1 transport, or an as yet unidentified transporter 
expressed on the Caco-2 membrane is facilitating B-to-A transport of raltegravir, and
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that this transporter is not fully inhibited by tariquidar. This could be facilitated by an 
efflux transporter on the apical surface (ABCC2, ABCC4) or possibly an uptake 
transporter on the basolateral surface (SLC22A1, SLC22A2) of the Caco-2 cell (Kis 
et ah, 2010a; Maubon et al, 2007). However, the remaining active transport was 
small (Efflux ratio of 1.33) and therefore any transporter involved is unlikely to 
dramatically influence raltegravir absorption in vivo.
The extent of raltegravir transport by ABCB1 was small when compared to the 
transport of the positive control ABCB1 substrate, digoxin. Indeed, the FDA 
guidelines recommend that a drug should achieve an efflux ratio of at least 2 in 
Caco-2 cell monolayers and show greater than 50% reduction in efflux ratio when an 
ABCB1 inhibitor is used, in order for ABCB1 transport to be considered relevant in 
vivo (Huang et al, 2008). In the Caco-2 monolayer experiments raltegravir only 
achieved an efflux ratio of 1.85 and a reduction in efflux ratio of 32% when 
tariquidar was used to inhibit ABCB1. The low rate of raltegravir transport by 
ABCB1 may explain the absence of major drug interactions with known potent 
ABCB1 inhibitors. This is consistent with a previous report that co-administration of 
ritonavir, a known ABCB1 inhibitor (Sankatsing et al, 2004), had no clinically 
significant effect on raltegravir pharmacokinetics and no raltegravir dose adjustment 
is required in patients (Iwamoto et al, 2008c).
Both the bidirectional transport study using Caco-2 cells and the cellular- 
accumulation study using CEM and CEMvblioo cells concluded that raltegravir was 
significantly transported by ABCB1. However, the extent of transport was not high, 
which was confirmed by the positive control substrates digoxin, saquinavir and
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lopinavir showing greater levels of ABCB1-mediated transport. This does not 
support the previous data performed in-house by Merck, which gave an efflux ratio 
of 11.1 for raltegravir using LLC-PK1 cells overexpressing human ABCB1, where 
the positive control verapamil only gave an efflux ratio of 5.2. Verapamil was used 
as both an ABCB1 substrate and a competitive inhibitor of ABCB1 transport in 
laboratory experiments. The level of ABCB1 expression in the LLC-PK1 cells used 
by Merck may have been much higher than in the cell lines used in the author’s 
experiments, which would explain the differences in the data. However, the level of 
ABCB1 expression detected on the surface of the CEMvblioo cells was far greater 
than seen in wild type CEMs, confirmed by flow cytometry (Figure 2.3).
We cannot dismiss the possibility that CEMvblioo cells over-express a transporter 
other than ABCB1 which potentially altered the results by increasing the CAR of 
raltegravir, therefore reducing the impact of ABCB1. Indeed, expression of the influx 
transporter SLCOl A2 was shown to be higher in CEMvblioo cells compared to CEM 
cells, and SLC03A1 expression was lower in CEMvblioo cells (Janneh et al, 2008). 
This emphasises the disadvantage of using a cell line subjected with high drug 
concentrations to induce transporter expression.
In order to assess the effect of physiologically relevant expression levels of ABCB1 
on raltegravir cellular accumulation, experiments were conducted using PBMCs ex 
vivo from four healthy volunteers. Only PBMCs from one individual showed an 
increase in raltegravir accumulation once tariquidar was added. No significant 
change was seen in the other three volunteers. The expression level of ABCB1 on 
PBMCs is expected to vary between individuals, which may explain why the
114
addition of tariquidar had varying effects between volunteers. Although ABCB1 is 
expressed in PBMCs, expression is not as high as in the liver, kidney or gut (Bleasby 
et ai'> 20°6) and may have a lower expression level than ABCC transporters 
(Turriziani et al, 2008). Considering that ABCB1-mediated raltegravir transport 
using ABCB1-overexpressing cell lines in vitro was low, it is unsurprising that 
ABCB1 appears not to alter raltegravir exposure in PBMCs.
Raltegravir failed either to reduce the accumulation of ABCB1 substrate digoxin or 
to increase the toxicity of vinblastine in CEMvblioo cells. Both these data suggest 
that raltegravir does not inhibit ABCB1 in vitro and is unlikely to reduce ABCB1 
activity in vivo. Also, pre-incubating a Caco-2 monolayer with 20 pM raltegravir for 
three days failed to alter the efflux ratio of lopinavir through the monolayer. 
Lopinavir is an ABCB1 substrate (Janneh et al, 2007) and the lack of effect from 
raltegravir suggests that ABCB1 expression was not sufficiently induced or inhibited 
over the three day raltegravir incubation. However, lopinavir is also a known 
substrate of other drug transporters, including ABCC2 (Agarwal et al, 2007) and 
SCLOIBI (Hartkoom et al, 2010); it is possible that raltegravir is inhibiting 
multiple drug transporters with the effect of “cancelling out” any changes in 
lopinavir efflux ratio, although this is unlikely. Also, raltegravir may require longer 
than three days to induce ABCB1 and further experiments are required to 
conclusively show a lack of induction.
The results showing no effect of raltegravir on ABCB1 functionality in vitro support 
data from patients and trial volunteers, as there is evidence that raltegravir is unlikely 
to inhibit or induce ABCB1 in vivo. For example, raltegravir did not alter the
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exposure of midazolam, a known ABCB1 substrate, in a PK study using healthy 
volunteers (Iwamoto et al, 2008a).
In conclusion, raltegravir is a weak substrate of ABCB1 and does not appear to 
inhibit or induce the function of this transporter in vitro. If raltegravir was highly 
transported by ABCB1 in vitro, then drugs or other xenobiotics which significantly 
alter ABCB1 functionality or expression would be expected to cause 
contraindications in vivo. These interactions have not been observed and the results 
obtained in this chapter use in vitro and ex vivo systems to suggest that raltegravir 
transport by ABCB1 is lower than previous data indicates and is unlikely to be an 
important factor in vivo.
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Chapter 3
Interactions between raltegravir and drug influx
transporters
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3.1 INTRODUCTION
The primary route of raltegravir metabolism is glucuronidation via UGT1A1 and 
raltegravir is not a substrate or an inhibitor of the major cytochrome P450 enzymes 
(Iwamoto el al., 2008a; Kassahun et ah, 2007). However, the involvement of human 
drug transporters in raltegravir absorption, disposition, metabolism and excretion 
(ADME) has not been fully investigated. Raltegravir has shown higher 
concentrations (1.7-fold) in semen (Barau et ah, 2010) and lower concentrations 
(0.04 to 0.39-fold) in cerebrospinal fluid (Calcagno et ah, 2010; Yilmaz et ah, 2009) 
compared to plasma (Section 1.6.5), These differences may be influenced by drug 
transporters present at membrane barriers.
There are important reasons why raltegravir should be screened for transport by 
known drug transporters. First, by regulating intracellular permeation, drug 
transporters could be an important factor in understanding the lack of a clear 
pharmacokinetic-pharmacodynamic (PK-PD) relationship, such as the similar 
virological response observed in patients given a wide range of raltegravir doses 
(Cattaneo et ah, 2012; Markowitz et ah, 2006). Second, an understanding of the 
mechanisms that control raltegravir disposition may help rationalise or even 
anticipate drug interactions in the clinic. Raltegravir represents the first member of a 
new drug class, possessing a unique chemical structure containing a diketo acid 
derivative (Summa et ah, 2008): class-specific trends in drug transport may be 
evident such as those reported for protease inhibitors with ABCB1 (Lee et ah, 1998; 
van der Sandt et ah, 2001) or for nucleoside reverse transcriptase inhibitors with 
organic anion and cation transporters (Takeda et ah, 2002; Uwai et ah, 2007).
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Finally, knowing which transporters are involved in raltegravir ADME will identify 
candidate genes for future pharmacogenetic studies.
The interactions between raltegravir and the efflux transporter ABCB1 were 
investigated in Chapter 2. However, the interactions between raltegravir and influx 
transporters are unknown and could be an important determining factor in raltegravir 
ADME. Antiretroviral drugs are known to interact with several influx transporters, 
including members of the organic anion and cation transporters of the SLCO and 
SLC22A gene subfamilies (Roth et al, 2012).
The SLCO transporters are believed to be important in the transport of antiretroviral 
drugs in the liver, intestine, kidney, placenta, central nervous system, as well as other 
tissues. SLC01A2, SLCOIBI and SLC01B3 are known to transport Pis and 
maraviroc in vitro and lopinavir and maraviroc plasma concentrations are influenced 
by the SLCOIBI 521T>C polymorphism (rs4149056) (Hartkoorn et al, 2010; 
Siccardi et al, 2010). Furthermore, several Pis are able to inhibit SLCO activity in 
vitro (Campbell et al, 2004), which could potentially result in drug-drug interactions 
with co-administered SLCO substrates.
The SLC22A transporters play a role in exposure of several antiretroviral drugs, 
particularly NRTIs (Takeda et al, 2002), and are expressed throughout the body with 
highest expression in the kidney and liver. SLC22A1 activity is inhibited in vitro by 
nelfinavir and ritonavir (Jung et al, 2008), although the inhibitory potential of 
raltegravir and other new antiretroviral drugs on SLC22A1 activity has yet to be 
determined and was investigated in this chapter. It can be seen that influx
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transporters are able to influence drug ADME properties and this emphasises the 
importance of assessing the in vitro interactions between raltegravir and influx 
transporters of the SLCO and SLC22A subfamlies.
The aim of this chapter was to increase our understanding of the interactions between 
influx drug transporters and newer antiretroviral compounds, with particular focus on 
raltegravir. This information will help to explain variability in raltegravir PK and 
may aid in the prediction and, hopefully, avoidance of potential transporter-mediated 
drug-drug interactions. First, the transport of raltegravir and other new antiretroviral 
drugs by a selection of influx transporters was evaluated using the Xenopus laevis 
oocyte expression system. The influx transporters screened for drug transporting 
activity were SLC01A2, SLC01B1, SLC01B3, SLC10A1, SLC15A1, SLC15A2, 
SLC22A1, SLC22A6 and SLC22A8 (see Section 1.5.2, Table 1.3 for transporter 
locations). Second, the ability of raltegravir and other antiretroviral drugs to inhibit 
SLC22A1 was determined using transfected SLC22Al-overexpressing KCL22 cells.
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3.2 METHODS
3.2.1 Materials
SLC22A1 -overexpressing KCL22 cells and mock-transfected KCL22 cells were 
donated by Athina Giannoudis, Department of Haematology, Royal Liverpool 
University Hospital (Liverpool, UK). Primary renal proximal tubule epithelial cells, 
renal cell basal medium and renal cell growth kit components were purchased from 
The Amexican Type Culture Collection (Virginia, USA). [3H]Raltegravir (specific 
activity — 32.85 Ci/mmol) and non-radiolabeled raltegravir sodium salt were gifts 
from Merck (New Jersey, USA). Etravirine was a gift from Janssen 
(Buckinghamshire, UK). [14C]Darunavir (specific activity = 39.19 mCi/mmol), non- 
radiolabelled darunavir, [14C]rilpivirine (specific activity = 20.00 mCi/mmol) and 
non-radiolabelled rilpivirine were gifts from Tibotec (Mechelen Belgium). 
Atazanavir was a gift from Bristol-Myers Squibb (New York, USA). Nevirapine was 
a gift from Boehringer Ingelheim (Berkshire, UK). Ritonavir was a gift from Abbott 
(Illinois, USA). Tenofovir, efavirenz and lamivudine were purchased from Toronto 
Research Chemicals (Toronto, Canada). Amprenavir was a gift from 
GlaxoSmithKline (Middlesex, UK). [3H]Estrone 3-sulphate (specific activity = 50 
Ci/mmol), [I4C]tetraethylammonium (specific activity = 55 mCi/mmol),
[ H]taurocholic acid (specific activity - 10 Ci/mmol), [3H]glycyl-sarcosine (specific 
activity = 60 Ci/mmol) and [3H]aminohippuric acid (specific activity = 5 Ci/mmol) 
were purchased from American Radiolabelled Chemicals (Missouri, USA). 
mMessage Transcription kits were purchased from Ambion Ltd. (Huntingdon, UK). 
Ultima Gold scintillation fluid was purchased from Perkin Elmer (Boston, USA).
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Restriction enzymes were purchased from New England Biolabs (Kitchen, UK). 
Adult female Xenopus laevis frogs were purchased from Xenopus Express (Lyon, 
France), All other drugs and reagents were obtained from Sigma (Poole, UK).
3.2.2 Production of uptake transporter cRNA for Xenopus 
laevis oocyte injection
SLC01A2, SLCOIBI and SLC01B3 transporter genes were previously cloned from 
cDNA extracted from Huh-7D12 and A549 cells (Hartkoorn et at, 2010). 
Transporter DNA-containing plasmids were isolated from these clones, linearised 
using restriction enzymes and used as a template in cRNA production using a T3 
mMessage mMachine RNA transcription kit (Ambion®) following the 
manufacturer s protocol. Following cRNA generation, plasmid DNA was degraded 
(1 pL Turbo DNase, 37°C, 15 minutes) and cRNA was concentrated using a lithium 
chloride precipitation method. Concentrated cRNA pellets were reconstituted in 
sterile water to a final concentration of 1 pg/mL for use in microinjection. SLC10A1, 
SLC15A1, SLC15A2, SLC22A1, SLC22A6 and SLC22A8 cRNA was provided at 1 
pg/mL by Becton Dickinson (Oxford, UK).
3.2.3 Xenopus laevis maintenance
Adult female Xenopus laevis frogs were housed in fresh, filtered water and provided 
with shelter. Frogs were monitored daily to check for signs of ill health and were fed 
dried frog food pellets twice daily. Frogs were sacrificed using anaesthetic solution 
(MS222, 5 g/L, 45 minutes) following Schedule 1 procedures.
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3.2.4 Xenopus laevis oocyte isolation, coliagenase treatment 
and microinjection
Oocytes were harvested from sacrificed adult female X laevis frogs and treated with 
modified Barth’s solution minus calcium (88 mM NaCl, 1 mM KC1, 15 mM HEPES, 
100 U penicillin, 100 pg/mL streptomycin, pH 7.4) containing coliagenase (1 
mg/mL, 22 °C, 60 rpm shaker, 1 hour). Cells were washed and transferred to Barth’s 
solution containing calcium (88 mM NaCl, 1 mM KC1, 15 mM HEPES, 0.3 mM 
CaCN03-6H20, 41 pM CaCl2'6H20, 0.82 mM MgS04'7H20, 100 U penicillin, 100 
pg/mL streptomycin, pH 7.4) and stored overnight in a cold room at 8°C. Healthy 
cells were selected and injected with transporter cRNA (50 ng per oocyte, 1 ng/nL) 
or sterile water (50 nL) and maintained in Barth’s solution containing calcium to 
allow transporter expression (5 days for SLC01B3-injected oocytes, 3 days for all 
other conditions, 18 C). Barth’s solution was replaced daily and damaged oocytes 
were removed to maintain viability of the healthy oocytes.
3.2.5 Antiretroviral drug accumulation in transporter cRNA- 
injected Xenopus laevis oocytes
Drug accumulation studies using Xenopus laevis oocytes were performed as 
described previously with slight modifications (Hartkoorn et al, 2010). Unless 
otherwise stated, radiolabelled drug was incubated in HBSS (pH 7.4) with > 4 
oocytes per condition in a 48-well nunc flat bottom plate (500 pL, 0.33 pCi/mL, 
22 C, 60 rpm shaker, 1 hour). Radiolabelled positive control drugs were tested 
alongside radiolabelled antiretroviral drugs to ensure successful transporter 
expression. Drug concentrations used for raltegravir, darunavir, efavirenz and
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rilpiviiine were 1 10 pM, 26 fiM and 25 pM, respectively (drug concentrations
were usually dictated by the specific activity of the drug). Darunavir, efavirenz and 
rilpivirine were not used when measuring transport by SLC01A2, SLCOIBI or 
SLC01B3 as this has been investigated previously (Hartkoorn et al., 2010; Kwan et 
al.t 2007) and rilpivirine was only assessed when sufficient oocytes were available. 
Positive control drugs used were [3H]estrone 3-sulphate (1 pM) for SLC01A2, 
SLCOIBI, SLC01B3 and SLC22A8, [3H]aminohippuric acid (1 pM) for SLC22A6, 
[3H]taurocholic acid (1 pM) for SLC10A1, [3H]glycyl-sarcosine (1 pM) for 
SLC15A1 and SLC15A2, and [14C]tetraethylammonium (6 pM) for SLC22A1. All 
incubations were terminated by transferring the oocytes to cell strainers and washing 
in ice cold HBSS to remove extracellular drug. Each oocyte was placed in a separate 
scintillation vial followed by 100 pL 10% SDS solution. After disintegration of the 
oocytes by the SDS, 4 mL scintillation fluid was added to all vials, which were then 
loaded into a liquid scintillation analyzer (TRI-CARB®). Results are expressed as the 
amount of drug per oocyte (pmol/oocyte) assuming that each oocyte had a volume of 
1 pL (Hartkoorn et al, 2010).
3.2.6 Culture of mock-transfected and SLC22A1- 
overexpressing KCL22 cells
KCL22 cells were maintained in cell culture medium (RPMI, 10% [vol/vol] FCS) 
prior to the experiment in a C02 incubator (37 °C, 5% C02). SLC22A1- 
overexpressing KCL22 cells and mock-transfected KCL22 cells were created 
previously by Athina Giannoudis at the Department of Haematology, Royal 
Liverpool University Hospital, Liverpool, UK (Giannoudis et at, 2008). In this 
previous work, SLC22A1-overexpressing KCL22 cells were created by transfecting
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pcDNA-hSLC22A1 plasmid into cells by nucleofection. Similarly, mock-transfected 
KCL22 cells were created by transfecting the empty vector pcDNAS.l into cells by 
nucleofection. Transfected cells were selected using neomycin and stable cell lines 
were established. KCL22 cells were used for human SLC22A1 transfection because 
it expresses a low basal amount of SLC22A1 in comparison to other chronic 
myelogenous leukemia cell lines (Thomas et al., 2004). All cell culture procedures 
were performed in a sterile environment. Frozen stocks of KCL22 cells were 
produced and thawed out using the same method as described for CEM cells in 
Section 2.2.2.S.
3.2.7 Evaluation of the effects of antiretroviral drugs on the 
accumulation of tetraethylammonium in SLC22A1- 
overexpressing KCL22 cells
SLC22A1-overexpressing KCL22 cells and mock-transfected KCL22 cells of a 
constant cell density (1 mL, 2.5 x 106 cells/mL) were incubated (37°C, 5% C02) for 
30 minutes in cell culture medium (RPMI, 10% [vol/vol] FCS) containing SLC22A1 
substrate [14C]tetraethylammonium (5.4 pM, 0.3 pCi/mL). Separate incubation were 
undertaken where SLC22A1-overexpressing KCL22 cells were preincubated for 30 
minutes prior to the substrate addition with cell culture medium (RPMI, 10% 
[vol/vol] FCS) containing one of a selection of co-incubated drugs, which included 
either 50 pM of SLC22A1 inhibitors prazosin or cepharanthine, or 50 pM of 
antiretroviral drug, which were also included during the 30 minutes of substrate 
incubation. The antiretroviral drugs examined as potential SLC22A1 inhibitors were 
atazanavir, lopinavir, amprenavir, indinavir, darunavir, ritonavir, nelfinavir,
126
lamivudine, tenofovir, zalcitabine, abacavir, zidovudine, stavudine, etravirine, 
nevirapine, rilpivirine, efavirenz and raltegravir.
Following incubation, cells were centrifuged (800 g, 1°C, 1 minute), lOOpL 
supernatant aliquots taken, added to scintillation vials and used to calculate 
extracellular drug concentrations. The remaining supernatant was discarded and the 
cells were washed with ice-cold HBSS and centrifuged (800 g, 1°C, 1 minute). This 
HESS wash was repeated a total of three times, after which the HBSS was discarded 
and 100 pL tap water was added to lyse the cells. The incubations were vigorously 
vortexed for five minutes and samples were added to scintillation vials. Four 
millilitres of scintillation fluid was added to scintillation vials, which were then 
loaded into a liquid scintillation analyzer (TRI-CARB®). Using intracellular 
radioactivity readings, cellular tetraethylammonium concentrations were determined 
in each cell line (pM ± SD, assuming 1 pL volume per cell).
Following this expeiiment, the procedure was repeated with modifications to produce 
IC5o data. Accumulation of [14C]tetraethylammonium (5.4 pM, 0.3 pCi/mL) was 
deteimined when cells were co-incubated with a log range of antiretroviral drug 
concentrations (0, 1, 2.5, 5, 10, 25, 50, 100 pM). Antiretroviral drugs used in this 
experiment were drugs that showed good SLC22A1 inhibition at 50 pM and have 
either not been investigated in previous literature (darunavir and rilpivirine) or have 
shown conflicting results to those previously published (efavirenz) (Jung et al, 2008; 
Jung et al, 2009). Raltegravir, although not showing SLC22A1 inhibition at 50 pM, 
is integral to the work in this thesis and was tested to confirm a lack of SLC22A1 
inhibition at 100 pM and below. Prazosin was used as a positive control SLC22A1
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inhibitor. Data was plotted using Prism 5 and the slopes were used to calculate 
relative IC5o (the amount of drug needed to achieve 50% SLC22A1 as determined 
from the maximum and minimum extremes of the non-linear regression plot) and the 
absolute IC5o (the amount of drug needed to achieve 50% SLC22A1 as determined 
from the maximum of the non-linear regression plot and 0% accumulation).
3.2.8 Statistical analysis
Data were analysed using SPSS 15.0 for Windows. All data were tested for normality 
using the Shapiro-Wilk test. An independent t test was used to determine the 
significance of normally distributed data and the Mann Whitney U test was used for 
all other data. A two-tailed p value of < 0.05 was accepted as being statistically 
significant.
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3.3 RESULTS
3.3.1 Antiretroviral drug accumulation in transporter cRNA- 
injected Xenopus laevis oocytes
The accumulation of raltegravir and several other newly developed antiretroviral 
drugs were determined in SLC01A2 (Figure 3.1), SLCOIBI (Figure 3.2), SLC01B3 
(Figure 3.3), SLC22A6 (Figure 3.4), SLC22A8 (Figure 3.5), SLC10A1 (Figure 3.6), 
SLC15A1 (Figure 3.7), SLC15A2 (Figure 3.8) and SLC22A1 (Figure 3.9) cRNA- 
injected Xenopus laevis oocytes. Darunavir, efavirenz and rilpivirine were not used 
when measuring transport by SLC01A2, SLCOIBI or SLC01B3 as this has been 
investigated previously (Hartkoorn el al, 2010; Kwan et al, 2007) and rilpivirine 
was only used when sufficient oocytes were available (SLC22A6 and SLC22A8). 
Water-injected Xenopus laevis oocytes were also used in accumulation experiments 
to determine passive diffusion of drug into oocytes, and control substrates were used 
to validate transporter expression. The ratio of drug accumulation in transporter 
cRNA-injected oocytes compared to water-injected control oocytes was determined 
and is given in Table 3.1.
Raltegiavir showed higher accumulation in SLC22A6 cRNA-injected oocytes (2.22- 
fold accumulation, p < 0.001) and SLC15A1 cRNA-injected oocytes (1.52-fold 
accumulation, p — 0.003) compared to water-injected oocytes. Darunavir showed 
highei accumulation in SLC22A6 cRNA-injected oocytes (1.29-fold accumulation, p 
— 0.022) and SLC22A1 cRNA-injected oocytes (1.20-fold accumulation, p = 0.001) 
compared to water-injected oocytes, although the increase was not large compared to 
control substrates. Efavirenz and rilpivirine did not show higher accumulation in
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transporter cRNA-injected oocytes. Control substrates all showed higher 
accumulation in transporter cRNA-injected oocytes compared to water-injected 
oocytes (Table 3.1), confirming the activity of the transporter proteins.
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Transporter Drug RNA-injected 
accumulation 
(pmol oocyte1) 
±SD
Water-injected 
accumulation 
(pmol oocyte1)
1 SD
RNA/water
ratio
Significance 
(p value)
SLC01A2 RAL 0.39 ±0.14 0.3510.07 1.11 0.091
E3S 1.48 ± 0.63 0.27 1 0.09 5.48 <0.001
SLC01B1 RAL 0.4110.05 0.38 1 0.05 1.08 0.09
E3S 2.68 ± 1.55 0.3410.17 7.97 <0.001
SLCOIBB RAL 0.6310.19 0.6510.13 0.97 0.092
E3S 0.5610.23 0.2110.03 2.60 <0.001
SLC22A6 RAL 0.4410.12 0.2010.03 2.22 <0.001
DRV 4.3111.24 3.33 11.05 1.29 0.022
EFV 225.52 1 72.48 244.80 1 43.99 0.92 0.121
RPV 54.81 14.4 60.311 7.94 0.91 0.083
AHA 9.39 1 2.64 0.1710.04 56.91 <0.001
SLC22A8 RAL 0.23 1 0.04 0.20 1 0.05 1.17 0.175
DRV 5.9511.61 5.4710.32 1.09 0.895
EFV 283.11 ±62.13 265.27 ±30.87 1.07 0.326
RPV 62.671 16.70 60.3117.94 1.04 0.674
E3S 0.84 1 0.44 0.1910.07 4.33 0.016
SLC10A1 RAL 0.2010.03 0.20 1 0.03 1.03 0.566
DRV 3.6311.21 3.33 11.05 1.09 0.501
EFV 248.02 1 58.96 244.80 143.99 1.01 1.000
TCA 0.2810.10 0.08 1 0.05 3.51 <0.001
SLC15A1 RAL 0.2610.12 0.17 10.03 1.52 0.003
DRV 4.77 1 0.70 5.3311.94 0.89 0.51
EFV 267.15 ±57.13 291.87181.45 0.92 0.299
GLY 0.4510.13 0.1110.05 4.22 <0.001
SLC15A2 RAL 0.19 1 0.04 0.1710.03 1.08 0.157
DRV 5.8212.20 5.33 11.94 1.09 0.336
EFV 251.15162.55 291.87 ±81.45 0.86 0.114
GLY 0.2910.19 0.1110.05 2.69 <0.001
SLC22A1 RAL 0.211 0.03 0.1710.04 1.21 0.059
DRV 7.29 1 0.72 6.06 1 0.47 1.20 0.001
EFV 241.89 1 74.38 239.911 33.88 1.01 0.958
TEA 0.34 1 0.06 0.17 1 0.04 1.99 0.001
Table 3.1. Accumulation of raltegravir, darunavir, efavirenz, rilpivirine and various 
positive control compounds in oocytes. Results are expressed as mean drug 
concentrations per oocyte (pmol/oocyte, n > 4 oocytes per condition) ± SD.
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p < 0.001
A B
Figure 3.1. Accumulation of raltegravir (Figure 3.1 A, 1 |aM) and estrone 3-sulphate 
(Figure 3.IB, 1 pM) in water-injected and SLC01A2 cRNA-injected oocytes. Data 
are presented as mean drug amount per oocyte (pmol/oocyte, n > 19 oocytes) ± SD.
A B
p< 0.001
Figure 3.2. Accumulation of raltegravir (Figure 3.2A, 1 pM) and estrone 3-sulphate 
(Figure 3.2B, 1 pM) in water-injected and SLCOIBI cRNA-injected oocytes. Data 
are presented as mean drug amount per oocyte (pmol/oocyte, n > 21 oocytes) ± SD.
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p< 0.001
A B
Figure 3.3. Accumulation of raltegravir (Figure 3.3A, 1 (iM) and estrone 3-sulphate 
(Figure 3.3B, 1 pM) in water-injected and SLC01B3 cRNA-injected oocytes. Data 
are presented as mean drug amount per oocyte (pmol/oocyte, n > 23 oocytes) ± SD.
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p = 0.022A p< 0.001 R
Figure 3.4. Accumulation of raltegravir (Figure 3.4A, 1 |aM) darunavir (Figure 3.4B, 
10 nM), efavirenz (Figure 3.4C, 26 |iM), rilpivirine (Figure 3.4D, 20 pM) and 
aminohippuric acid (Figure 3.4E, 1 pM) in water-injected and SLC22A6 cRNA- 
injected oocytes. Data are presented as mean drug amount per oocyte (pmol/oocyte, 
n > 17 oocytes) ± SD.
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Figure 3.5. Accumulation of raltegravir (Figure 3.5A, 1 nM) darunavir (Figure 3.5B, 
10 nM), efavirenz (Figure 3.5C, 26 ^iM), rilpivirine (Figure 3.5D, 20 pM) and 
estrone 3-sulphate (Figure 3.5E, 1 pM) in water-injected and SLC22A8 cRNA- 
injected oocytes. Data are presented as mean drug amount per oocyte (pmol/oocyte, 
n > 4 oocytes) ± SD.
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Figure 3.6. Accumulation of raltegravir (Figure 3.6A, 1 |iM), darunavir (Figure 
3.6B, 10 fiM), efavirenz (Figure 3.6C, 26 jaM) and taurocholic acid (Figure 3.6D, 1 
(iM) in water-injected and SLC10A1 cRNA-injected oocytes. Data are presented as 
mean drug amount per oocyte (pmol/oocyte, n > 21 oocytes) ± SD.
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Figure 3.7. Accumulation of raltegravir (Figure 3.7A, 1 jiM), darunavir (Figure 
3.7B, 10 ^M), efavirenz (Figure 3.7C, 26 ^M) and glycyl-sarcosine (Figure 3.7D, 1 
^M) in water-injected and SLC15A1 cRNA-injected oocytes. Data are presented as 
mean drug amount per oocyte (pmol/oocyte, n > 21 oocytes) ± SD.
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Figure 3.8. Accumulation of raltegravir (Figure 3.8A, 1 fiM), darunavir (Figure 
3.8B, 10 fiM), efavirenz (Figure 3.8C, 26 jiM) and glycyl-sarcosine (Figure 3.8D, 1 
^M) in water-injected and SLC15A2 cRNA-injected oocytes. Data are presented as 
mean drug amount per oocyte (pmol/oocyte, n > 18 oocytes) ± SD.
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Figure 3.9. Accumulation of raltegravir (Figure 3.9A, 1 |iM), darunavir (Figure 
3.9B, 10 nM), efavirenz (Figure 3.9C, 26 ^M) and tetraethylammonium (Figure 
3.9D, 6 nM) in water-injected and SLC22A1 cRNA-injected oocytes. Data are 
presented as mean drug amount per oocyte (pmol/oocyte, n > 7 oocytes) ± SD.
3.3.2 Accumulation of tetraethylammonium in SLC22A1- 
expressing KCL22 cells co-incubated with antiretroviral 
drugs
The inhibition of SLC22A6-mediated tetraethylammonium transport by HIV Pis 
(Figure 3.10), NRTIs (Figure 3.11), NNRTIs (Figure 3.12) and raltegravir (Figure
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3.12) was determined in transfected SLC22A1-overexpressing KCL22 cells. 
Prazosin and cepharanthine are control SLC22A1 inhibitors and were used to 
validate the experiment. Results are given as tetraethyl ammonium (TEA) 
concentration in cells after 30 minutes incubation (pM, n = 3 experimental 
replicates) ± SD.
Tetraethylammonium cellular accumulation was significantly higher in SLC22A1- 
expressing KCL22 cells compared to mock transfected control KCL22 cells (10.5 ± 
0.6 pM versus 0.3 ± 0.004 pM, p < 0.001). Tetraethylammonium cellular 
accumulation was significantly reduced in SLC22A1-expressing KCL22 cells when 
cells were co-incubated with 50 pM lopinavir (7.2 ± 1.8 pM, p = 0.018), amprenavir 
(6.8 ± 1.6 pM, p = 0.007), indinavir (5.2 ± 0.6 pM, p < 0.001), darunavir (4.7 ± 0.4 
pM, p < 0.001), ritonavir (4.0 ± 0.3 pM, p < 0.001), nelfmavir (3.1 ± 2.5 pM, p = 
0.033), zalcitabine (9.1 ± 0.7 pM, p - 0.042), abacavir (8.8 ± 0.8 pM, p = 0.027), 
stavudine (7.6 ± 0.6 pM, p — 0.001), etravirine (8.2 ±1.4 pM, p = 0.032), nevirapine 
(8.0 ± 1.5 pM, p = 0.026), rilpivirine (6.3 ± 0.2 pM, p < 0.001), efavirenz (5.4 ± 0.7 
pM, p < 0.001), or control SLC22A1 inhibitors prazosin (2.1 ± 0.4 pM, p < 0.001) 
and cepharanthine (2.4 ± 0.2 pM, p < 0.001). Tetraethylammonium cellular 
accumulation was not significantly altered in SLC22A1-expressing KCL22 cells 
when cells were co-incubated with 50 pM atazanavir (10.2 ± 0.8 pM, p = 0.649), 
lamivudine (11.4 ± 0.6 pM, p = 0.083), tenofovir (9.7 ± 0.6 pM, p = 0.158), 
zidovudine (8.5 ± 3.1 pM, p = 0.39) or raltegravir (9.6 ± 1.4 pM, p = 0.34), 
indicating that these antiretrovirals do not inhibit this transporter.
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Figure 3.10. The effect of Pis on accumulation of tetraethylammonium in KCL22 
cells. Yellow bar = mock transfected cells (no transfection-induced SLC22A1 
expression). Green bar = SLC22A1-expressing transfected cells. Red bars = 
Transfected cells with 50 pM control SLC22A1 inhibitors present. Blue bars = 
Transfected cells with 50 pM PI drugs present. Results are given as 
tetraethylammonium (TEA) concentration in cells after 30 minutes incubation (pM, 
n = 3 experimental replicates) ± SD. * = p<0.05, ** = pO.Ol, *** = pO.OOl.
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Figure 3.11. Effect of NRTIs on accumulation of tetraethylammonium in KCL22 
cells. Yellow bar = mock transfected cells (no transfection-induced SLC22A1 
expression). Green bar = SLC22A1-expressing transfected cells. Red bars = 
Transfected cells with 50 pM control SLC22A1 inhibitors present. Blue bars = 
Transfected cells with 50pM NRTI drugs present. Results are given as 
tetraethylammonium (TEA) concentration in cells after 30 minutes incubation (pM. 
n = 3 experimental replicates) ± SD. * = p<0.05, ** = p<0.01, *** = pO.OOl.
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Figure 3.12. Effect of NNRTIs and raltegravir on accumulation of TEA in KCL22 
cells. Yellow bar = mock transfected cells (no transfection-induced SLC22A1 
expression). Green bar = SLC22A1-expressing transfected cells. Red bars = 
Transfected cells with 50 pM control SLC22A1 inhibitors present. Blue bars = 
Transfected cells with 50pM NNRTI drugs or raltegravir present. Results are given 
as TEA concentration in cells after 30 minutes incubation (pM, n = 3 experimental 
replicates ± SD). * = p<0.05, ** = p<0.01, *** = p<0.001.
3.3.3 SLC22A1IC50 of antiretroviral drugs
The inhibition of SLC22A1 using a concentration range of antiretrovirals was used to 
determine IC50 values. Data are presented in Figure 3.13 and relative and absolute 
IC50 values were determined (Table 3.2). Control SLC22A1 inhibitor prazosin 
achieved an 84% reduction in cellular tetraethylammonium accumulation at 100 pM 
and a relative IC50 value of 2.3 pM, which is similar to values found in published 
literature (Minematsu et al., 2010).
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Figure 3.13. Inhibition of tetraethylammonium accumulation in SLC22A1- 
expressing KCL22 cells using a concentration range of raltegravir, rilpivirine, 
darunavir, efavirenz and control SLC22A1 inhibitor prazosin. Data are expressed as 
mean percentage tetraethylammonium (TEA) accumulation compared to 
accumulation in drug-free control cells (n = 3 experimental replicates).
Inhibitor
TEA accumulation when 100 
pM inhibitor used (% 
compared to inhibitor-free 
control)
Relative
ICsolnM)
Absolute
ICmIuM)
Prazosin 16.1 2.3 2.8
Raltegravir 93.4 >100 >100
Rilpivirine 47.9 28.5 61.6
Darunavir 41.3 15.9 46.2
Efavirenz 39.7 7.4 21.8
Table 3.2. Maximum observed SLC22A1 inhibition and calculated relative IC5o 
values for raltegravir, rilpivirine, darunavir, efavirenz and control SLC22A1 inhibitor
prazosin.
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3.4. DISCUSSION
This chapter has investigated how raltegravir and several other antiretroviral drugs 
interact with a selection of influx drug transporters. The inhibition of SLC22A1 by a 
wide range of antiretroviral drugs, including raltegravir, was also determined.
The oocyte expression system was used to assess the transport of raltegravir, 
darunavir, efavirenz and rilpivirine by a selection of influx transporters. The only 
transporters which significantly increased raltegravir accumulation were SLC15A1 
(52% increase) and SLC22A6 (120% increase). The peptide transporting protein 
SLC15A1 is highly expressed in the intestine (Daniel et ah, 2004) and acts by 
transporting substrate compounds from the lumen into the cells lining the intestine. 
This would suggest that SLC15A1 has the potential to increase the absorption of 
raltegravir from the intestine. However, the extent of raltegravir transport was only 
small and unlikely to have an important role in vivo. Furthermore, Caco-2 
monolayers are known to express high levels of SLC15A1 (Hubatsch et al, 2007) 
which are expressed on the apical surface, therefore transporting substrates in the A- 
to-B direction. Raltegravir Caco-2 monolayer permeability was predominantly in the 
B-to-A direction under normal experimental conditions detailed in Chapter 2, which 
does not support the hypothesis that SLC15A1 has a major effect on raltegravir in 
this model. The anion transporter SLC22A6 is predominantly expressed in the 
proximal tubule of the kidney but is also expressed in the brain, central nervous 
system, skeletal muscle and placenta (Roth et al, 2012). The transport of raltegravir 
by SLC22A6 is investigated in further detail in Chapter 4.
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Efavirenz oocyte accumulation was not increased by any influx transporter tested 
using the oocyte expression system. The impact of drug transporters on efavirenz is 
largely unknown, although efavirenz is not transported by ABCB1 in vitro (Janneh et 
al., 2009). Efavirenz is a CYP2B6 substrate and efavirenz plasma concentrations 
have been linked to polymorphisms in CYP2B6, such as the 516G>T variant 
(is3745274) (Haas et ah, 2004). Although not all possible transporters of efavirenz 
have been screened, our data suggest that active transport of efavirenz by the studied 
transporteis is unlikely to be as important for its ADME properties as metabolism.
The only tiansporters which significantly increased darunavir oocyte accumulation 
were SLC22A1 (20% increase) and SLC22A6 (29% increase). However, both 
transporters only caused a small increase in oocyte accumulation in comparison to 
control substrates and, since in oocytes the transporters are likely to be more highly 
expressed than at physiological levels, it is unlikely that these transporters would 
play a major role in darunavir disposition in vivo.
The Xenopus laevis oocyte expression system has several advantages when 
investigating drug transport. The large size and high protein production of oocytes 
provides lobust and reliable data. Also, expression of endogenous primary and 
secondary active xenobiotic transporters in oocytes is low (Sobczak et al, 2010). 
However, there are disadvantages also. Temperature must be maintained at 18°C 
during protein expression and around room temperature during any accumulation 
experiments to avoid degradation and this may impact transporter kinetics. Also, as 
in other models, the expression of investigated transporters is super-physiological. 
Therefoie, although they allow investigation of low-affinity or high permeability
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substrates, this means that caution should be taken when extrapolating to in vivo 
observations.
The organic cation transporter SLC22A1 is predominantly expressed in the liver and 
is localised to the basolateral membrane of hepatocytes (Nies et al., 2008) where it 
mediates the uptake of substrate from the blood and facilitates drug elimination. 
Raltegiavii did not reduce the accumulation of tetraethylammonium, a confirmed 
SLC22A1 substrate, in SLC22A1-overexpressing KCL22 cells at 100 pM or below. 
Therefore, it is unlikely that raltegravir reduces the activity of SLC22A1 in vivo.
Several antiretroviral drugs inhibited SLC22A1 activity: all Pis apart from atazanavir 
were able to reduce tetraethylammonium accumulation. These findings agree with 
published data, where the Pis saquinavir, indinavir, ritonavir and nelfinavir were able 
to reduce tetraethylammonium accumulation in SLC22A1-overexpressing Hela cells 
(Zhang et al, 2000) and atazanavir was found to have no SLC22A1-inhibiting ability 
in vitro (Jung et al, 2008). There are no previous published data on the inhibition of 
SLC22A1 by darunavir or lopinavir and both were investigated. Lopinavir showed 
significant but only minor inhibition of SLC22A1 (29.4% reduction in SLC22A1 
activity using 50 pM lopinavir) and darunavir showed more substantial SLC22A1 
inhibition (53.9% reduction in SLC22A1 activity using 50 pM darunavir).
The NRTIs were not SLC22A1 inhibitors or only showed minor inhibition. 
Lamivudine did not inhibit SLC22A1 and this contradicts previous published data 
which showed significant inhibition (Jung et al, 2008). However, Jung et al used 1- 
methyl-4-phenyIpyridinium as the control SLC22A1 substrate and this could explain
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the conflicting data. Indeed, it may suggest the existence of separate substrate 
binding sites on SLC22A1, only one of which is able to be inhibited by lamivudine.
The NNRTIs all showed some level of SLC22A1 inhibition although inhibition by 
etravirine and nevirapine was small (22.5% and 24.5% reduction in SLC22A1 
activity, respectively, when using 50 pM drug), Efavirenz and rilpivirine showed 
more substantial SLC22A1 inhibition (50.0% and 41.2% reduction in SLC22A1 
activity, respectively, when using 50 pM drug). Efavirenz did not show SLC22A1 
inhibition in previous literature, which contradicts our data (Jung et al, 2008). 
However, Jung et al used l-methyl-4-phenylpyridinium as the control SLC22A1 
substrate. Also, incubations were only 1 minute (compared to 30 minutes used in the 
author s experiments) and inhibition may therefore be time-dependent. Furthermore, 
the experiment in this thesis used multiple efavirenz concentrations to detennine the 
IC50 and Jung et al only used efavirenz at a concentration of 5 pM. The inhibitory 
potential of efavirenz for SLC22A1 should be determined using a separate in vitro 
method to confirm results seen in this chapter. It is also important to note that 
efavirenz was not found to be a substrate for SLC22A1 in oocyte accumulation 
experiments detailed in this chapter.
All antiretroviral drugs showed less SLC22A1 inhibition than with prazosin (82.3% 
reduction in SLC22A1 activity using 50 pM prazosin). However, antiretroviral drugs 
may also inhibit other organic cation transporters important in drug disposition, such 
as SLC22A2 and SLC22A3. Indeed, certain antiretroviral drugs, such as ritonavir 
and nelfmavir, have been shown to inhibit both SLC22A1 and SLC22A2 in vitro 
(Jung et al, 2008). The inhibition of SLC22A3 by antiretroviral drugs requires
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investigation and the potential for drug-drug interactions in vivo needs to be 
evaluated.
In conclusion, of all transporters tested, only SLC15A1 and SLC22A6 showed 
significant raltegravir transport in vitro. The clinical significance of these 
observations need further study but SLC15A1 -meiated raltegravir transport was low 
and an impact of this transporter in vivo seems unlikely. With the possible exception 
of SLC22A6, the studied drug transporter proteins do not appear to play a major role 
in raltegravir cellular permeation in vitro. Chapter 4 investigates the role of 
SLC22A6 in raltegravir cellular permeation in more detail and also details the 
competition between raltegravir and tenofovir for SLC22A6 transport.
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Chapter 4
Competition between raltegravir and tenofovirfor
SLC22A6 transport
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4.1 INTRODUCTION
The human SLC22A influx transporter family currently contains 24 members on the 
Human Gene Nomenclature Committee website (http://www.genenames.org/), some 
of which are known to be important transporters of many endogenous and xenobiotic 
substances. Substrate specificity generally differs from ABCB1, as SLC22A 
substrates are usually negatively charged (anions) and less lipophilic.
The organic anion transporter, SLC22A6, is a membrane-bound protein of 550 amino 
acids and is predominantly expressed in the kidney, with low levels of mRNA also 
detected in retina, brain, choroid plexus, liver, pancreas, stomach, bladder, mammary 
glands, salivary glands and PBMCs (Bleasby et al, 2006). Expression of SLC22A6 
in the kidney is localised to the basolateral (blood-facing) surface of the renal 
proximal tubule cells (Motohashi et al., 2002), where it removes substrates from the 
blood and facilitates renal elimination. The importance of SLC22A6 for drug 
transport in other human tissues has not been fully determined. Figure 4.1 gives the 
expression and location of several transporter proteins in renal proximal tubule cells 
(Daniel et al., 2003; Kis et at, 2010a). The mRNA of several other transporters, such 
as ABCG2 (Huls et al, 2008), have also been detected in renal proximal tubule cells 
(Hilgendorf et al., 2007), although the importance of these transporters in renal drug 
elimination is not fully understood.
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Figure 4.1. The expression and location of several drug-transporting proteins in renal 
proximal tubule cells (Daniel et al., 2003; Kis et ai, 2010a). Transporters displayed 
in bold typeface are the transporters with highest expression.
SLC22A6 has been shown to transport a wide range of currently prescribed drugs, 
including some diuretics, statins, antibiotics and antivirals (including anti-HIV drugs) 
(Burckhardt et al, 2011). The anti-herpes simplex virus acyclic nucleoside analogues 
acyclovir (Km of 342 pM) and ganciclovir (Km of 896 pM) were found to be low 
affinity SLC22A6 substrates in vitro (Takeda et al, 2002). Several anti-HIV NRTIs 
and NtRTIs are also SLC22A6 substrates, including didanosine, lamivudine, 
stavudine, zalcitabine, zidovudine and tenofovir (Burckhardt et al, 2011).
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There is a low frequency of SLC22A6 polymorphisms, suggesting an important 
endogenous role for the wild type transporter (Fujita et al, 2005). However, 
polymorphisms have been described which are known to alter SLC22A6 
functionality. Increased affinity (Km) but reduced maximum rate (Vmax) for tenofovir 
transport has been reported by SLC22A6 in oocyte expression experiments using the 
arginine/histidine SLC22A6 polymorphism (rsl 1568626) (Kra of 14.4 pM and Vmax 
of 27.1 pmol/oocyte/20 min) compared to wild type SLC22A6 (Km of 21.1 pM and 
Vmax of 60.3 pmol/oocyte/20 min) (Bleasby et al, 2005).
Drug interactions have been observed which are believed to involve SLC22A6- 
mediated, and possibly SLC22A8-mediated, transport. Probenecid is a potent 
inhibitor of SLC22A6 and was created to reduce the renal excretion of (3-lactam 
antibiotics such as penicillin (Overbosch et al, 1988) and various cephalosporins 
(Brown, 1993). Probenecid was also able to reduce the renal excretion of 
methotrexate in humans (47% increase in half-life compared to control patients) 
(Aheme et al, 1978) and published in vitro data supports the involvement of 
SLC22A6 in this interaction (probenecid inhibited methotrexate transport by rat Oatl 
with a Ki of 15.8 pM) (Uwai et al, 2000). The elimination half-life of the diuretic 
furosemide was increased when co-administered with probenecid (69% increase 
compared to control patients) and caused prolonged diuretic drug action (Vree et al, 
1995). Nonsteroidal anti-inflammatory drugs (NSAIDs) are also potent inhibitors of 
SLC22A6 and were shown to reduce methotrexate transport by rat Oatl in vitro 
(indomethacin inhibited methotrexate transport by rat Oatl with a Ki of 4.2 pM) 
(Uwai et al, 2000). Adefovir accumulation and cytotoxicity in SLC22A6-expressing 
CHO cells was reduced by NSAIDs in vitro (Mulato et al, 2000) and the authors
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suggested that NSAIDs may reduce adefovir nephrotoxicity in vivo. It is clear that 
SLC22A6 is important in the elimination of several drugs and that drug interactions 
involving SLC22A6 are possible in vitro and in vivo.
Wenning et al (2008) studied the interaction of raltegravir (400 mg twice-daily) and 
tenofovir (300 mg once-daily). The study showed increased raltegravir AUC (49%) 
and Cmax (64%), but no effect on raltegravir Cnijn, and a decrease in tenofovir AUC 
(10%), Cmax (23%) and Cmin (13%) (Wenning et al, 2008). Investigations in Chapter 
3 showed that 1 pM raltegravir was significantly transported by SLC22A6 over a one 
hour accumulation time course using SLC22A6-expressing Xenopus laevis oocytes. 
Given that tenofovir has previously been shown to be an SLC22A6 
substrate/inhibitor, competition between raltegravir and tenofovir for SLC22A6 
transport may reduce raltegravir renal elimination.
To better understand the affinity of raltegravir for SLC22A6, time-dependent and 
concentration-dependent kinetics experiments were undertaken and results are given 
in this chapter. The potential for raltegravir-drug interactions involving SLC22A6 
were also evaluated. The Knl and Vmax of raltegravir and tenofovir were calculated 
using the Xenopus laevis oocyte expression system. The competition between these 
drugs for SLC22A6 transport was also determined. Aminohippuric acid is a 
prototypical SLC22A6 substrate and was used to validate experiments. The impact of 
SLC22A6 on raltegravir accumulation in PBMCs and cultured primary renal cells 
was also determined.
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4.2 METHODS
4.2.1 Materials
[ H]Raltegravir (specific activity = 32.85 Ci/mmol) and non-radiolabeled raltegravir 
sodium salt were gifts from Merck (New Jersey, USA). [3H]Tenofovir (specific 
activity = 3.4 Ci/mmol) was purchased from Moravek (California, USA). Non- 
radiolabelled tenofovir was a purchased from Toronto Research Chemicals (Toronto, 
Canada). [3H]Aminohippuric acid (specific activity = 5 Ci/mmol) was purchased 
from American Radiolabelled Chemicals (Missouri, USA). mMessage mMachine 
RNA Transcription kits were purchased from Ambion Ltd. (Huntingdon, UK). 
Ultima Gold scintillation fluid was purchased from Perkin Elmer (Boston, USA). 
Restriction enzymes were purchased from New England Biolabs (Kitchen, UK). 
Adult female Xenopus laevis frogs were purchased from Xenopus Express (Lyon, 
France). IMAGE clones of SLC22A6 were purchased from Geneservice 
(Nottingham, UK). GC5™ competent E.coli cells, SOC medium, Genelute™ 
plasmid miniprep kits and Genelute™ PCR clean-up kits and TRI reagent® were 
purchased from Sigma (Poole, UK). The Taqman® reverse transcriptase kit and 
Taqman custom array plates were purchased from Invitrogen UK (Paisley, UK). 
Ficoll-Paque PLUS was purchased from GE Healthcare (Buckinghamshire, UK). All 
other drugs and reagents were obtained from Sigma (Poole, UK).
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4.2.2 Transformation of a SLC22A6-containing plasmid into 
competent E.coli
An IMAGE clone of the wild-type human SLC22A6 gene (clone number 5190748) 
was purchased from Geneservice (Nottingham, UK) and transformed into GC5™ 
competent E.coli cells using the following protocol. Cells (50 pL) were thawed and 
incubated on ice with 50 ng pCMV-SPORT6 plasmid containing the wild type 
human SLC22A6 gene (30 minutes). Cells were briefly heat shocked in a water bath 
(37°C, 45 seconds) before being returned to ice (2 minutes). SOC medium (450 pL) 
was added to each transformation reaction and cells were placed in a shaking 
incubator (225 rpm, 37 C, 1 hour). Transformation reactions were plated onto agar 
containing ampicillin (100 pg/mL) using a sterile spreader and incubated (37°C, 18 
hours) to select for successful transformants (pCMV-SPORT6 plasmid contains an 
ampicillin resistance gene). A successful clone was selected and grown in LB 
containing ampicillin (100 pg/mL, 37°C, 8 hours) and aliquots were stored at -80°C 
in freezing solution (80% LB, 20% glycerol) for future use.
4.2.3 Production of SLC22A6 cRNA for Xenopus laevis oocyte 
injection
The pCMV-SPORT6 plasmid containing the SLC22A6 gene was isolated from 
transformed GC5™ E.coli using a Genelute™ plasmid miniprep kit as described in 
the manufacturer’s protocol. The pCMV-SPORT6 plasmid was linearised with the 
Xhol restriction enzyme (1 x NEB buffer 4, 1 x BSA, 1 pg plasmid DNA, 37°C, 1 
hour) and purified using a Genelute™ PCR clean-up kit as described in the 
manufacturer s protocol. An SP6 mMessage mMachine RNA transcription kit
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(Ambion®) was used to generate SLC22A6 cRNA from linear plasmid DNA as 
described in the manufacturer’s protocol. Following cRNA generation, plasmid DNA 
was degraded (1 pL Turbo DNase, 37°C, 15 minutes) and cRNA was concentrated 
using a lithium chloride precipitation method. Concentrated cRNA pellets were 
reconstituted in sterile water to a final concentration of 1 pg/mL for use in 
microinjection.
4.2.4 Xenopus taevis maintenance
Adult female Xenopus laevis frogs were housed in fresh, filtered water and provided 
with shelter. Frogs were monitored daily to check for signs of ill health and were fed 
dried frog food pellets twice daily. Frogs were sacrificed using anaesthetic solution 
(MS222, 5 g/L, 45 minutes) following Schedule 1 procedures.
4.2.5 Xenopus laevis oocyte isolation, collagenase treatment 
and microinjection
Oocytes were harvested from sacrificed adult female X laevis frogs and treated with 
modified Barth’s solution minus calcium and prepared for microinjection as 
described in Section 3.2.4. Healthy cells were selected and injected with SLC22A6 
cRNA (50 ng per oocyte, 1 ng/nL) or sterile water (50 nL) and maintained in Barth’s 
solution containing calcium to allow transporter expression (3 days, 18°C). Barth’s 
solution was replaced daily and damaged oocytes were removed to maintain viability 
of the healthy oocytes.
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4.2.6 Determination of raitegravir and tenofovirKm and Vmax 
using SLC22A6-injected oocytes
Unless otherwise stated, radiolabelled drug was incubated in HESS (pH 7.4) with > 4 
oocytes per condition in a 48-well nunc flat bottom plate (500 pL, 0.33 pCi/mL, 
22 C, 60 rpm shaker). Time-dependent SLC22A6-mediated transport of 
[3H]raltegravir, [3H]tenofovir and control SLC22A6 substrate, [3H]aminohippuric 
acid, was investigated by incubating each drug with SLC22A6- and water-injected 
oocytes at a standard concentration of 1 pM for various lengths of time (1, 2, 5, 10, 
15, 30, 60, 120, 180 or 240 minutes) and terminating incubations as described in 
Section 3.2.5. Results are shown in Figures 4.2, 4.3 and 4.4 and from these results an 
incubation time was chosen that gave a high accumulation rate in SLC22A6 cRNA- 
injected oocytes compared to the water-injected controls and also allowed enough 
radiolabelled drug to enter the oocytes for it to be detectable (1 hour incubations 
were chosen for both drugs). Kinetics experiments were then performed in which 
[3H]raltegravir and [3H]tenofovir were incubated with SLC22A6- and water-injected 
oocytes for one horn using a range of drug concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 
300 and 1000 pM for raitegravir and 0.3, 1, 3, 10, 30, 100, 200 and 300 pM for 
tenofovir). All incubations were terminated and processed as described in Section 
3.2.5. Transport of drug by SLC22A6 was determined by subtracting drug 
accumulation in water-injected oocytes from drug accumulation in SLC22A6 cRNA- 
injected oocytes. The Km and Vmax values were calculated by plotting initial rate of 
drug transport by SLC22A6 (pmol/oocyte/hr) against drug incubation concentration 
(pM). Intrinsic clearance (Clint) was calculated by dividing Vmax by Km.
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4.2.7 Determination of competition between raitegravir and 
tenofovir for SLC22A6 transport
[3H]raltegravir (033 (uCi/mL, 1 jaM) was incubated for 1 hour with SLC22A6 
cRNA-injected oocytes with varying concentrations of non-radiolabelled tenofovir 
(1, 3, 10, 30, 100 and 300 |iM) and the effect on [3H]raltegravir uptake was 
deteimined. [ H] raitegravir (033 pCi/mL, 1 pM) was also incubated with water- 
injected cells with and without 300 pM tenofovir in order to confirm the role of 
SLC22A6. This experiment was repeated using [3H]tenofovir as the substrate and 
non-radiolabelled raitegravir as the competitor drug, using the same concentration 
ranges. All incubations were terminated and processed as described in Section 3.2.5. 
Relative IC5o values were generated for both drugs using Prism 5.0.
4.2.8 Isolation of peripheral blood mononuclear cells from 
healthy volunteer human blood
Venous blood samples (60 mL) were obtained from healthy volunteers (n = 4) via 
venipuncture. PBMCs were isolated from blood and prepared for accumulation 
experiments as described in Section 2.2.7.
4.2.9 Cellular accumulation of raitegravir in peripheral blood 
mononuclear cells
Accumulation of raitegravir in PBMCs was determined using the same method as 
used in Section 2.2.8, with modifications. Briefly, cells of a constant cell density (1 
mL, 5x10 cells/mL) were incubated (37 °C, 5% CO2) for 30 minutes in cell culture 
medium (RPMI, 10% [vol/vol] PCS) containing [3H]raitegravir (1 pM, 0.2 pCi/mL).
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Separate incubations were undertaken where cells were pre-incubated with cell 
culture medium (RPMI, 10% [vol/vol] FCS) containing either the competitive 
SLC22A6 inhibitor probenecid (1 mM, 30 minutes) or the competitive SLC15A1 
inhibitor glycyl-sarcosine (1 mM, 30 minutes), which were also included during the 
30 minutes of substrate incubation. Cells were washed and treated for analysis as 
described in Section 2.2.8. Using supernatant fraction and intracellular radioactivity 
readings, CARs were calculated for raltegravir as described in Section 2.2.5. Data are 
expressed as mean CAR (n — 4 biological replicates, n > 3 experimental replicates 
per biological replicate) ± SD.
4.2.10 Culture of human primary renal proximal tubule 
epithelial cells
Human primary renal proximal tubule epithelial cells (“renal cells”) were maintained 
in complete growth medium. Complete growth medium was supplemented with 
0.5% [vol/vol] FCS, 10 nM triiodothyronine, 10 ng/mL Epidermal growth factor, 100 
ng/mL hydrocortisone hemisuccinate, 5 pg/mL insulin, 1 pM epinephrine, 5 pg/mL 
transferring, 2.4 mM L-alanyl-L-glutamine and 100 pg/mL penicillin/streptomycin. 
Once a cell confluence of approximately 95% was reached, renal cells were washed 
three times with HBSS (37°C) and incubated with trypsin-EDTA solution (37°C, 5 
minutes). Flasks were gently tapped to remove renal cells and supplemented 
complete growth medium was added to neutralise the trypsin. Cells were added to a 
50 mL skirted tube and centrifuged (800 g, 4°C, 5 minutes). Supernatant fraction was 
removed and replaced with fresh supplemented complete growth media to a final 
density of 5 x 105 cells/mL. Cells were seeded onto new culture flasks at a density of 
1 x 105 cells/cm2.
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4.2.11 Cellular accumulation of raltegravir, tenofovir and 
aminohippuric acid in primary renal proximal tubule epithelial 
cells
When confluent, renal cells (passage 4) were seeded onto polyester membrane 
transwells at a density of 5 x 105 cells/cm2. Media was replaced daily and plates were 
used in experiments after five days. On the day of the experiment, media was 
replaced with buffered HESS (25 mM HEPES, pH 7.4) containing either 
[3H]raltegravir (1 pM, 0.6 pCi/mL), [3H]tenofovir (1 pM, 0.6 pCi/mL) or the control 
SLC22A6 substrate [3H]amminohippuric acid (1 pM, 0.6 pCi/mL) and incubated (3 
hours, 37°C, 5% CO2). A separate incubation was undertaken where the cells were 
pre-incubated prior to substrate addition with buffered HESS (25 mM HEPES, pH 
7,4) containing the SLC22A6 inhibitor probenecid (1 mM, 30 minutes), which was 
also included during the three hours of substrate incubation. We also investigated the 
competition between raltegravir and tenofovir by incubating [3H]raltegravir (1 pM, 
0.6 pCi/mL) with 100 pM tenofovir and incubating [3H]tenofovir (1 pM, 0.6 
pCi/mL) with 100 pM raltegravir (3 hours, 37°C, 5% CO2). Once incubations were 
complete, extracellular samples were taken and incubations were terminated by 
washing each well with cold HESS (4°C, 3 mL) three times to remove excess drug. 
Cells were lysed with 0.5 mL tap water and contents were analysed by liquid 
scintillation as described in Section 2.2.5.
4.2.12 Determination of transporter mRNA expression in 
primary renal proximal tubule cells and whole kidney
Messenger RNA (mRNA) from primary renal proximal tubule cells were isolated 
using TRI reagent® according to the manufacturer’s protocol. Specifically, TRI
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reagent was added to cells (ImL for every 10cm2 cell monolayer culture) and 
thoroughly mixed using a pipette. Cell homogenate was incubated (5 minutes, 22°C), 
added to l-bromo-3-chloropropane (BCP, 100 pL for every 1 mL TRI reagent) and 
further incubated (15 minutes, 22°C). Mixtures were centrifuged (12000 g, 15 
minutes, 4°C) and supernatant fraction was transferred to a new tube. Isopropanol 
was added to samples (500 pL for every 1 mL TRI reagent) and tubes were mixed 
and incubated (10 minutes, 22°C). Tubes were centrifuged (12000 g, 8 minutes, 4°C) 
and supernatant fraction was discarded. The mRNA pellets were resuspended in 
75%/25% ethanol/water mixture (ImL for every 1 mL TRI reagent) and centrifuged 
(7000 g, 5 minutes, 22°C). Supernatant fraction was discarded and RNA pellets were 
allowed to air dry (5 minutes, 22 °C) before being resuspended in nuclease-ffee water 
for use in reverse transcriptase experiments.
The mRNA was reverse transcribed using the TaqMan® Reverse Transcription kit 
according to the manufacturer’s protocol. Specifically, the ingredients of a 20 pL 
reaction were: 2 pL 10X TaqMan reverse transcriptase buffer, 4 pL 25 mM 
magnesium chloride, 4 pL 10 mM deoxyNTP mixture, 0.5 pg random hexamers, 0.5 
pL RNase inhibitor, 0.5 pL MultiScribe Reverse Transcriptase (50 U/pL) and 2 pg 
mRNA. Reactions were incubated at 42°C (15 minutes) followed by a denaturing 
incubation at 95°C (5 minutes).
TaqMan® array plates (custom designed and containing primers for a selection of 
transporter genes) were loaded with reverse-transcribed cDNA (40ng) and used to 
quantify mRNA expression by standard real-time PCR methodology. Specifically, 
the ingredients of a 20 pL reaction were: 10 pL TaqMan Master Mix, 50 ng cDNA
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and DNase-free water (to make up 20 pL volume total). Real-time polymerase chain 
reactions (RT-PCR) were run using the following times; 50°C for 2 minutes, 95°C 
for 10 minutes, followed by 40 cycles of [95°C for 15 seconds, 60°C for 1 minute).
This process was repeated and mRNA quantification obtained for whole kidney 
purchased from Ambion (UK), which was created from a pool of three individuals. 
Transporters were quantified using the 55Ct method and included SLC22A6, 
SLC22A1, SLC22A2, SLC22A3, ABCC1, ABCC2, ABCC3, ABCC4 and ABCC10. 
GAPDH was used as the housekeeping gene.
4.2.13 Statistical analysis
Data were analysed using SPSS 15.0 for Windows. All data were tested for normality 
using the Shapiro-Wilk test. An independent t test was used to determine the 
significance of normally distributed data and the Mann Whitney U test was used for
all other data. A two-tailed p value of < 0.05 was accepted as being statistically 
significant.
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4.3 RESULTS
4.3.1 Time-dependent accumulation of raltegravir, tenofovir 
and aminohippuric acid in SLC22A6-injected oocytes
All drugs tested had a greater accumulation rate in SLC22A6-injected oocytes 
compared to water-injected oocytes (Figures 4.2, 4.3 and 4.4). Raltegravir 
concentrations continued to increase in SLC22A6-injected oocytes throughout the 
four hour incubation whereas saturation was reached in water-injected oocytes after 
around two hours. Both tenofovir and aminohippuric acid showed virtually no 
accumulation in water-injected oocytes over the four hour incubation.
Incubation time (min)
Figure 4.2. SLC22A6-injected (orange circle) and water-injected (blue circle) oocyte 
uptake of [ Hjraltegravir over a tour hour incubation. Data are expressed as mean 
[ Hjraltegravir accumulation (pmol/oocyte, n = 5 experimental replicates from one 
biological replicate) ± SE.
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Incubation time (min)
Figure 4.3. SLC22A6-injected (orange circle) and water-injected (blue circle) oocyte 
uptake of [ Hjtenofovir over a four hour incubation. Data are expressed as mean 
[ Hjtenofovir accumulation (pmol/oocyte, n = 5 experimental replicates from one 
biological replicate) ± SE.
E 5-
Incubation time (min)
Figure 4.4. SLC22A6-injected (orange circle) and water-injected (blue circle) oocyte 
uptake of [3H]aminohippuric acid over a four hour incubation. Data are expressed as 
mean [ Hjaminohippunc acid accumulation (pmol/oocyte, n = 5 experimental 
replicates from one biological replicate) ± SE.
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4.3.2 Raltegravir and tenofovir Km and Vmax values using 
SLC22A6-injected oocytes
An incubation of one hour was chosen for subsequent kinetic studies. Raltegravir and 
tenofovir kinetics were determined for SLC22A6 in the oocyte expression system 
(Figures 4.5 and 4.6). Raltegravir Km and Vmax were calculated to be 150 pM and 36 
pmol/oocyte/hr, respectively. Raltegravir Cllnt (Vmax/Km) was calculated as 0.2 
pL/oocyte/hr. Tenofovir Km and VmiK were calculated as 25 pM and 129 
pmol/oocyte/hr, respectively. The determined Km value for tenofovir was similar to a 
previously published value of 21.1 pM using the Xenopus laevis oocyte expression 
system (Bleasby et al, 2005). Tenofovir Clint was calculated as 5.2 pL/oocyte/hr.
(0 o
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Figure 4.5. Concentration dependency of the uptake of raltegravir by SLC22A6. 
Data are expressed as mean rate of raltegravir transport (pmol/oocyte/hour, n > 4 
experimental replicates from one biological replicate) ± SE.
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Figure 4.6. Concentration dependency of the uptake of tenofovir by SLC22A6. Data 
are expressed as mean rate of tenofovir transport (pmol/oocyte/hour, n > 4 
experimental replicates from one biological replicate) ± SE.
4.3.3 Competition between raitegravir and tenofovir for 
SLC22A6 transport
When incubated at 1 pM for one hour, raitegravir showed significantly higher 
accumulation in SLC22A6 cRNA-injected oocytes than in water-injected oocytes 
(1.73 ± 0.46 pmol/oocyte versus 0.54 ± 0.06 pmol/oocyte, n = 5, p = 0.014) (Figure 
4.7A). The co-incubation of raitegravir with 1, 3, 10, 30, 100 and 300 pM tenofovir 
resulted in levels of raitegravir in SLC22A6-injected oocytes of 1.78 ± 0.41 
pmol/oocyte, 1.63 ± 0.62 pmol/oocyte, 1.48 ± 0.58 pmol/oocyte, 1.28 ± 0.27 
pmol/oocyte, 0.96 ± 0.28 pmol/oocyte and 0.83 ± 0.31 pmol/oocyte, respectively 
(Figure 4.7B). There was a statistically significant decrease (p < 0.05) in raitegravir 
accumulation when concentrations of 100 pM tenofovir and higher were added to the 
incubation mixture.
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Similar results were seen when tenofovir accumulation was investigated in the 
presence of various concentrations of raltegravir. When incubated at 1 jiM for one 
hour', tenofovir showed significantly higher accumulation in SLC22A6 cRNA- 
injected oocytes than in water-injected oocytes (2.11 ± 0.37 pmol/oocyte vs 0.03 ± 
0.01 pmol/oocyte, n = 5, p < 0.01) (Figure 4.7C). The co-incubation of tenofovir with 
1, 3, 10, 30, 100 and 300 pM raltegravir resulted in tenofovir accumulation in 
SLC22A6-injected oocytes of 2.11 ± 0.14 pmol/oocyte, 2.07 ± 0.38 pmol/oocyte, 
1.47 ± 0.43 pmol/oocyte, 0.78 ± 0.50 pmol/oocyte, 0.49 ± 0.06 pmol/oocyte and 0.28 
± 0.08 pmol/oocyte, respectively (Figure 4.7D). There was a statistically significant 
decrease (p < 0.05) in tenofovir accumulation when concentrations of 10 pM 
raltegravir and higher were added to the incubation mixtures.
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Figure 4.7 (A) Accumulation of 1 |uM raltegravir in SLC22A6- and water-injected 
oocytes with and without the addition of 300 |aM tenofovir. (B) Accumulation of 1 
tenotovir in SLC22A6- and water-injected oocytes with and without the addition 
of 300 jj.M raltegravir. Data in A and B are expressed as mean drug concentration per 
oocyte (pmol/oocyte) (n = 5 experimental replicates from one biological replicate) ± 
SE. (C) Determination of IC5o for inhibition of 1 pM raltegravir SLC22A6 transport 
by tenofovir. Data are expressed as mean raltegravir oocyte concentration 
(pmol/oocyte) (n = 5 experimental replicates from one biological replicate) ± SE. (D) 
Determination of IC50 value for inhibition of 1 pM tenofovir SLC22A6 transport by 
raltegravir. Data are expressed as mean tenofovir oocyte concentration (pmol/oocyte) 
(n = 5 experimental replicates from one biological replicate) ± SE.
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4.3.4 Effect ofSLC22A6 and SLC15A1 inhibitors on the 
accumulation of raltegravir in peripheral blood mononuclear 
cells
Raltegravir accumulation in PBMCs from four healthy human subjects was 
determined (Figure 4.8). Probenecid and glycyl-sarcosine were used to determine the 
extent of raltegravir transport by SLC22A6 and SLC15A1, respectively. Data are 
expressed as mean CAR ± SD. Raltegravir CAR was not significantly altered in 
glycyl-sarcosine-treated cells compared to non-treated cells in subject 1 (3.47 ± 0.36 
versus 3.78 ± 0.70, p = 0.513), subject 2 (4.54 ± 1.62 versus 3.13 ± 0.22, p = 0.146), 
subject 3 (2.70 ± 0.53 versus 3.03 ± 0.97, p = 0.564) or subject 4 (2.33 ± 0.57 versus 
2.15 ± 0.30, p = 0.827). Raltegravir CAR was not significantly altered in probenecid- 
treated cells compared to non-treated cells in subject 1 (2.83 ± 0.85 versus 3.78 ± 
0.70, p = 0.127), subject 3 (3.90 ± 0.80 versus 3.03 ± 0.97, p = 0.149) or subject 4 
(2.27 ± 0.21 versus 2.15 ± 0.30, p = 0.513), but was significantly higher in 
probenecid-treated cells compared to non-treated cells in subject 2 (3.94 ± 0.57 
versus 3.13 ± 0.22, p = 0.042). When combining the average results from each 
subject, raltegravir CAR was not significantly different in glycyl-sarcosine-treated 
cells compared to non-treated cells (3.23 ± 0.83 versus 3.02 ± 0.67, p = 0.77) or in 
probenecid-treated cells compared to non-treated cells (3.26 ± 0.98 versus 3.02 ± 
0.67, p = 0.77).
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Combined data
Figure 4.8. Raltegravir (RAL; 1 |aM) accumulation in PBMCs and PBMCs co­
incubated with 1 mM glycyl-sarcosine (GLY; SLC15A1 inhibitor) or 1 mM 
probenecid (PRO, SLC22A6 inhibitor). Data for subjects 1, 2, 3 and 4 are expressed 
as mean CAR (n > 3 experimental replicates) ± SD. Combined data are expressed as
mean CAR (n = 4 biological replicates, n > 3 experimental replicates per biological 
replicate) ± SD.
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4.3.5 Cellular accumulation of raltegravir, tenofovir and 
aminohippuric acid in primary renal proximal tubule epithelial 
cells
The cellular accumulation of raltegravir (CAR = 2.01 ± 0.20) (Figure 4.9A), 
tenofovir (CAR = 3.45 ± 0.76) (Figure 4.9B) and aminohippuric acid (CAR = 0.50 ± 
0.02) (Figure 4.9C) were determined in renal proximal tubule epithelial cells. 
Raltegravir cellular- accumulation was not significantly altered by 1 mM probenecid 
(CAR - 2.19 ± 0.45, p = 0.56) or 100 pM tenofovir (CAR - 2.07 ± 0.08, p = 0.66). 
Tenofovir showed a high level of cellular accumulation, which was not significantly 
altered by treatment with 1 mM probenecid (CAR - 2.59 ± 0.56, p = 0.19) or 100 
pM raltegravir (CAR = 3.15 ± 0.74, p = 0.65). For aminohippuric acid a trend was 
seen towards a lower level of cellular accumulation when incubated with 1 mM 
probenecid (CAR = 0.44 ± 0.03, p = 0.08).
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Figure 4.9. (A) Raltegravir (RAL; 1 jaM) accumulation in primary renal proximal 
tubule cells alone or treated with 1 mM probenecid (PRO; SLC22A6 inhibitor) or 
100 pM tenotovir (TFV). (B) Tenofovir (1 pM) accumulation in primary renal 
proximal tubule cells alone or treated with 1 mM probenecid or 100 pM raltegravir. 
(C) Aminohippuric acid (AHA; 1 pM) accumulation in primary renal proximal 
tubule cells alone or treated with 1 mM probenecid. Data are expressed as mean 
CAR (n = 3 experimental replicates) ± SD.
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4.3.6 Transporter expression in cultured renal cells and 
kidney tissue
All transporters tested showed lower or undetectable expression in primary renal 
proximal tubule cells compared to whole kidney (Figure 4.10). Importantly, 
SLC22A6 was undetectable in the primary renal cells.
100»
Figure 4.10. Relative abundance of transporter RNA in cultured renal proximal 
tubule cells compared to transporter RNA in whole kidney (log scale %. n = 1 
experimental replicate).
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4.4. DISCUSSION
This chapter investigated the affinity of raltegravir and tenofovir for influx 
transporter SLC22A6 using the Xenopits laevis oocyte expression system. 
Competition between raltegravir and tenofovir for SLC22A6 transport was also 
determined. In SLC22A6 cRNA-injected oocytes, raltegravir and tenofovir inhibited 
the accumulation of each other in a concentration-dependent manner (Figure 4.7). 
This competition was not observed in water-injected oocytes, which supports the 
hypothesis that raltegravir and tenofovir compete for SLC22A6 transport and are not 
having non-specific effects on oocyte membrane permeability.
Raltegravir accumulation in SLC22A6-expressing oocyte was inhibited by tenofovir 
with an IC50 value of 27.3 pM. Tenofovir accumulation in SLC22A6-expressing 
oocyte was inhibited by raltegravir with an IC5o value of 14.0 pM. The IC5o obtained 
for raltegravir was much lower than the observed Km determined for SLC22A6 (IC5o 
of 14.0 pM versus a Km of 147 pM). This suggests that raltegravir is a more 
efficient SLC22A6 inhibitor than it is a substrate. Previous studies have indicated 
that SLC22A6 and SLC15A1 are absent from PBMCs (Bleasby et al., 2006) and so 
these transporters are unlikely to explain the unusual PK-PD relationship for 
raltegravir. Indeed, our studies in PBMCs with known inhibitors of SLC22A6 and 
SLC15A1 revealed no significant interaction with raltegravir.
Wenning et al (2008) studied the interaction of raltegravir (400 mg twice-daily) and 
tenofovir (300 mg once-daily). The study showed increased raltegravir AUC (49%) 
and Cmax (64%), but no effect on raltegravir Cmin, and a decrease in tenofovir AUC
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(10%), Cmax (23%) and Cmin (13%) (Wenning et al, 2008), SLC22A6 is 
predominantly expressed in the proximal tubule of the kidney on the basolateral 
(blood-facing) surface, thereby facilitating removal of drugs out of the blood and into 
the urine (Rizwan et al., 2007). Therefore, a possible mechanism of this interaction is 
inhibition of SLC22A6-mediated raltegravir transport at the kidney proximal tubule 
by tenofovir, resulting in increased raltegravir plasma concentrations.
In order to investigate interactions at the level of the kidney we conducted a number 
of experiments in primary renal proximal cells. No interaction between tenofovir and 
raltegravir was observed in these cells but neither was an interaction between 
positive control substrate aminohippuric acid and inhibitor probenecid. Subsequent 
analyses revealed expression of SLC22A6 mRNA to be undetectable in primary 
renal proximal cells, unlike in kidney tissue. Furthermore, all other transporters that 
were assessed were at lower expression than kidney tissue. It is possible that 
stimulating the primary cells to divide using Complete Growth Media results in 
reduced transporter expression. Indeed, the human kidney clear cell carcinoma cell 
line, Caki-1, has been shown to have undetectable SLC22A6 mRNA expression 
(Hilgendorf et al, 2007). The same study showed significantly lower or absent 
mRNA expression of other several transporters in Caki-1, Caco-2 and HepG2 (liver) 
cell lines, emphasising the issue with using immortalised cell lines in transporter 
studies. The absence of a robust primary cell model for these studies is a limitation 
that precluded further in vitro investigation of this mechanism.
Since only a small percentage (around 30%) of raltegravir excreted via the kidney is 
in the parent form, with the remaining 70% being a glucuronide metabolite
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(Kassahun et aL, 2007), it is important to determine if the raltegravir glucuronide is 
also transported by SLC22A6 and inhibited by tenofovir. It would also be interesting 
to investigate the transport and inhibitory potential of tenofovir diphosphate (fully 
phosphorylated tenofovir) or tenofovir disoproxil fumerate (prodrug of tenofovir) for 
SLC22A6 and whether this affects raltegravir transport to the same extent.
In conclusion, raltegravir and tenofovir show competition for SLC22A6 transport in 
vitro, although the significance of this interaction requires further investigation in 
vivo. The reduced exposure of raltegravir in patients when co-administered with 
tenofovir may involve the SLC22A6 transporter. However, even if SLC22A6 is 
shown to influence raltegravir disposition in humans, it is unlikely that this will fully 
explain the large intra- and inter-patient variability seen in raltegravir PK.
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Chapter 5
The impact of pH, metal binding and omeprazole on 
raltegravir physicochemistry and disposition
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5.1 INTRODUCTION
The pH of the GI tract is an important factor in the absorption of many drugs, 
potentially altering drug release, solubility, chemical stability, charge state and/or 
intestinal permeation (Charman et al^ 1997). Ionic drugs with a pKa within the 
physiological pH range are susceptible to alterations in GI pH because drugs with an 
ionic charge are less able to permeate the intestine wall without active transport. In 
healthy volunteers, raltegravir GMR for AUC, Cmax and C12hr increased 3.1, 4.2 and 
1.5-fold, respectively, following five days of 20 mg once-daily omeprazole (Iwamoto 
et al, 2009b); higher solubility at increasing pH was postulated as the mechanism of 
interaction (Brainard et al, 2011c). However, GI pH was not measured in this study 
and there are no published data showing the effect of pH on raltegravir solubility in 
vitro. In a similar study using HIV-infected patients, raltegravir GMR for AUC, Cmax 
and Cnhr was 1.4, 1.5 and 1.2-fold higher, respectively, following five days of 20 mg 
once-daily omeprazole and 1.5, 1.6 and 1.1-fold higher, respectively, following a 
single dose of 20 mg famotidine (Rhame et al, 2009). HIV-infected patients, 
particularly those with advanced disease progression, have higher gastric pH than 
uninfected individuals (Shelton et al, 2000) and this may explain why acid-reducing 
agents showed less impact on raltegravir PK in the study involving HIV-infected 
patients.
After ingestion of a meal, gastric pH is briefly elevated due to the buffering and 
diluting effect of the food (Charman et al, 1997). The extent of gastric pH increase 
and the rate at which pH is lowered to fasting state levels depends on the volume of 
the food, the ability of the food to stimulate gastric acid secretion and the rate of 
gastric emptying. Other factors, such as fat and protein content of food, are also
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important. In a steady-state food-effect study using healthy subjects, alterations in 
raltegravir exposure from a fasted state were shown for low fat (GMR of AUC, Cmax 
and Cnhr of 0.54, 0.48 and 0.86, respectively), medium fat (GMR of AUC, Cmax and 
Cnhr of 1.13, 1.05 and 1.66, respectively) and high fat (GMR of AUC, Cmax and Ci2hr 
of 2.11, 1.96 and 4.13, respectively) meals (Brainard et al, 2011a). However, this 
study concluded that the effect of food was not clinically significant and 
recommended that raltegravir can be taken without regard to food.
Integrase strand transfer inhibitors work by chelating magnesium ions at the 
integrase enzyme active site, therefore preventing the insertion of viral DNA into the 
host cell’s DNA (Espeseth et al, 2000). Therefore, it is possible that by binding with 
free magnesium (and possibly other polyvalent cationic metals), the absoiption of 
raltegravir may decrease. Indeed, interactions between integrase inhibitors and metal- 
containing products have been investigated. Raltegravir Ci2hr and Tmax were reduced 
by 67% and 1.75 horns, respectively, when taken with an antacid containing 
magnesium and aluminium, although the AUC and Cmax were not significantly 
altered (Kiser et al, 2010). Importantly, 75% of subjects taking antacids had a 
raltegravir Ci2hr lower than 15 ng/mL (IC95 of raltegravir in 50% human serum). The 
authors hypothesised that this interaction may be mediated by an increase in 
raltegravir solubility with increased pH (decreasing the Tmax) and binding of 
raltegravir to the metal ions in the antacid (decreasing Ci2hr).
The investigations in this chapter aimed to establish the solubility, lipophilicity and 
pKa of raltegravir in vitro using a range of buffered pH solutions and solvents. The 
breakdown rate of raltegravir 400 mg tablets were determined in different pH
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solutions to help explain delayed and double peaks in raltegravir PK profiles. The 
impact of pH, metal cations and omeprazole on raltegravir transcellular permeation 
across a a Caco-2 monolayer were also determined. Raltegravir is a substrate of 
ABCB1 in vitro (Moss et a/., 2011) (Chapter 2) and the inteiplay between pH and 
ABCB1 transport was investigated in cellular accumulation assays to ascertain 
whether active transport of raltegravir by ABCB1 was influenced by pH.
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5.2 METHODS
5.2.1 Chemical reagents and materials
Caco-2 cells were purchased from the European Collection of Cell Cultures 
(Salisbury, UK). Raltegravir potassium salt, [3H]raltegravir and standard 400 mg 
raltegravir tablets were gifts from Merck (New Jersey, USA). Lopinavir was a gift 
from Abbott (Illinois, USA). [3H]Lopinavir was purchased from Moravek 
Biochemicals (California, USA). Tariquidar was purchased from Xenova (Sloane, 
UK). Acetonitrile was purchased from J. T Baker (Deventer, Holland). [14C]Mannitol 
was purchased from American Radiolabelled Chemicals (Missouri, USA). All other 
reagents were obtained from Sigma (Poole, UK).
5.2.2 Creation of buffered pH solutions for solubility, 
lipophilicity, pKa and tablet breakdown experiments
Stock aqueous solutions were buffered to pH 1 (50 mM potassium chloride + 134 
mM hydrogen chloride), 2 (50 mM potassium chloride +13 mM hydrogen chloride), 
3 (50 mM potassium hydrogen phthalate + 22.3 mM hydrogen chloride), 4 (50 mM 
potassium hydrogen phthalate + 0.1 mM hydrochloric acid), 5 (50 mM potassium 
hydrogen phthalate + 22.6 mM sodium hydroxide), 6 (50 mM monopotassium 
phosphate + 5.6 mM sodium hydroxide), 7 (50 mM monopotassium phosphate + 
29.1 mM sodium hydroxide), 8 (50 mM tris hydroxymethyl aminomethane + 29.2 
mM hydrogen chloride) and 9 (50 mM tris hydroxymethyl aminomethane + 5.7 mM 
hydrogen chloride). These stock solutions were used in experiments or were adjusted 
using 1 M hydrochloric acid or 1 M sodium hydroxide to create the required pH.
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5.2.3 Determination of raitegravir solubility
Raltegravir solubility was determined at 1 mM and 10 mM (estimated range of drug 
concentrations in the stomach and duodenum of the gut following raltegravir 
dissolution) in a pH range of 1 to 8. Solutions were mixed on a mechanical shaker 
(120 rpm, 37°C, 2 horns) and vigorously mixed to allow maximum dissolution of 
raltegravir. Samples were then centrifuged to pellet undissolved drug (3000 g, 10 
minutes, 22 C) and the supernatant carefully removed. Raltegravir concentrations in 
the supernatant were determined using LC-MS/MS analysis (Section 5.2.12)
5.2.4 Determination of raltegravir lipophilicity
Raltegravir lipophilicity was determined across a physiologically relevant pH range 
of 1 to 9 using the octanohwater Shake Flask Method. The organic solvent used was 
either 1-octanol, which allows hydrogen bonding, or cyclohexane, which does not 
allow hydrogen bonding. The aqueous and organic solvents were mutually saturated 
on a mechanical shaker (240 rpm, 24 hours, 22°C) before use. Raltegravir was added 
to the aqueous solvent at 10 pM (a concentration ensuring complete solubility in all 
pH solutions) before combining the aqueous and organic solvents in a 1:1 ratio and 
shaking the mixtures for 30 minutes. Mixtures were centrifuged (800 g, 30 minutes, 
22 C) and a sample taken from the aqueous compartment for LC-MS/MS analysis 
(Section 5.2.12). Calculation of the apparent logP (also referred to as “logP” in this 
chapter) was based on the following equation:
Apparent logP = log (C0rganic/ CaqueoUs)
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Where Caqueous is the concentration of raltegravir in the aqueous solvent and Corganic is 
the concentration of raltegravir in the organic solvent (estimated by deducting 
raltegravir in the aqueous compartment from the total amount in the mixture).
5.2.5 Determination of raltegravir pKa
Raltegravir pKa was determined using UV spectroscopy (Blanco et al, 2005). 
Raltegravir was prepared in buffered pH solutions to a final concentration of 8 pM (a 
concentration giving an adequate signal for detection). The buffered pH solutions 
ranged between pH 3.5 and 9.5. Drug solutions were added to cuvettes and placed in 
a UV spectrophotometer (Perkin Elmer lambda 25 UV-vis) and allowed to 
acclimatise (25 C, 5 minutes). Following this, the UV-vis spectra were measured 
between 200 nm and 500 nm. The absorbance values were recorded at 300 nm 
(absorbance peak predominant at lower pH) and 333 nm (absorbance peak 
predominant at higher pH). For each pH the absorbance at 333 nm was divided by 
the absorbance at 300 nm and plotted to calculate the pKa.
5.2.6 Determination of raltegravir tablet breakdown rate
The breakdown rate of standard raltegravir 400 mg tablets were determined across a 
pH range of 1 to 8. The weight of each tablet was first recorded before the 
experiment. Tablets were then added to 150 mL pH buffer solution (roughly the 
volume of a fasted stomach) and gently rotated in an incubator to simulate the 
churning of the stomach (10 ipm, 37°C). Tablets were removed from solutions after 
30 minutes incubation and allowed to completely dry (4 hours, 50°C). The weight of
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each tablet was recorded and compared to the initial weight. Data was then used to 
calculate tablet dissolution rate (% of total tablet broken down/minute, n = 1 
experimental replicate).
5.2.7 Caco-2 cell culture
Caco-2 cells were maintained in cell culture (37°C, 5% C02) by passaging at 70% 
confluence using cell culture medium (DMEM, 15% [vol/vol] PCS). The passage 
numbei of the cells used in this study was between 25 and 35. Caco-2 monolayers 
were cultured as previously described in Section 2.2.2.4 and were subsequently used 
to determine the effects of pH, metal salts and omeprazole on raltegravir monolayer 
permeation. Briefly, confluent Caco-2 cells were seeded onto polycarbonate 
membrane transwells at a density of 5 x 105 cells/cm2. Media was replaced initially 
after 24 hours and then every 48 hours. Plates were used in the experiments 21 days 
after seeding. Monolayer integrity was checked on the day of the experiment using a 
MillicellERS (Millipore) to determine the TEER across the monolayer. A TEER of > 
600 was deemed acceptable. In addition, radiolabelled [14C]mannitol was added to 
separate wells on each plate (n = 3 replicates) to confirm monolayer integrity. 
[I4C]Mannitol samples were analysed by liquid scintillation counting (Beckman TRI- 
CARB®) and plates were only used for experiments if the average Papp of mannitol 
was less than 1 cm x 10'6 s"1.
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5.2.8 impact of pH on raltegravir cell monolayer permeation
On the day of study, the TEER was assessed and the media in each plate was 
replaced with the appropriate pH-buffered incubation solutions. The pH in the 
basolateral compartments was maintained at pH 7.4 (HBSS containing 25 mM 
HEPES) and the pH in the apical compartments were maintained at pH 5, 6, 6.5 
(HBSS containing 10 mM MES), 7, 7.4, 8 (HBSS containing 25 mM HEPES) or 8.5 
(HBSS containing 10 mM Tricine). Compartments were allowed to equilibrate 
(37°C, 30 minutes). The incubation buffer in the apical (for apical to basolateral 
transport) and basolateral (for basolateral to apical transport) compartments were 
replaced with the appropriate incubation buffer containing raltegravir (50 pM) and 
plates were incubated (37°C, 5% C02). A concentration of 50 pM raltegravir, which 
was shown to be non-toxic to Caco-2 cells in Chapter 2, was used to ensure complete 
dissolution of drug at all pH solutions (as predicted by the solubility data) and to 
ensure drug concentrations in receiver compartments were sufficiently high to be 
quantifiable by LC-MS/MS. Samples were taken from the receiver compartments at 
0, 30, 60, 90, and 120 minutes and replaced with fresh incubation buffer of the 
correct pH. Samples were analysed using LC-MS/MS (Section 5.2.12). Results were 
used to determine Papp (cm x 10'6 s'1) for each direction and to determine the efflux 
ratio, as described in Section 2.2.6.
5.2.9 Impact of divalent and monovalent metals on raltegravir 
cell monolayer permeation
On the day of study, the TEER was assessed and the media in each plate was 
replaced with the appropriate pH-buffered incubation solution. The pH in the
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basolateral compartments was maintained at pH 7.4 (HBSS without calcium chloride 
or magnesium sulphate (SIGMA code: H6648) containing 25 mM HEPES) and the 
pH in the apical compartments was maintained at pH 5 (HBSS without calcium 
chloride or magnesium sulphate containing 10 mM MES) or pH 7.4 (HBSS without 
calcium chloride or magnesium sulphate containing 25 mM HEPES). In the apical 
compartments at pH 5, magnesium chloride (1 mM, 10 mM or 25 mM), magnesium 
sulphate (25 mM), calcium chloride (25 mM) or potassium chloride (25 mM) were 
added. In the apical compartments at pH 7.4, magnesium chloride (1,10 or 25 mM) 
was added. A maximum concentration of 25 mM was used for magnesium chloride 
as higher concentrations used in validation showed Caco-2 cell toxicity. Control 
apical compartments at pH 5 and pH 7.4 were also used, which were not 
supplemented with metal salts (other than those in the original buffer: 5.4 mM 
potassium chloride, 0.4 mM monopotassium phosphate, 4.2 mM sodium bicarbonate, 
138 mM sodium chloride and 3.4 mM disodium phosphate). The pH in the 
basolateral compartments were maintained at pH 7.4 and were not supplemented 
with additional metal salts. A concentration of 1 pM was used for all test compounds 
in order to maximise the metal-to-drug ratio. Lopinavir was used as a negative 
control as there is no evidence that it binds to metals. The incubation buffer in the 
apical (for A-to-B transport) and basolateral (for B-to-A transport) compartments 
were replaced with the appropriate incubation buffer containing radiolabelled 
[3H]raltegravir (1 pM, 0.5 pCi/mL) or [3H]lopinavir (1 pM, 0.5 pCi/mL) and plates 
were incubated (37°C, 5% CO2). Samples were taken from the receiver 
compartments at 0 and 30 minutes and were analysed by liquid scintillation counting 
(Beckman TRI-CARB®). The Papp and efflux ratios were calculated as described in 
Section 2.2.6.
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5.2.10 Impact of omeprazole on raltegravir cell monolayer 
permeation
For induction studies using transwells, the cell monolayers were incubated with 
omeprazole (10 fiM) for the last three days of the 21-day monolayer maturation. On 
the day of the experiment, the TEER was assessed and the media in each plate was 
replaced with warm incubation buffer (HESS containing 25 mM HEPES, pH 7.4) 
and allowed to equilibrate (37°C, 30 minutes).
For inhibition studies, the incubation buffer contained omeprazole at 20 pM, as 
lower concentrations are known to inhibit CYP2C9 and CYP2C19 in vitro. The 
incubation buffer in the apical (for A-to-B transport) and basolateral (for B-to-A 
transport) compartments were replaced with incubation buffer containing the test 
substrate raltegravir (1 pM) with or without 20 pM omeprazole, and plates were 
incubated (37°C, 5% CO2). A concentration of 1 pM raltegravir was used to avoid 
saturation of drug transporters (Hubatsch et ctl, 2007). Samples were taken from the 
receiver compartments at 0 and 60 minutes and were analysed by liquid scintillation 
counting (Beckman TRI-CARB®). The Papp and efflux ratios were calculated as 
described in Section 2.2.6.
5.2.11 Cellular accumulation
Caco-2 cells were seeded (5 x 104 cells/mL) onto 6-well plates and grown for five 
days to reach the required confluence (DMEM, 15% [vol/vol] FCS, 37°C, 5% C02). 
Media was removed and cells were washed with warm HBSS and replaced with the 
appropriate pH-buffered incubation solution and allowed to equilibrate (37°C, 15
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minutes). The pH in the wells was fixed at either pH 5, 6 (HESS containing 10 mM 
MES), 7 or 8 (HESS containing 25 mM HEPES). The test substrate raltegravir (1 
pM) was added to the wells and plates were incubated (37°C, 5% C02, 10 minutes). 
A concentration of 1 pM raltegravir was used to avoid saturation of drug transporters 
(Hubatsch et al, 2007). A separate incubation was undertaken where cells were pre­
incubated (DMEM, 15% FES, 37°C, 5% CO2) prior to raltegravir addition with the 
potent non-competitive ABCB1 inhibitor, tariquidar (300 nM, 30 minutes), which 
was also included during the 10 minutes of raltegravir incubation. Following 
incubation, an extracellular sample was removed from each well for analysis, wells 
were washed three times with ice cold HESS and 500 pL tap water was added to 
each empty well to lyse cells. Plates were frozen at minus 20°C overnight to aid 
removal of cells. Plates were thawed and 500 pL acetonitrile added to each well to 
release drug from protein. The well contents were transferred to separate 1.5 mL 
tubes for centrifugation (3000 g, 10 minutes, 22°C) and supernatant was removed. 
Supernatant fraction was vacuum-dried and reconstituted in HPLC-grade water for 
LC-MS/MS analysis (Section 5.2.12).
5.2.12 LC-MS/MS analysis
Samples from all studies using non-radiolabelled raltegravir (other than from cell 
accumulation studies) could be directly injected into the LC-MS/MS after dilution 
with HPLC-grade water. Samples from cell accumulation studies were prepared as 
described in the cellular accumulation method Section 5.2.11. The LC-MS/MS 
system used for sample analysis consisted of an autosampler model Surveyor, and 
LCQ DecaXP ion trap detector (Thermo, UK). Chromatographic separation was
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performed at 30°C on a Fortis C-18 3 pm column (50 X 2.1 mm i.d., Fortis 
technologies, UK). Mobile phases were solution A (95% HPLC grade water, 5% 
acetonitrile, 0.05% formic acid) and solution B (10% HPLC-grade water, 90% 
acetonitrile, 0.05% formic acid) and flow rate was 0.4 mL / minute. Separation was 
achieved with a gradient elution beginning with 80% solution A and 20% solution B. 
Solution B was gradually increased to 100% over 0.5 minutes and maintained for a 
further 2 minutes. Solution A was increased to 80% over 0.1 minutes and maintained 
for 3.9 minutes, giving a total run time of 6.5 minutes. The retention time of 
raltegravir was 4.78 minutes and the lowest limit of quantification was 31.25 ng/mL. 
High quality control (QC) (2000 ng/mL) had an inter-day and intra-day accuracy of 
98.2% and 97.1%, respectively, and an inter-day and intra-day precision of 97.0% 
and 93.1%, respectively. Medium QC (200 ng/mL) had an inter-day and intra-day 
accuracy of 96.8% and 99.1%, respectively, and an inter-day and intra-day precision 
of 89.1% and 89.2%, respectively. Low QC (100 ng/mL) had an inter-day and intra­
day accuracy of 96.5% and 92.8%, respectively, and an inter-day and intra-day 
precision of 90.0% and 95.3%, respectively. All QC gave higher than 85% accuracy 
and precision, in accordance with FDA guidelines(23)(23) and the linear range for 
raltegravir quantification was 31.25-1000 ng/mL.
5.2.13 Statistical Analysis
Data were analysed using SPSS 15.0 for Windows. All data were tested for normality 
using the Shapiro-Wilk test. An independent t-test was used to determine 
significance of normally distributed data. The Mann Whitney U test was used for all 
other data. A two-tailed p value < 0.05 was accepted as being statistically significant.
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5.3 RESULTS
5.3.1 Raltegravir solubility
Figure 5.1 shows raltegravir solubility in buffers ranging from pH 1 to 8. A 
concentration of 1 mM raltegravir was fully soluble across the pH range. However, 
10 mM raltegravir was only fully soluble at pH 6.8, 6.9, 7 and 8 and achieved a mean 
supernatant concentration of 8.0 mM at pH 6.6, 6.3 mM at pH 6.4, 5.0 mM at pH 6.2, 
3.7 mM at pH 6 and around 3 mM at pH 5 and below.
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Figure 5.1. Raltegravir solubility at 1 mM (red squares ■) and 10 mM (blue circles 
• ) in a range of pH solutions. Data are expressed as mean raltegravir dissolved in 
solution (mM, n > 3 experimental replicates) ± SD.
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5.3.2 Raltegravir lipophilicity
When using cyclohexane as the organic solvent, raltegravir remained predominantly 
in the aqueous compartment (-90%) in all pH solutions, whereas using octanol 
resulted in low raltegravir concentrations (—7%) in the aqueous compartments of pH 
5 or less (Figure 5.2). When using octanol as the organic solvent, raltegravir apparent 
log? was stable between aqueous pH 1 and 5 but decreased from 1.06 to -1.29 
between pH 5 and 9 (p < 0.05, Figure 5.3). A negative logP is usually associated with 
poor cell membrane permeation (Goodwin et al, 2001).
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♦Octanol/water
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Figure 5.2. Partition of raltegravir (10 pM) between cyclohexane and water (blue 
squares ■, n = 4 experimental replicates) and between octanol and water (red 
diamonds +,n = 4 experimental replicates, n = 3 biological replicates) at different 
pH solutions. Data are expressed as mean percentage of raltegravir in water (% of 
total drug) ± SD.
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1.5
Figure 5.3. Apparent logP of raltegravir (10 (J.M) using octanol and water at different 
pH solutions. Data are expressed as mean log of raltegravir partition (logP, n = 4 
experimental replicates, n = 3 biological replicates)) ± SD.
5.3.3 Raltegravir pKa
Figure 5.4 shows the relative absorbance at two wavelengths (333 nm versus 300 
nm) as a function of the pH of the buffer solution. The most substantial change in the 
curve occurred between pH 6 and 8. Assuming this change in peak ratios was due to 
an alteration of the charge state of raltegravir, the pKa was calculated as 6.7.
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Figure 5.4. Determination of raltegravir pKa using UV spectroscopy. Data are 
expressed as relative absorbance at two wavelengths (333 nm versus 300 nm) as a 
function of the pH of the buffer solution (n = 1 experimental replicate).
5.3.4 Raltegravir tablet breakdown rate
The breakdown rate of standard raltegravir 400 mg tablets was determined across a 
pH range of 1 to 8 and was seen to increase as pH was increased (Figure 5.5). The 
loss of tablet weight was measured after 30 minutes and showed a 237% increase in 
weight loss as pH was increased from 1 to 8 (Figure 5.6). However, only a single
replicate was performed for every pH solution, therefore statistical analysis could not 
be performed.
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Figure 5.5. Photos of a raltegravir tablet after dissolving for 30 minutes in specified 
pH butters. Tablets are places next to a centimetre ruler for comparison.
3
2.5
1 2 3 4 5 6 7 8
pH
Figure 5.6. Dissolution rate of a 400 mg RAL tablet in a range of buffered pH 
solutions. Data are expressed as tablet dissolution rate (% of total tablet broken 
down/minute, n = 1 experimental replicate)
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5.3.5 Impact of pH on raltegravir cell monolayer permeation
Figure 5.7 depicts the A-to-B raltegravir permeation through Caco-2 cell monolayers 
using various apical pH values. Increasing the apical pH from 5 to 8.5 decreased the 
rate and extent of raltegravir monolayer permeation in the A-to-B direction (p < 
0.05). The Papp and efflux ratio of raltegravir at 60 minutes incubation is shown in 
Table 5.1. Raltegravir efflux ratio increased 12-fold as apical pH was increased from 
5 to 8.5 (p < 0.05). When both apical and basolateral pH was 7.4 the efflux ratio was 
2.5, suggesting active transport in the basolateral to apical direction. However, 
reducing apical pH to 6 or below caused raltegravir permeation to predominate in the 
apical to basolateral direction, suggesting that pH has the potential to overcome the 
effect of active drug transport.
pH 6.5 "pH 7
■pH 7.4 •pH 8
■pH 8.5
Incubation time (min)
Figure 5.7. Time course experiment showing A-to-B permeation of raltegravir (50 
pM) in Caco-2 monolayers over 120 minutes. Results are presented when using a 
range of apical pH buffers shown in the figure key. The basolateral pH was 
maintained at 7.4. Data are expressed as mean raltegravir accumulation in the 
basolateral (receiver) compartment (pM, n = 3 experimental replicates).
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pH of apical 
compartment
A-to-B Papp
{cm x 10'6 
second'1)
B-to-A Papp
(cm x 10'6 
second'1)
Efflux ratio
Efflux ratio 
significance 
compared to p H5
5 27.3 ± 1.2 11.9 ± 1.5 0.4 -
6 17.6 ± 1.7 13.1 ±2.3 0.7 p < 0.05
6.5 9.2 ± 1.1 14.5 ± 1.5 1.6 p < 0.05
7 8.4 ± 1.2 14.5 ±2.1 1.7 p < 0.05
7.4 6.6 ± 0.8 16.4 ±2.9 2.5 p < 0.05
8 3.5 ±0.5 13.8 ±0.7 3.9 p < 0.05
8.5 2.9 ±0.3 14.1 ± 1.3 4.9 p < 0.05
Table 5.1. The effect of pH on raltegravir (50 pM) permeation using a Caco-2 
monolayer. Column one gives the range of apical pH buffers used (basolateral pH 
was maintained at 7.4). Columns two and three give apparent permeation of 
raltegravir in the A-to-B and B-to-A directions, respectively. Data are presented as 
mean Papp (cm x 10'6 second'1, n = 3 experimental replicates) ± SD. Column four 
gives the efflux ratio of raltegravir (Papp B-to-A / Papp A-to-B). Column five compares the 
efflux ratio at pH 5 with other pH values (a significant difference was deemed to 
have a p value of < 0.05).
5.3,6 Impact of divalent and monovalent metals on raltegravir 
cell monolayer permeation
All Papp and efflux ratio calculations were made using samples taken after 30 minutes 
of incubation and sink conditions were maintained at this time point (Table 5.2). A 
positive correlation between concentration of magnesium chloride in the apical 
compartment and raltegravir efflux ratio is shown in Figure 5.8. When the apical 
compartment was pH 7.4, raltegravir efflux ratio was significantly increased when 
comparing control wells with no additional metal salt (efflux ratio - 1.3) to wells 
supplemented with 1 mM (efflux ratio = 1.6, p < 0.05), 10 mM (efflux ratio = 3.4, p 
< 0.05) or 25 mM (efflux ratio = 3.7, p < 0.05) magnesium chloride. Lopinavir efflux
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ratio was unaltered when comparing control wells with no additional metal salt 
(efflux ratio = 5.1) to wells supplemented with 25 mM magnesium chloride (efflux 
ratio — 5.4, p — 0.83) illustrating that the effect of magnesium chloride on raltegravir 
cellular permeation was not a result of general changes in monolayer integrity.
When the apical compartment was pH 5, raltegravir efflux ratio was unchanged when 
comparing control wells with no additional metal salt (efflux ratio = 0.8) to wells 
supplemented with 1 mM magnesium chloride (efflux ratio = 0.7, p = 0.28), but a 
significant increase in efflux ratio was observed when supplemented with 10 mM 
(efflux ratio - 1.1, p < 0.05) or 25 mM (efflux ratio = 1.9, p < 0.05) magnesium 
chloride. Also, the effects of magnesium in a different salt form (magnesium 
sulphate), an additional divalent metal salt (calcium chloride) and a monovalent 
metal salt (potassium chloride) were investigated. Raltegravir efflux ratio was 
significantly increased when comparing control wells with no additional metal salt 
(efflux ratio = 0.8) to wells supplemented with 25 mM magnesium sulphate (efflux 
ratio = 1.6, p < 0.05) or 25mM calcium chloride (efflux ratio = 1.2, p < 0.05). The 
efflux ratio was unaltered when 25 mM potassium chloride was added to the apical 
compartment (efflux ratio - 0.8, p = 0.83). This supports the hypothesis that divalent 
metals, but not monovalent metals, have the potential to affect raltegravir cell 
membrane permeation.
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Drug
Apical
chamber
pH
Metal salt 
added to 
apical 
chamber
Metal
concentration
(mM)
A-to-B Papp 
(cm x 10*® 
second1)
B-to-A Papp 
(cm x 10"6 
second'1)
Efflux ratio 
(B-to-A / A- 
to-B)
Efflux ratio 
significance 
compared to no 
added salt
Raltegravir 5 none 0 22.8 ±2.8 17.5 ± 1.0 0.8 _
MgCI2 1 18.6 + 3.9 13.1 ±2.0 0.7 p=0.28
10 12.3 ±0.8 13.2 ±2.4 1.1 p<0.05
25 7.8 ±2.3 15.0 ±0.3 1.9 p<0.05
MgS04 25 10.2 ± 1.8 16.0 ± 0.9 1.6 p<0.05
CaCI2 25 14.7 ± 2.3 17.0 ±4.2 1.2 p<0.05
KCI 25 18.8 ± 2.8 14.7 ± 0.3 0.8 p=0.83
7.4 None 0 11.5 ± 1.0 15.0 ± 0.5 1.3
MgCl2 1 7.2 ±1.1 11.5 ±0.8 1.6 p<0.05
10 4.0 ±0.6 13.5 ± 0.5 3.4 p<0.05
25 3.4 ±0.8 12.5 ±0.4 3.7 p<0.05
Lopinavir 7.4 none 0 9.9 ± 0.7 50.0 ± 4.6 5.1 _
MgCI2 25 10.0 ±0.8 54.4 ± 5.4 5.4 p=0.83
Table 5.2. The effect of metal cations on raltegravir (1 pM) permeation using a 
Caco-2 monolayer. Column four gives the concentration of metal salt used. Columns 
five and six give apparent permeation of raltegravir in the A-to-B and B-to-A 
directions, respectively. Data are presented as mean Papp (cm x 10'6 second'1, n = 3 
experimental replicates) ± SD. Column seven gives the efflux ratio of raltegravir 
(Papp B-to-A / Papp A-to-B). Column eight compares the efflux ratios with the the 
efflux ratio when no additional salt was added (a significant difference was deemed 
to have a p value of < 0.05).
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Figure 5.8. Efflux ratio of raltegravir (1 jaM) in Caco-2 monolayers using a range of 
magnesium chloride concentrations in the apical compartment. The apical 
compartment was maintained at pH 5 (■) or pH 7.4 (■) and the basolateral 
compartment was maintained at pH 7.4. Data are expressed as mean drug efflux ratio 
(Papp B-to-A/ Papp A-to-B, n = 3 experimental replicates) ± SD.
5.3.7 Impact of omeprazole on raltegravir cell monolayer 
permeation
Figure 5.9 depicts the efflux ratio of 1 pM raltegravir through Caco-2 cell 
monolayers in the presence and absence of omeprazole as an inhibitor (20 pM added 
during raltegravir incubation) or as an inducer (72 hour pre-incubation of cells with 
10 pM omeprazole). All Papp and efflux ratio calculations were made using samples 
taken after 60 minutes of incubation and sink conditions were maintained. In 
inhibition studies, there was no significant difference in raltegravir efflux ratio 
between control cells and cells co-incubated with 20 pM omeprazole (efflux ratio of 
2.7 versus 2.6, p = 0.83). Similarly, in induction studies there was no significant
204
difference in raltegravir efflux ratio between control cells and cells pre incubated for 
72 hours with 10 pM omeprazole (efflux ratio of 2.7 versus 2.6, p = 0.51).
3.5
3
Control Omeprazole Omeprazole 
(inhibitor) (inducer)
Figure 5.9. Efflux ratio of raltegravir (1 pM) in the presence of omeprazole 
(inhibitor study, 20 pM) or with cells pre-incubated with omeprazole for 3 days 
(induction study, 10 pM). Data are expressed as mean drug efflux ratio (Papp B-to-A/ 
Papp A-to-B, n = 3 experimental replicates) ± SD.
5.3.8 Impact of pH and ABCB1 inhibition on raltegravir 
cellular accumulation
Figure 5.10 depicts the accumulation of raltegravir in Caco-2 cells using various pH 
buffers and using tariquidar to inhibit ABCB1. Raltegravir accumulation in Caco-2 
cells increased 3.4-fold when incubation buffer pH was decreased from 8 to 5 (p < 
0.05). This pH-related increase in raltegravir accumulation was also observed in cells 
treated with the ABCB1 inhibitor tariquidar (3.3-fold decrease, p < 0.05). Inhibiting 
ABCB1 led to increased raltegravir accumulation at pH 5 (1.4-fold, p < 0.05), 6 (1.5-
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fold, p < 0.05), and 7 (1.4-fold, p < 0.05) but not significant at pH 8 (p = 0.08). These 
results suggest that pH impacts upon cellular permeation of raltegravir to a greater 
extent than ABCB1 transport and that ABCB1 transport of raltegravir is independent 
of pH.
2.5
Figure 5.10. Accumulation of raltegravir (1 pM) in Caco-2 cells at extracellular pH 
of 5 to 8, with (■) and without (■) ABCB1 inhibitor tariquidar (300 nM). Data are 
expressed as mean intracellular raltegravir (pM, n = 3 experimental replicates) ± SD.
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5.4 DISCUSSION
In this chapter the influence of pH on raltegravir solubility, lipophilicity, tablet 
breakdown and cellular permeation was investigated. Raltegravir exhibited solubility 
of less than 10 mM at pH 6.6 and below. It is likely that the drug obtains a negative 
charge at higher pH by deprotonation of the hydroxyl group at the 5-position of the 
6-oxo-1,6-dihydropyrimidine ring (Figure 5.11). This negative charge would 
dramatically increase the solubility of the drug in aqueous buffer. Additionally, 
raltegravir logP was shown to decrease as pH was increased above 6, presumably 
due to the introduction of a charge to the drug. Indeed, the solubility and lipophilicity 
data were supported by the UV spectroscopy data, where raltegravir pKa was 
calculated at 6.7. This pKa is located within the pH range that would be encountered 
by the drug during passage through the GI tract. Also, raltegravir tablet breakdown 
rate was influenced by environmental pH, where increasing pH led to a more rapid 
dissolution. These investigations offer a convincing explanation for the large intra- 
and inter-patient variability of raltegravir PK in healthy and HIV-infected subjects 
(Cattaneo et al, 2012).
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Figure 5.11. The hypothesised effect of increasing pH on the charge state of 
raltegravir.
In experiments assessing raltegravir cellular permeation, raltegravir was less able to 
cross a Caco-2 cell monolayer as the incubation buffer pH was increased from 5 to 
8.5. This is most likely due to the introduced charge at the active site, preventing the 
drug from passing through the phospholipid bilayer of the cell membrane. Similar 
results were seen in accumulation studies, where less raltegravir was present in the 
cells when pH was increased from 5 to 8. ABCB1 inhibition had less impact on 
raltegravir intracellular concentrations than changes in extracellular pH. Permeation 
and accumulation were assessed using raltegravir concentrations from 1 pM to 50 
pM and our solubility studies show that the drug was fully soluble at all pH values at 
these concentrations. Therefore, the introduction of a charge to raltegravir by 
increasing pH could have opposing consequences depending on the concentration of
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the drug: At high drug concentrations the introduced charge would be predicted to 
increase dissolution and therefore absorption. Conversely, at lower concentrations 
solubility is unlikely to be an absorption-limiting factor and therefore the introduced 
charge may reduce the rate of absorption.
In previous clinical studies, co-administration of omeprazole and famotidine resulted 
in an increase in raltegravir Cmxi (Rhame et al, 2009). This may result from the 
predicted increased solubility of raltegravir in the stomach and the duodenum, where 
drug concentrations would be highest. The Ci2iir of raltegravir was only slightly 
higher or unchanged when taken with omeprazole or famotidine (Rhame et al, 
2009). It is tempting to speculate that over time raltegravir dissolution normalizes in 
all subjects and the benefit of increased gastric pH is overcome. Results from 
inhibition and induction studies using omeprazole indicated that there were no direct 
effects on raltegravir cellular permeation, indicating that the effect of omeprazole 
most likely results from its pH-altering properties.
Ingestion of a meal has been shown to result in an increase in gastric pH (Charman et 
al, 1997), which would be predicted to increase raltegravir solubility. However, only 
high fat meals have been shown to increase raltegravir exposure with low fat meals 
resulting in a reduction (Brainard et al, 2011a). It is possible that a high fat meal 
may dilute stomach acid to a greater extent or that the fat in the meal could increase 
the solubility of raltegravir.
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Raltegravir cellular permeation decreased in the presence of the divalent cations 
magnesium and calcium in the incubation medium. This decrease was not found 
when the monovalent cation potassium was used. Raltegravir may bind to the 
divalent metals and form a metal-drug complex which is unable to cross the cell 
membrane. It is important to note that binding of raltegravir to a divalent metal 
(magnesium) is a prerequisite for inhibition of the HIV integrase enzyme (Loizidou 
et ah, 2009). Antacids containing magnesium caused no significant change in 
raltegravir Cmax or AUC but did reduce Cniu, resulting in 75% of patients having 
Ci2hr less than the IC95 (Kiser et al, 2010). The impact of antacids may be explained 
by a combination of the effects of pH and metal binding. It can be hypothesised that 
Cmax remains unchanged while raltegravir solubility improves with increased pH but 
absorption is inhibited by magnesium binding. At later time points, when raltegravir 
solubility is no longer an issue, the elevated presence of magnesium in the gut may 
reduce the amount of raltegravir being absorbed, thus reducing raltegravir Ci2hr. If 
true, co-administration of products containing polyvalent metal cations that do not 
alter gastric pH (e.g. multivitamin tablets) would be expected to reduce raltegravir 
exposure. This is certainly now worthy of empirical determination.
These data may also have implications for newer integrase strand transfer inhibitors, 
elvitegravir and dolutegravir. Elvitegravir and dolutegravir exposure have been 
shown to be reduced when taken with antacids containing magnesium and 
aluminium, being less marked when taken 2 hours before the antacid (Patel et al, 
2011; Ramanathan et al.s 2007a). In healthy subjects, elvitegravir and dolutegravir 
absorption have also been shown to be influenced by food according to fat content 
(German et al., 2009; Song et al, 2011) and it is recommended that elvitegravir is
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taken with food (Ramanathan et al, 2011). Interestingly, dolutegravir exposure has 
also been shown to be moderately reduced when taken with a multivitamin 
containing magnesium, calcium, iron, zinc and copper (Patel et al, 2011).
In conclusion, the physicochemical properties of raltegravir are heavily influenced by 
pH. Both pH and polyvalent metals have the potential to alter the pharmacokinetics 
of raltegi avir and these data help provide a rationale for the variability in raltegravir 
exposure seen in patients. The evaluation of how divalent metal-containing products, 
such as multivitamins that do not affect gastric pH, alter raltegravir pharmacokinetics 
in patients is now justified.
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Chapter 6
Development of a population-based ADME simulator 
to predict raltegravir exposure
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6.1 INTRODUCTION
Raltegravir shows unusually large variability in PK both between patients and in the 
same patient over time. For example, Siccardi et al observed high variability in 
raltegravir Ctrough, with median coefficient of variation (CV%) of 128% and 245% for 
inter- and intra-patient variability, respectively (Siccardi et al, 2012b). This high 
variability has impeded the inclusion of raltegravir in therapeutic drug monitoring.
Over half (141 of 255) of patients who failed raltegravir therapy in a recent 
multicenter drug efficacy study had HIV with no detectable integrase resistance 
mutations (Geretti et al, 2010). A smaller study found that 18% (2 of 11) of patients 
who failed raltegravir therapy had no evidence of HIV integrase mutations (da Silva 
et al, 2010). These studies suggest that raltegravir therapy failure may occur 
independently of HIV resistance mutations. Raltegravir PK may be an influencing 
factor, although this could not be shown as patient PK samples were not obtained in 
the studies.
A statistically significant correlation between raltegravir PK and virological response 
has recently been demonstrated in patients. The QDMRK study investigated the PK 
parameters of raltegravir 400 mg twice-daily versus 800 mg once-daily in treatment- 
naive HIV-infected patients, and whether PK was predictive of virological efficacy 
(Rizk et al, 2012). Results showed the once-daily treatment was less effective than 
the twice-daily treatment at achieving HIV RNA < 50 copies/mL (83% versus 89%). 
No correlation between raltegravir PK and virological response was found in patients 
taking 400 mg twice-daily raltegravir, possibly due to high PK variability, whereas 
Ctrough was a predictor of raltegravir treatment failure in patients taking 800 mg once-
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daily. Specifically, the lowest quartile C^ugh in the once-daily arm (13.6 ng/mL) 
showed increased virological failure. Importantly, this Chough was below 15 ng/mL, 
the IC95 of raltegravir against HIV-1 in 50% human serum. These data give evidence 
that raltegravir PK is potentially a determining factor in treatment success and that 
high inter-patient and inter-occasion variability (and often low patient numbers) in 
raltegravir PK studies may be the main issue in establishing a reliable raltegravir PK- 
PD relationship.
A population PK model has been published based on the data from six fasted healthy 
volunteers given a single 400 mg dose of raltegravir (Wang et al, 2011). Another 
model has been published based on the data from 145 HIV-infected patients and 19 
healthy volunteers (Arab-Alameddine et al., 2012). The PK data used in both of 
these studies was highly variable and both concluded that the lack of information on 
factors with a potential effect on raltegravir absorption limits the interpretation of the 
results. This is the problem that this thesis has set out to tackle by investigating the 
impact of transporters, pH and various other factors on raltegravir disposition in 
vitro. However, in vitro data of this type is of only limited use to traditional 
population PK modelling, as the main sources of data for these models come from 
clinical studies and patient data. Therefore, a computational drug PK modelling 
system that combines both in vitro and in vivo data would be seen as the most 
productive option for raltegravir.
In vitro in vivo extrapolation (IVIVE) is the process of using in vitro data such as 
drug physicochemistry, permeability and metabolism to predict in vivo drug 
characteristics using PK simulation modelling. The Simcyp population-based ADME
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simulator (Soldin et al, 2011) utilises a “bottom-up” approach that integrates 
demographic factors (age, weight, height, sex, genetic polymorphisms, race, disease, 
etc), anatomical and physiological factors (organ size, blood flow, enzymes, 
transporters, plasma protein, gastric pH, transit time, etc) and drug-specific factors 
(molecular weight, pKa, logP, solubility, permeability, etc). These data are included 
in physiologically-based pharmacokinetic (PBPK) models, based on multi- 
compartmental equations that mimic the absorption, distribution, metabolism and 
elimination processes in the human body.
Oral absorption of a drug can be simulated using different approaches and taking into 
account the dynamic interplay of tablet disintegration, dissolution, solubility, 
intestinal permeation, and, for some drugs, metabolism. The Advanced Dissolution 
Absorption and Metabolism (ADAM) Model within Simcyp represents the GI tract 
as compartments based upon their physiological and anatomical characteristics and 
the relationship between permeability, metabolism and dissolution, amongst other- 
factors, can be simulated (Darwich et al, 2010).
This approach can be used to investigate drug disposition in drug discovery and 
development, such as PK profiling, drug-drug interactions, bioavailability and drug 
exposure in special populations (children, liver disease, kidney disease, etc). 
Moreover, design of a clinical trial can be optimized by IVIVE by determining how 
factors such as sample size, sex ratio and age may influence the final results.
The aim of this chapter was to develop an IVIVE model for simulating raltegravir 
PK and to investigate the role of GI pH and ingested magnesium using the ADAM
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model. The influence of multiple dosing on raltegravir PK was also determined and 
compared to single dose. The model detailed in this chapter included data from 
pievious clinical trials and also contained in vitro data generated during this project. 
This combined approach has provided a system to help determine which 
physiological and drug-based attributes are important in predicting raltegravir PK in
virtual individuals.
6.2 METHODS
6.2.1 In vitro-in vivo extrapolation: drug parameters
Raltegravir PK properties were simulated using the full PBPK model implemented in 
the Simcyp Population-based Simulator (Version 11.0, Simcyp Limited, UK). Data 
describing raltegravir physiochemical and pharmacological properties were added to 
the model and were either derived from in-house in vitro data, literature sources or 
predicted by the Simcyp model (Figure 6.1) and are summarised in Table 6.1. 
Intrinsic solubility of raltegravir at pH 1-9 was predicted using ACD/PhysChem 
Suite (Toronto, Canada) and data were added to the Simcyp model (Figure 6.2).
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Figure 6.1. The interface screen of the Simcyp Population-based Simulator.
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Figure 6.2. Predicted intrinsic solubility of raltegravir across a physiological pH 
range. Solubility was predicted using molecular structure, charge state and pKa using 
ACD/PhysChem Suite (Toronto, Canada) and data was added to the Simcyp model.
Input parameters Value Reference
PhysChem Molecular weight 445.16 (Summa et a!., 2008)
LOgPo:W 0.58 In-house
pKa 6.67 In-house
B/P 0.6 (Lauferet a!., 2009)
fu 0.17 (Laufer et al., 2009)
Absorption Papp pH 7.4 (xlO'6 cm/s) 6.6 In-house
Tablet release rate (see Figure 5.6) In-house
Solubility-pH profile (see Figure 6.2) Predicted
Distribution Vss(L/kg) 0.308 SimCyp predicted
Elimination Hepatic Clin, (pL/min/106) 12.4 (Wang et al., 2011)
CIR (L/hr) 3.6 (Iwamoto et al., 2008d)
Table 6.1. Input parameters detailing raltegravir properties. LogPo:w = Log partition 
coefficient between octanol and water (pH 7); B/P = blood to plasma drug ratio; fu = 
free drug fraction in plasma; Papp pH 7.4 = apical to basolateral apparent permeability 
in Caco-2 monolayer at pH7.4; Vss = volume of distribution (L/kg); Clint = intrinsic 
clearance (pL/min/lO6); C1R = renal clearance (L/hr).
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6.2.2 In vitro-in vivo extrapolation: population parameters
All system parameters were taken from the North European Caucasian population 
library within Simcyp (Jamei et al, 2009) with the exception of patient GI pH 
values, which were obtained from literature sources (Charman et al9 1997; McCloy 
et al, 1984; Rune et ah, 1969). All simulations except the simulation in Section 6.3.1 
were performed in 5 separate groups of 50 healthy individuals, named Groups 1,2, 3, 
4 or 5. These groups contained individuals with the same physiological attributes to 
each other except for average GI pH values, which differed between groups and are 
shown in Table 6.2. All simulations consisted of 50% female subjects.
Group 1 
(very iow pH)
Group 2 
(low pH)
Group 3 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Stomach residence time (hours) 0.4 0.4 0.4 0.4 0.4
Stomach pH 1 2.5 3 5 6
Intestine residence time (hours) 3.34 3.34 3.34 3.34 3.34
Duodenum pH 4 4.5 5 6 6.4
Jejunum pH 4.4 5 5.5 6.8 7
lieum pH 6.4 6.8 7.4 7.6 8
Colon residence time (hours) 12 12 12 12 12
Colon pH 5 5.5 6 6.2 6.5
Table 6.2. Values for mean GI pH and residence time added to the model. Each pH 
value is the mean for a population representative and each segment had a CV% of 
2% when determining pH for individuals in a group. Each residence time is the mean
for a population representative and each segment had a CV% of 30% when
determining GI transit time for individuals in a group.
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6.2.3 In vitro-in vivo extrapolation: simulation design
Raltegravir (400 mg, single dose) PK was simulated in healthy volunteers (20-50 
years old, 0.5 proportion female) over 12 hours. The number of simulated subjects in 
each group was initially investigated (5-75 individuals, Figure 6.3) and 50 
individuals were chosen as the optimal population number for each group and used in 
all subsequent simulations. Simulated PK results were compared with actual PK in 
published data and used to calculate the geometric mean values for Cmax (ng/mL), 
AUCo-i2hr (ng/mL.hr), Ctrough (ng/mL) and fa (fraction of dose absorbed), which were 
given with 5th and 95th percentiles. Median Tmax (hours) was calculated and given 
with range.
A parallel trial was performed as described above to simulate the impact of elevated 
GI magnesium concentrations on raltegravir PK values. Drug parameters were 
altered so that Caco-2 monolayer Papp of raltegravir was reduced from 6.6 to 3.4 
(obtained from data in Chapter 5), simulating the impact of 25 mM magnesium salt 
on raltegravir Papp.
In order to assess the effect of long-term multiple dosing on raltegravir PK, a parallel 
trial was performed where subjects were given 400 mg raltegravir every 12 hours for 
a total of five doses, simulating the current twice-daily dosing of patients in the 
clinical setting. PK values were determined for the final dose only and was compared 
with single dose raltegravir PK.
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6.3 RESULTS
6.3.1 The impact of subject sample size on raltegravir 
exposure and result accuracy
In order to determine a suitable number of subjects to use in each simulation which 
balanced simulation run time with result reliability, an initial simulation was run to 
assess the impact of subject sample size on raltegravir AUCo-i2hr using subjects from 
Group 3 (Figure 6.3). The geometric mean AUCo-uhr (ng/mL.hr, 95% Cl) when 5, 
10, 25, 50 or 75 subjects were used was 6141.3 (3807.2-9906.6), 7588.3 (5598.6- 
10285.2), 7927.5 (6771.5-9280.9), 8164.6 (7281.1-9155.4) and 8453.0 (7757.6- 
9210.7), respectively. Fifty subjects per group was chosen as the number to use in all 
subsequent simulations, as 95% Cl were considered acceptable and the geometric 
mean AUCo-i2hr for 50 subjects was not significantly different to when 75 patients 
were used (p = 0.58).
20000-1
_ 15000-
•••••
5000-
Number of healthy subjects
Figure 6.3. The effect of subject sample size on average simulated raltegravir 
exposure. Group 3 individuals were used and given a single 400 mg raltegravir 
tablet. Data are given as geometric mean AUC0.i2hr(mg/mL.hr) with 95% Cl.
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6,3.2 The impact of Gl pH on ra/tegravir solubility
The impact of pH on raltegravir solubility in the GI tract is shown in Table 6.3. A 
general trend towards increased raltegravir solubility in all GI segments can be 
observed by progressing from Group 1 to 5. The subjects between groups only differ 
in average GI pH values (Group 1 has very low GI pH, progressing to Group 5 with 
very high GI pH; see Table 6.2), therefore the increase in raltegravir solubility is 
likely a direct effect of increased GI pH.
Group 1
(very low pH)
Group 2 
(low pH)
Group 3 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Solubility in stomach (mg/mL) 0.04 0.04 0.04 0.12 0.98
Solubility in duodenum (mg/mL) 0.04 0.08 0.12 0.98 2.4
Solubility in jejunum (mg/mL) 0.07 0.12 0.33 5.78 8.89
Solubility in ileum (mg/mL) 2.4 5.78 20.27 29.95 37.33
Solubility in colon (mg/mL) 0.12 0.33 0.98 1.57 2.93
Table 6.3. Raltegravir solubility in each segment of the GI tract. Results are shown 
as the mean solubility (mg/mL) for each group. Each group contained 50 individuals.
6.3.3 The impact of GI pH on raltegravir PK parameters
The impact of GI pH on raltegravir PK parameters in subject Groups 1 to 5 is shown 
in Table 6.4. A general trend towards increased raltegravir exposure can be observed 
by progressing from Group 1 (very low GI pH) to 5 (very high GI pH). Median Tmax 
values are decreased as GI pH increased, which may be due to decreased tablet 
dissolution time and higher drug solubility during the earlier stages of the GI tract. 
Bivariate analysis showed that intestinal transit time strongly correlated with the 
fraction of raltegravir dose absorbed in individuals from each group (p < 0.001) and
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that a decrease in intestinal transit time resulted in decreased raltegravir absorbance. 
The absoiption rate of drug from individual GI segments, the total drug absorbed 
from each GI segment and the PK profile is given for Group 1 (Figure 6.4), Group 2 
(Figure 6.5), Group 3 (Figure 6.6), Group 4 (Figure 6.7) and Group 5 (Figure 6.8).
Group 1 
(very low pH)
Group 2 
(low pH)
Group 3 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Cmax (ng/mL) 1491.8 1980.0 2094.0 2541.3 2545.4
5th-95,h percentile (821.4-2835.7) (1376.3-3402.9) (1415.5-3657.4) (1675.8-4382.6) (1645.2-4147.9)
AUCo-nhr (ng/mL.hr) 5756.2 7285.4 8164.6 10136.7 11045.8
5,h-95th percentile (2485.5-12335.4) (3769.7-14644.7) (4308.2-16230.6) (5320.9-18916.3) (6169.1-19690.5)
Tmax (hours) 3.7 3.3 3.2 2.3 2.1
Range (1.3-5.3) (1.4-4.4) (1.3-4.3) (1.3-3.1) (1.2-2.9)
Ctroirgh (ng/mL) 30.9 51.4 113.2 153.2 188.2
S,h-95th percentile (8.4-60.9) (21.6-93.6) (58.4-210.1) (87.3-254.7) (95.4-312.8)
fa 0.39 0.49 0.55 0.69 0.75
5th-95th percentile (0.16-0.60) (0.26-0.67) (0.34-0.73) (0.45-0.86) (0.54-0.91)
Table 6.4. Simulated PK values after a single dose of 400 mg raltegravir. Groups 1-5 
each had 50 individuals and represented very low (Group 1) to very high (Group 5) 
GI pH. Geometric mean values for Cmax (ng/mL), AUC0-i2hr (ng/mL.hr), C^ugh 
(ng/mL) and fa (fraction of dose absorbed) are given with 5th and 95th percentiles. 
Median Tmax (hours) is given with range.
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Figure 6.4. A. Mean simulated raltegravir absorption rate (mg/hour) in each GI 
segment from 50 Group 1 subjects. B. Mean simulated fraction of raltegravir 
absorbed (drug absorbed in segment/total drug) in each GI segment from 50 Group 1 
subjects. C. Simulated raltegravir plasma concentration-time profile (ng/mL, green 
line) with 5th and 95th percentiles (grey lines) from 50 Group 1 subjects.
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Figure 6.5. A. Mean simulated raltegravir absorption rate (mg/hour) in each GI 
segment from 50 Group 2 subjects. B. Mean simulated fraction of raltegravir 
absorbed (drug absorbed in segment/total drug) in each GI segment from 50 Group 2 
subjects. C. Simulated raltegravir plasma concentration-time profile (ng/mL, green 
line) with 5th and 95th percentiles (grey lines) from 50 Group 2 subjects.
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Figure 6.6. A. Mean simulated raltegravir absorption rate (mg/hour) in each GI 
segment from 50 Group 3 subjects. B. Mean simulated fraction of raltegravir 
absorbed (drug absorbed in segment/total drug) in each GI segment from 50 Group 3 
subjects. C. Simulated raltegravir plasma concentration-time profile (ng/mL, green 
line) with 5th and 95th percentiles (grey lines) from 50 Group 3 subjects.
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Figure 6.7. A. Mean simulated raltegravir absorption rate (mg/hour) in each GI 
segment from 50 Group 4 subjects. B. Mean simulated fraction of raltegravir 
absorbed (drug absorbed in segment/total drug) in each GI segment from 50 Group 4 
subjects. C. Simulated raltegravir plasma concentration-time profile (ng/mL, green 
line) with 5th and 95th percentiles (grey lines) from 50 Group 4 subjects.
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Figure 6.8. A. Mean simulated raltegravir absorption rate (mg/hour) in each GI 
segment from 50 Group 5 subjects. B. Mean simulated fraction of raltegravir 
absorbed (drug absorbed in segment/total drug) in each GI segment from 50 Group 5 
subjects. C. Simulated raltegravir plasma concentration-time profile (ng/mL, green 
line) with 5th and 95th percentiles (grey lines) from 50 Group 5 subjects.
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6.3.4 Comparison between reference and simulated 
rattegravir PK values
Reference PK values (mean ± SD) for Cmax (2519 ± 1930 ng/ml), AUC042hr (7076 ± 
4071 ng/ml) and Ctrough (71 ± 50 ng/mL.h) are shown in Table 6.5 and are the 
averages of geometric mean values for fasted, healthy volunteers in selected previous 
studies (Brainard et al, 2011a; Iwamoto et al, 2009b; Iwamoto et al, 2008d; 
Kassahun et al.t 2007; Kiser et al, 2010; Wang et al, 2011). All reference values 
displayed high inter-study variability, as shown by the large standard deviations, and 
this is why an average between studies was used. Simulated PK fell within the range 
of reference PK values. Group 2 displayed the best match with reference value AUC0. 
i2hr (+4% deviation) and Ctrough (-30% deviation), although the reference Craax value 
was most closely predicted in Group 4 (+3% deviation). Groups 2 and 4 reperesent 
populations with “low” and “high” GI pH values, respectively (Table 6.2).
Reference 
value {+ SD)
Group 1 
(very iow pH)
Group 2 
(low pH)
Group 3 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Cmax (ng/mL) 2519 ±1930 1466 1952 2101 2599 2654
% diff from real life N/A -42% -23% -17% +3% +5%
AUCo42hr (ng/mL.hr) 7076 ± 4071 5783 7356 8454 10509 11788
% diff from real life N/A -18% +4% +19% +49% +67%
Ctrough (ng/mL) 71 ± 50 29 50 112 152 200
% diff from real life N/A -60% -30% +57% +113% +180%
Table 6.5. Comparison of actual PK values with simulated PK values. Each 
simulated group contained 50 individuals. Geometric mean values for Cmax (ng/mL), 
AUC0.12hr (ng/mL.hr), Ctrough (ng/mL) and fa (traction of dose absorbed) are given and 
the percentage difference of each simulated result to the reference value is calculated.
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6.3.5 The impact of magnesium on raltegravir exposure
The impact of magnesium binding on raltegravir PK values in subject Groups 1 to 5 
is shown in Table 6.6. GMR were generated which were the ratios between 
raltegravir PK values in the presence of elevated GI magnesium concentrations 
compared with the standard conditions given in Table 6.4. Simulated Cmax, AUC and 
Gtrough were all significantly (p < 0.008) reduced by the presence of magnesium in the 
GI tract. Raltegravir Tmax was not significantly altered by magnesium in Groups 1 (p 
= 0.49), 2 (p = 0.29) or 3 (p = 0.34) but was significantly increased in Groups 4 (2.6 
hours versus 2.3 hours, p = 0.003) and 5 (2.5 hours versus 2.1 hours, p = 0.001). The 
increased Tmax in Groups 4 and 5 are likely a result of an inhibited rate of raltegravir 
absorption, caused by reduced tablet breakdown and lower drug solubility.
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Group 1
(very low pH)
Group 2 
(low pH)
Group 3 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Ctnax (ng/mL) 841.7 1215.3 1300.5 1603.9 1616.2
5th-95th percentile (446.3-1610.8) (831.4-2113.8) (858.0-2330.8) (1013.9-2842.4) (1028.0-2671.5)
GMR 0.56 0.61 0.62 0.63 0.63
p value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
AUCo-i2iir (ng/mLhr) 3435.7 4634.9 5208.0 6711.6 7358.9
Range (1394.3-7542.3) (2214.6-9766.6) (2623.0-10697.6) (3305.1-13023.4) (3769.1-13570.3)
GMR 0.60 0.64 0.64 0.61 0.67
p value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Tmax (hours) 3.8 3.5 3.3 2.6 2.5
Range (1.4-5.7) (1.4-4.7) (1.4-4.5) (1.3-3.5) (1.3-3.4)
Median ratio 1.03 1.06 1.03 1.13 1.19
p value 0.49 0.29 0.34 0.003 0.001
Ctroueh (ng/mL) 21.9 33.3 66.2 90.3 152.1
5th-95th percentile (4.6-58.2) (11.8-63.2) (32.5-119.8) (48.4-153.5) (88.9-253.6)
GMR 0.71 0.65 0.58 0.59 0.81
p value 0.008 < 0.001 < 0.001 <0.001 0.005
fa 0.23 0.31 0.35 0.45 0.50
5th-95th percentile (0.09-0.38) (0.15-0.46) (0.20-0.50) (0.27-0.64) (0.31-0.67)
GMR 0.59 0.63 0.64 0.65 0.67
p value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Table 6.6. Simulated raltegravir PK values in the presence of elevated magnesium 
GI concentrations. Each group contained 50 individuals. Geometric mean values for 
Cmax (ng/mL), AUC0-i2hr (ng/mL.hr), Ctrough (ng/mL) and fa (fraction of dose absorbed) 
are given with 5th and 95th percentiles. Median Tmax (hom*s) is given with range. 
Values in Table 6.6 have been divided by corresponding values in Table 6.4 to 
calculate the GMR (Cmax, AUC0.12hr? Ctrough and fa) or median ratios (Tmax). p values 
were calculated between values in Table 6.6 and Table 6.4.
6.3.6 The impact of multiple dosing on raltegravir exposure
The impact of multiple consecutive dosing on raltegravir PK values in subject 
Groups 1 to 5 is shown in Table 6.7. Subjects were given 400 mg raltegravir every 
12 hours until a total of five doses had been taken and PK values in Table 6.7 are for
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the final dose. GMR values were generated which were the ratios between raltegravir 
PK multiple dosing compared with the standard single dose given in Table 6.4. No 
significant change in raltegravir PK values was observed in any group on multiple 
dosing. This suggests no evidence of increased raltegravir exposure following 
multiple twice-daily dosing.
Group 1
(very low pH)
Group 2
(low pH)
Groups 
(medium pH)
Group 4 
(high pH)
Group 5 
(very high pH)
Cmax (ng/mL) 1465.9 1951.8 2100.7 2599.0 2654.3
5th-95th percentile (879.0-2625.4) (1335.7-3155.7) (1440.0-3320.9) (1719.2-4099.0) (1765.7-4172.3)
GMR 0.98 0.96 1.01 1.04 1.04
p value 0.92 0.83 0.89 0.59 0.48
AUCo-uhr (ng/mLhr) 5782.7 7355.9 8453.9 10508.9 11788.1
Range (2890.1-12080.0) (3927.8-14565.8) (4430.7-16418.3) (5613.8-18137.1) (6867.5-20330.3)
GMR 1.00 1.01 1.04 1.04 1.07
p value 0.98 0.88 0.62 0.49 0.31
Tmax (hours) 3.7 3.3 3.3 2.1 2.1
Range (1.5-5.5) (1.5-4.6) (1.5-4.3) (1.2-3.0) (1.2-3.0)
Median ratio 1.00 1.00 1.03 0.91 1.00
p value 0.77 0.93 0.93 0.54 0.50
Ctrough (n§>/^L) 28.9 49.8 112.3 152.4 199.8
5th-95th percentile (7.8-54.6) (17.9-85.8) (50.2-210.8) (77.6-241.0) (105.0-339.2)
GMR 0.94 0.97 0.99 0.99 1.06
p value 0.90 0.95 0.96 0.98 0.61
fa 0.39 0.49 0.56 0.69 0.78
5th-95th percentile (0.17-0.59) (0.26-0.67) (0.35-0.73) (0.45-0.87) (0.46-0.96)
GMR 1.00 1.00 1.02 1.00 1.04
p value 0.70 0.99 0.77 0.76 0.21
Table 6.7. Simulated raltegravir PK values after five consecutive twice-daily doses. 
Each group contained 50 individuals. Geometric mean values for Cmax (ng/mL), 
AUCo-i2hr (ng/mL.hr), Qrough (ng/mL) and fa (fraction of dose absorbed) are given 
with 5th and 95th percentiles. Median Tmax (hours) is given with range. Values in 
Table 6.7 have been divided by corresponding values in Table 6.4 to calculate the 
GMR (CmaX} AUCo.12hr, Ctrough and fa) or median ratios (Tmax)- p values were 
calculated by comparing values in Table 6.7 and Table 6.4.
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6.4. DISCUSSION
The IVIVE model developed in this chapter predicted the PK of raltegravir in virtual 
individuals with different GI pH profiles. The main PK variables were predicted with 
good accuracy compared with reference data, with each simulated PK parameter 
achieving less than a 2-fold difference in at least one of the groups (Table 6.5).
The simulations in Section 6.3.5 showed evidence of decreased raltegravir exposure 
when individuals were exposed to 25mM magnesium salt in the GI tract. This was 
simulated by using the permeability values determined in Chapter 5, where 25mM 
magnesium chloride significantly reduced raltegravir Papp through Caco-2 
monolayers. This is not an ideal situation, as the concentration of GI magnesium in 
real life would fluctuate depending on compartment volume and magnesium 
absorption, thus the intestinal permeation of raltegravir would also fluctuate. 
However, it can be seen from the model that the rate of raltegravir absorption is a 
limiting factor in ultimate exposure. The data from these simulations support the 
hypothesis given in Chapter 5 that the combined effect of increased solubility and 
reduced intestinal permeability could explain the interaction observed between 
raltegravir and magnesium-containing antacid in vivo (Kiser et at, 2010).
The simulations in Section 6.3.6 showed no evidence of increased raltegravir 
exposure following multiple twice-daily dosing, when compared to single dose. This 
partially agrees with published literature (Iwamoto et at, 2008d). The study by 
Iwamoto et al compared the PK of steady-state raltegravir (400 mg twice-daily for 10 
days) and single dose raltegravir (400 mg) in healthy subjects and found that the
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steady-state/single dose ratio for Cmax, AUCo-mir and Qrough was 0.98, 1.05 and 1.48, 
respectively. Both Cmax and AUCo-mr ratios are similar to the results generated in the 
Simcyp model and show no evidence of increased exposure following multiple 
doses. The Qrough following multiple doses, however, was claimed to be 48% higher 
than single dose. This does not match the results from the Simcyp model, which 
showed no evidence of increased Qr0ugh following multiple doses. However, a 
statistical comparison was not made on the Qrough data presented by Iwamoto et al 
and therefore the apparent increase may be due to sample variability. Furthermore, 
only 6 healthy subjects were used during the 400mg single and multiple dose studies 
and all these subjects were male. Being aware that the variability in raltegravir PK 
sampling is high, the small sample size and bias towards male subjects may have 
decreased the reliability of the data.
A recent study found a statistically significant 65% increase (p = 0.01) in raltegravir 
bioavailability in females compared to males(Arab-Alameddine et al, 2012). 
Females have higher gastric pH and longer GI transit time than males (Soldin et al, 
2011) and results from the Simcyp model suggest both of these factors could 
potentially increase raltegravir exposure. However, the data from another study 
found that raltegravir Qrough was 58% lower in females compared to males (p = 
0.007), with AUCo-oo and Cmax unchanged (Iwamoto et al, 2008d). The discrepancy 
between these studies may be explained by the smaller female subject number in the 
study by Iwamoto et al (6 females) compared to the study by Arab-Alameddine et al 
(31 females). Also, the subjects used in the study by Arab-Alameddine et al were a 
combination of HIV-negative and HIV-positive subjects, with the majority being
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HIV-positive (88%), whereas HIV-negative healthy subjects were included in the 
study by Iwamoto et al.
The IVIVE model has limitations and further in vitro data could potentially improve 
the model’s predictive ability. Elimination of raltegravir from virtual subjects was 
determined by whole organ clearance obtained from published literature: information 
about the actions of individual metabolism enzymes was not included. The 
metabolism of raltegravir is well characterised and includes enzymes UGT1A1, 
UGT1A3 and UGT1A9 (Iwamoto et al, 2008a). A model which included the actions 
of these individual enzymes on raltegravir metabolism, combined with known 
phenotypic variations and expression levels in the virtual population, could provide a 
more accurate model for determining raltegravir elimination. Similarly, the impact of 
drug transporters on raltegravir exposure in vivo is not fully understood and was not 
included in the final model.
Raltegravir PK profiles occasionally contain multiple peaks or delayed (>8 hours 
after dosing) peaks and, in an attempt to explain these peaks, it has been suggested 
that raltegravir is able to undergo enterohepatic recirculation via conversion of the 
raltegravir metabolite back to the parent form in the intestine and can subsequently 
be re-absorbed (Arab-Alameddine et al, 2012). However, a PK study in healthy 
subjects using radiolabelled raltegravir did not support the theory, as there was no 
evidence of drug reabsorption (da Silva et al, 2010). Therefore, enterohepatic 
recirculation of raltegravir was investigated in the validation process but was not 
included in the final model. Further investigation is needed to determine the extent of
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raltegravir enterohepatic recirculation and these data would have the potential to 
further improve the Simcyp model.
In conclusion, the Simcyp population-based ADME simulator has been used to 
create a model simulating raltegravir PK parameters with acceptable accuracy to real 
life data. The most useful feature of this model is to investigate “what-if ’ scenarios, 
by directly altering subject physiological parameters such as GI pH and drug 
absorption rate and observing the effect on raltegravir PK. This also provides a tool 
for investigating other drugs, including HIV integrase inhibitors currently in 
development, which have also shown interactions with food and metal-containing 
products.
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Chapter 7
General discussion
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7.1 SUMMARY OF EXPERIMENTAL DATA
The primary goal of this thesis was to identify factors influencing raltegravir 
pharmacokinetics and cellular exposure. Investigations have included the 
determination of raltegravir transport by known drug transporters in vitro (Chapters 
2, 3 and 4), the effect of pH and metal binding on raltegravir physicochemical 
properties and cell permeation (Chapter 5), and the use of computer-based PK 
modelling to better understand how these in vitro characteristics may translate into 
patient PK (Chapter 6).
In Chapter 2, raltegravir transport by ABCB1 was confirmed in vitro. Transport of 
raltegravir by ABCB1 has also recently been confirmed in vitro by Minuesa et al, 
where a 47% reduction in raltegravir accumulation was observed in CEMvblioo cells 
compared to CEM cells (de Kanter et al, 2012), However, the impact of ABCB1 on 
raltegravir disposition in vivo has yet to be fully determined.
Evidence supporting a strong role for ABCB1 in influencing raltegravir PK is 
limited. Indeed, most studies have suggested no significant role for ABCB1 in 
raltegravir disposition in vivo. The potential effect of ABCB1 inhibitor ritonavir on 
raltegravir PK was examined in healthy subjects administered raltegravir alone (400 
mg single-dose), followed by ritonavir (100 mg twice daily) for 16 days with a single 
dose of raltegravir (400 mg) on day 14. In the presence of ritonavir, raltegravir 
pharmacokinetics were not significantly affected; the GMR (90% Cl) for Ci2hr> AUC 
and Cmax were 0.99 (0.70, 1.40), 0.84 (0.70, 1.01) and 0.76 (0.55, 1.04), respectively 
(Iwamoto et al, 2008c). The ABCB1 3435C>T mutant variant (rs 1045642) has been 
reported to affect ABCB1 expression and in a recent study the effect of this mutation
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on raltegravir PBMC and cerebrospinal fluid concentrations were assessed in healthy 
volunteers. Penetration into CSF and PBMC was not altered by ABCB1 34350T 
(Johnson et ah, 2012). The study also investigated 276 polymorphisms across 
ABCCh ABCC4, ABCC5, ABCG2, SLC15A1, SLC15A2, SLC22A2, SLC22A3, 
SLC22A6, SLC22A8, SLCOU2, SLCOICI, SLC02B1, and SLCQ3A1 and found no 
correlation between polymorphisms and concentrations of raltegravir in PBMC or 
CSF.
In Chapter 3, raltegravir was significantly transported by SLC22A6 and SLC15A1 
using the Xenopus laevis oocyte expression system. Caco-2 monolayers express high 
levels of SLC15A1 on the apical cell membrane, facilitating A-to-B permeability of 
substrates (Behrens et ah, 2004) and results from Caco-2 monolayer permeability 
experiments in this thesis suggest there was no significant active transport of 
raltegravir in the A-to-B direction (efflux ratio of 2.5 when both chambers were pH 
7.4) and that inhibition of ABCB1 in this system did not result in predominant A-to- 
B permeability. Therefore, SLC15A1 is unlikely to play a major role in luminal 
absorption predicted from the Caco-2 cell model. As such, further investigations of 
raltegravir transport by SLC15A1 were not conducted.
In Chapter 4, raltegravir and tenofovir were shown to compete for SLC22A6 using 
the Xenopus laevis oocyte expression system. Transport of tenofovir by SLC22A6 
was reduced in the presence of raltegravir and this presents the possibility that 
raltegravir could reduce renal clearance of SLC22A6 substrates when co­
administered. Raltegravir inhibited transport of tenofovir by SLC22A6 with an IC5o 
value of 14 pM. This figure is comparable to raltegravir plasma concentrations in a
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PK study using healthy volunteers, where mean raltegravir Cmax was 10.6 |iM after 
administration of a single standard 400 mg tablet (Iwamoto et al, 2008d). However, 
mean raltegravir Cmax concentrations in most PK studies are substantially lower, for 
example 4.9 pM (Kassahun et al, 2007), 2.9 pM (Iwamoto et al, 2009b) and 2.0 
pM (Kiser et al, 2010) and therefore raltegravir is unlikely to achieve plasma 
concentrations which would substantially alter SLC22A6 activity at the kidney. 
However, it is possible that raltegravir is able to concentrate in the kidneys and 
achieve local concentrations higher than those detected in the plasma. Although 
possible, this seems unlikely because raltegravir is predominantly eliminated via the 
liver and only around 30% of total drug is excreted via the kidney (with only 30% of 
this being in the parent drug form). Furthermore, in a clinical study co-administered 
raltegravir did not alter tenofovir C24hr and actually caused a minor but significant 
decrease in tenofovir Cmax (23% reduction, p < 0.05), which contradicts the 
hypothesis that raltegravir can reduce the renal excretion of SLC22A6 substrates. 
Raltegravir concentration in the cerebrospinal fluid is more than 20-fold lower than 
in plasma (Yilmaz et al, 2009) and it is possible that SLC22A6 (which his expressed 
on the apical surface of the blood-cerebrospinal fluid barrier) is actively removing 
raltegravir from the cerebrospinal fluid, although this remains a hypothesis and has 
not been demonstrated in this thesis.
To summarise this initial stage of the thesis, raltegravir has only shown interactions 
with drug transporters ABCB1, SLC22A6 and SLC15A1 in vitro. However, transport 
in each case was less than that observed for positive control substrates, and clinical 
evidence does not suggest a crucial role of these transporters in raltegravir PK. The 
minimal interaction of raltegravir with transporters may be seen as beneficial; much
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like with the lack of interaction between raltegravir and cytochrome P450 enzymes. 
This reduces the risk of drug interactions and also reduces the risk of raltegravir 
exposure being altered by polymorphisms in transporters. If ABCB1 and SLC22A6 
have a minor role in raltegravir disposition in vivo, the actions of these transporters 
would not be predicted to explain why patients receiving raltegravir display such 
large variation in exposure. It should be noted however that there are over 400 
transporters coded for by the human genome (http://www.genenames.org/) and only 
relatively few have been characterised in any detail for drug transport.
Following transporter investigations in Chapter 2, 3 and 4, more fundamental 
physicochemical properties of raltegravir were investigated in relation to how these 
properties influence cellular exposure. There were several reasons why the focus of 
the investigations changed. First, no plausible transporters had been identified to 
explain the large intra- and inter- patient variability in raltegravir exposure and 
characterising the remaining transporters in the genome without a solid hypothesis 
was not feasible. Second, when initially validating Caco-2 monolayer experiments, 
the cellular permeability of raltegravir was observed to be sensitive to small changes 
to transport buffer pH. This suggested that pH could be a greater determining factor 
than ABCB1 in raltegravir Caco-2 cell permeability. Third, there has been steadily 
growing evidence from clinical studies that food and pH-altering agents could 
substantially alter raltegravir PK.
In Chapter 5, the effects of pH and metal binding on various pharmacological 
characteristics of raltegravir were investigated. Raltegravir was determined to be a 
weak acid with pKa of 6.67 and increasing pH above the pKa caused decreased logP,
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increased solubility, increased tablet breakdown and (at lower drug concentrations) 
decreased cell membrane permeability. Additionally, the presence of divalent metals, 
but not monovalent metals, decreased raltegravir cell membrane permeability, 
presumably via the formation of metal-drug complexes. Figure 7.1 hypothesises how 
these factors may play a role in raltegravir absorption.
In Chapter 6, data generated in Chapter 5 was used to construct a computer model 
simulating raltegravir absorption, which was used to predict the effects of GI pH and 
metal binding on raltegravir bioavailability. Predictions were comparable to real 
subject PK data and have confirmed that environmental factors in the GI tract can 
play a significant role in raltegravir PK variation.
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Figure 7.1. A hypothetical scenarios when a raltegravir tablet is taken by either a 
patient with low GI pH (Figure 7.1 A), a patient having taken omeprazole (Figure 
7.IB) or a patient having taken a divalent metal-containing antacid (Figure 7.1C). 
Figure 7.1 A shows slow tablet dissolution and low luminal drug solubility caused by
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the low pH environment. The raltegravir tablet may remain wholly or partially intact 
until later sections of the GI tract, where pH is higher. This may be the cause of the 
delayed or double peaks seen in some subject’s PK profiles. Figure 7.IB shows rapid 
tablet dissolution and high luminal drug solubility, resulting from an increased pH 
environment and the addition of charge to the drug. Figure 7.1C shows rapid tablet 
dissolution and drug solubility caused by high GI pH, but low drug permeation 
through the gut wall. This reduced permeation results from raltegravir binding 
directly to the magnesium in the antacid, forming a drug-metal complex which is 
unable to permeate a cell membrane. As drug concentration in the lumen reduces as 
it passes through the intestine, drug solubility would no longer be a restricting factor, 
whereas the presence of ingested divalent metals will reduce drug absorption 
throughout the GI tract.
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7.2 FUTURE INVESTIGATIONS
An investigational human trial to determine how metal-containing products 
affect raltegravir PK
Following the investigations in this thesis it is reasonable to ask; does this new 
information provide new avenues of investigation to improve clinical management 
with raltegravir, for example by increasing bioavailability or reducing PK 
variability?
Data in Chapters 5 and 6 show that divalent cation binding has the potential to reduce 
raltegravir cell membrane permeability in vitro and in silico. Clinical data also shows 
that divalent metal-containing antacids reduce the exposure of elvitegravir and 
dolutegravir. Therefore, the likelihood of an interaction between raltegravir and co­
administered multivitamins in vivo is high and is certainly worthy of empirical 
determination. In this context, the author has recently secured funding to conduct a 
single centre, open label, three arm, five phase controlled study using 15 healthy 
subjects, investigating the impact of several co-administered metal-containing 
substances on the PK of subjects given a single dose 400 mg raltegravir tablet 
(Figure 7.2). Each subject will also have GI pH monitored by ingesting a 
radiotelemetric pH-recording capsule with the raltegravir tablet. Each phase will 
consist of a different treatment, as detailed in Figure 7.2.
Volunteers will be assigned into one of the three arms, ensuring that each treatment 
is performed by the completion of the trial. This assignment into separate arms will
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help reduce any bias resulting from having identical order of treatments for each 
volunteer. Following the administration of treatment, blood samples will be taken 
across a 12 hour time course, which will be used to quantify raltegravir plasma 
concentration and create PK profiles. During the 12 hour blood sampling time 
course, the GI pH of volunteers will be monitored and data used to determine 
correlations between GI pH and raltegravir PK. The five phases will be separated by 
wash-out periods of four days to allow for total removal of raltegravir from the 
subject. As food has been shown to exacerbate raltegravir PK variability and increase 
or decrease raltegravir absorption depending on fat content, volunteers will fast 
overnight before beginning treatment.
The primary endpoint for the study will be the determination of a change in 400 mg 
raltegravir AUCo-i2hr, Cnhr, Cmax and Tmax following dosing of monovalent metal- 
containing antacid, divalent metal-containing antacid or multivitamin. The secondary 
endpoints will be the safety and tolerability of raltegravir with/without concomitant 
substances, the correlation between GI pH and raltegravir PK, the selection of an 
alternative antacid that does not cause a reduction in raltegravir Ci2hr and the 
selection of an alternative dosing regimen which will allow divalent antacids and 
raltegravir to be co-administered and that does not cause a reduction in raltegravir 
Ci2hr* The protocol for this trial has now been finalised and the trial is to be 
undertaken at the University of Liverpool with an expected start date of August 
2012.
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Figure 7.2. A study investigating the impact of several co-administered metal- 
containing substances on PK of subjects given a single dose 400 mg raltegravir 
tablet. The co-administered substances are; 1) Maalox Plus Extra, which raises 
gastric pH and contains divalent metals; 2) a standard multivitamin tablet, which
contains several monovalent and polyvalent metals; 3) Alka Seltzer Gold, which
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raises gastric pH and contains monovalent metals. The effect of taking Maalox Plus 
Extra two hours prior to taking the raltegravir tablet will also be investigated, as it is 
hypothesised that separating the treatments may prevent the drug interaction.
Utilising nanodispersed raltegravir to reduce drug pH sensitivity
Recent work at the University of Liverpool has indicated that the bioavailability of a 
number of Pis and NNRTIs can be enhanced using nanotechnology. Therefore, 
another possibility for future investigations is the use of raltegravir nanodispersions 
to overcome pH-determined solubility and to improve bioavailability. Using 
technology developed in Liverpool (Zhang et al, 2008) a panel of raltegravir 
nanodispersions could be synthesised with controlled size, surface charge and 
polydispersity. These nanodispersions could then be characterised for their 
transcellular permeability across Caco-2 cell monolayers. Resulting Papp values 
would be used to simulate PK of the nanodispersions using the SimCyp population 
simulator to enable I VIVE, as in Chapter 6. The results from I VIVE could then be 
used to inform selection of appropriate doses for study in rodents. For this, adult 
male Wistar rats could be dosed with nanodispersions by oral gavage and plasma and 
tissue drug concentrations quantified by mass spectrometry. The PK properties could 
then be determined using NONMEM and used to provide an early risk/benefit 
assessment of the nanodispersion relative to an aqueous solution of raltegravir.
Nanodispersions of raltegravir are unlikely to be altered by pH, although this would 
need to be confirmed in vitro. This may represent a novel means of protecting the 
drug from pH changes and food effect in the GI tract. In addition, metal cations
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would theoretically be excluded from the nanodispersion and therefore products with 
high metal contents (antacids, multivitamins, etc) would be unlikely to alter the 
absorption of nanoformulated raltegravir.
A previous clinical study by Dechamps et al provides an example of nanodispersions 
being used to protect megestrol acetate from influencing factors in the GI 
(Deschamps et al, 2009). Megestrol acetate oral suspension, an appetite stimulant, is 
available as a standard formulation (MAOS) and a nanodispersion formulation (MA­
ES). The PK of both was determined in healthy volunteers under both fed and fasted 
conditions. Both formulations achieved a similar Cmax under fed conditions, whereas 
under fasted conditions MAOS Cmax reduced by 86% and MA-ES only reduced by 
30%, indicating that the nanodispersion PK was protected from the influence of 
fasting.
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7.3 FINAL SUMMARY
In summary, the data within this thesis indicate that environmental factors such as 
the pH of the GI, the binding of raltegravir to divalent metals and food effects are 
major determinants of raltegravir cellular exposure. Drug transporters also appear to 
play a role but the contribution of the studied transporters to the large variability in 
raltegravir PK in the same patient appears to be minimal (Cattaneo et at, 2012). 
However, distribution of raltegravir varies between tissues, with high drug 
concentrations in genital tract and low drug concentrations in CSF (Section 1.6.5). 
This variability in tissue penetration may be influenced by active transport across 
blood-tissue border membranes, but may also involve different affinities in tissue 
protein binding. Induction by rifampicin (Wenning et al, 2009a) and inhibition by 
atazanavir (Iwamoto et ah, 2008b) of UGT1A1 both remain important causes of 
raltegravir-drug interactions (Figure 7.3).
The knowledge gained from these investigations can help to improve future integrase 
inhibitor design. Additionally, immediate investigations to determine the effects of 
divalent metal-containing products on raltegravir exposure in subjects are warranted. 
This is important because these interactions have the potential to reduce raltegravir 
Gtrough to sub-optimal concentrations, as seen with divalent metal-containing antacids 
(Kiser et al, 2010). Also, improved raltegravir formulation to prevent pH influencing 
tablet breakdown could provide a relatively simple strategy to reduce high patient PK 
variability.
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The benefits of raltegravir include its low toxicity, rapid reduction in viral load and 
effectiveness against HIV resistant to other antiretrovirals. A successful once-daily 
regimen of raltegravir would be of great advantage. Although previous efforts failed 
to show non-inferiority of a once-daily raltegravir regimen, an improved knowledge 
of factors influencing raltegravir disposition provide a rational basis in which to 
achieve this goal.
Figure 7.3. Some factors which may influence raltegravir absorption, distribution 
and elimination in humans. Factors include UGT1A1-mediated drug metabolism, 
pH-influenced drug absorption, drug-metal binding and drug transport. Both the 
existence of raltegravir enterohepatic recirculation and the main factors influencing 
raltegravir tissue distribution are not fully understood, but provide for exciting future 
research.
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